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Abstract 
Liver X Receptors (LXRα and β) are members of the nuclear receptor superfamily of 
ligand-activated transcription factors. LXRs are activated by oxidised metabolites of 
cholesterol and several synthetic ligands, play a crucial role in the regulation of 
cholesterol and fatty acid homeostasis, and act as strong modulators of inflammation 
and immunity. This has positioned them as targets for the treatment of several 
pathologies, including atherosclerosis and obesity. Besides ligand binding, LXR activity 
can be modulated by post-translational modifications, and previous work has shown that 
phosphorylation of LXRα alters its transcriptional activity in a gene-specific manner in a 
macrophage cell line.  
This thesis has focused on better understanding the regulation of LXRα phosphorylation 
and investigating how changes in the receptor’s phosphorylation status modulate its 
activity in vivo; more specifically, in relation to its effects on hepatic lipid metabolism, and 
the development of inflammation and fibrosis. To do so, I have used a novel mouse 
model that expresses a whole-body non-phosphorylatable mutant version of LXRα 
(S196A) and have assessed its responses to a High Fat and High Cholesterol diet, as a 
dietary model of Non-Alcoholic Fatty Liver Disease (NAFLD). Furthermore, I have 
studied how the transcriptional capacity of the mutant receptor is modulated, assessing 
its differential binding to DNA and to other proteins. In order to evaluate the relevance of 
my findings in the context of human disease, I have also examined LXR activity on the 
activation of human hepatic stellate cells, key players in the development of liver fibrosis. 
Lastly, I have sought to examine new stimulants capable of inducing LXRα 
phosphorylation in vitro, and how this phenomenon can be pharmacologically impaired 
by using already-available kinase inhibitors. 
Overall, the work described in this thesis shows that LXRα phosphorylation critically acts 
as a novel nutritional sensor that promotes a unique diet-induced transcriptome and 
modulates metabolic, inflammatory and fibrotic responses that are key in NAFLD 
progression This novel work significantly contributes to our understanding of LXRα 
activity in liver disease in a pre-clinical setup, and places the modulation of LXRα 
phosphorylation as a potential anti-inflammatory/anti-fibrotic therapeutic target. 
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Impact statement 
 
Benefits inside academia 
To date, the physiological roles of modifications such as phosphorylation, sumoylation 
and acetylation of LXRα have only been studied in vitro or non-specifically in animal 
models, by pharmacologically or genetically altering the enzymes enhancing or inhibiting 
these modifications. My PhD thesis is the first study to address the pathophysiological 
impact of LXRα phosphorylation by directly impeding this modification genetically, and 
has positioned the S196A mice as an optimal in vivo model for the study of this 
modification. This could benefit the academic community by establishing this animal 
model as an important tool to investigate regulation of LXRα phosphorylation as a 
potential therapeutic target. This impact will be brought about by dissemination of results 
in conferences and scientific journals, as well as future collaborations with other 
academic experts in the field of nuclear receptor biology. 
 
Benefits outside academia 
The WHO estimates over 650m people worldwide have a chronic liver condition. 
Alarming increases in obesity rates and parallel increases in rates of non-alcoholic fatty 
liver disease (NAFLD), plus an ageing population predicts it to become the most frequent 
indication for liver transplantation by 2030. In the UK, NAFLD affects about 33% of the 
UK population, and 2-5% progress to non-alcoholic steatohepatitis (NASH). 
Despite its vast clinical relevance, current treatment options such as lifestyle changes 
(diet change and weight loss) are inadequate for a large number of patients. 
Pharmacological therapies such as insulin sensitizers, antioxidants, and lipid-lowering 
agents are aimed at treating its associated conditions and therefore display only limited 
efficacy. Thus, there is a clear unmet medical need for development of novel direct 
pharmacological therapies targeting NAFLD. My PhD findings could be the basis for 
further research into the discovery of new pharmaceutical therapies for Non Alcoholic 
Liver Disease (NAFLD). This impact could be brought about by dissemination of results 
in conferences and scientific journals, as well as future collaborations with partners in 
industry.  
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Chapter 1. Introduction 
1.1. Liver X Receptors 
1.1.1. LXR structure and activity 
LXRs are members of the nuclear receptor superfamily, a set of structurally conserved, 
ligand-dependent transcription factors that act as integrators of several diverse signals 
(inflammatory, nutritional and hormonal) and regulate diverse aspects of development 
and homeostasis through changes in gene expression. Most proteins in the nuclear 
receptor family share a similar structure, consisting of a variable amino-terminal 
activation domain (AF-1), a central DNA-binding domain (DBD) which recognizes 
specific DNA sequences known as response elements, a hinge region that permits 
structural flexibility, and a ligand-binding domain (LBD) located on the carboxy-terminal 
part (Figure 1.1. A). Nuclear receptors can be grouped into four categories according to 
their ligand, DNA binding and dimerization properties (1). The LXR family consists of two 
different subtypes, LXRα and LXRβ (NR1H3 and NR1H2, respectively) and its name 
comes from the initial isolation of the LXRα receptor from a human liver cDNA library, 
where it is highly expressed (2,3). The two receptors share approximately 75% sequence 
homology in both their DBD and LBD, and differ mainly on their N-terminal sequence 
and their expression pattern; while LXRα is most highly found in liver and other 
metabolically active tissues and cell types, such as intestine and macrophages, LXRβ is 
ubiquitously expressed (2–4). The mechanisms controlling expression of the LXR genes 
are not fully understood. In the case of LXRα, its promoter has been shown to be under 
the regulation of the peroxisome proliferator-activated receptors alpha (PPARα) and 
gamma (PPARδ) in liver, adipocytes and macrophages (5–7). For example, expression 
of the LXRα receptor has been shown to be induced in the presence of fatty acids, which 
are classic PPARα ligands, through an increase in its transcriptional rates but also 
stabilization of the LXRα transcript (8). In addition, expression of the LXRα gene has 
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been demonstrated to be autoregulated by LXR activation in mouse adipose tissue (9) 
and human macrophages (10).  
Both LXRs regulate transcription by forming permissive heterodimers with the Retinoid 
X Receptor (RXR), where ligands for either partner can activate the complex (3,11). 
Upon dimerization with RXR, LXRs bind to the DNA through their DBD, which contains 
a double zinc structure. The LXR/RXR heterodimer binds with high affinity to specific 
motifs known as LXR-responsive elements (LXREs), which consist of direct repeats 
(DRs) of several derivatives of the consensus half-site AGGTCA separated by 4 
nucleotides (DR4), located in the regulatory regions (promoter and/or enhancers) of their 
target genes (2,3,12) (Figure 1.1. B,C).  
 
 
Figure 1.1. Primary structure and general action mechanisms of Liver X Receptors 
A) Scheme of the primary structure of LXRα receptor with location of residues modified 
by acetylation (brown), phosphorylation (blue) and SUMOylation (black). Residues are 
depicted based on the species of the receptor sequence: human (h) or murine (m). 
B-C) Ligand-dependent transactivation. In the absence of ligand, gene transcription is 
silenced. Binding of agonist leads to the exchange from corepressor to coactivator 
complexes, and induction of gene transcription. D) Ligand-dependent transrepression. 
LXRs can antagonize the activity of other transcription factors upon ligand activation 
without binding directly to DNA. 
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Early work by Willy and colleagues showed that the RXR receptor sits on the 5’ end of 
the LXRE and is responsible for the ligand activation of the complex, whereas LXRs 
contribute to the DNA specificity and bind to the 3’ region (13).  
Gene activation and repression is mediated by changes in chromatin structure, mediated 
by a wide variety of proteins that will affect mainly DNA methylation (14), chromatin 
remodelling and histone modifications (15). In the absence of ligand, the LXR/RXR 
heterodimer is sitting on the LXREs and interacting with corepressors such as the 
nuclear receptor corepressor (NCoR) (16) and silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT) (17), thereby silencing gene expression, also known 
as ligand-independent active repression (18) (Figure 1.1. B). The repressive activity of 
cofactors such as NCoR or SMRT is believed to be caused, in part, by their capacity to 
recruit histone deacetylases (HDACs), which in turn deacetylase histones and thus 
compact chromatin and reinforce its repressive effect (19). For example, HDAC1 and 2 
are present in the Sin3 complex, where they interact with the NCoR (20) and SMRT (21) 
corepressors. HDAC3 also binds these corepressors albeit within distinct complexes 
(22,23).  
Once nuclear receptors bind to the ligand, their LBD suffers a structural shift onto a more 
stable position, inhibiting co-repressor interaction and creating a high-affinity site for co-
activator proteins, which interact mainly through the specific sequence motif LXXLL 
(where L is for Leucine and X for any aminoacid) (24), also known as NR box. These co-
activator complexes are responsible for the modification of chromatin structure, thus 
facilitating the assembly of the general transcriptional machinery to the gene promoter 
and inducing ligand-dependent transactivation of gene expression (25) (Figure 1.1. C).  
Nonetheless, this model of transactivation doesn’t seem to be exclusive, as other studies 
have shown that this exchange between corepressor-coactivator complexes and 
subsequent de-repression of genes requires at times the active removal of the former 
complex by a proteasome-dependent mechanism (26–28). This process has been 
proven to be mediated, in part, by transducin beta like 1 X-linked receptor 1 (TBLR1X1 
or TBLR1) and its partner TBL1, originally discovered as members of the NCoR/SMRT 
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complex (27,29–31). Therefore, those signals that induce activation of gene expression 
must do so in a parallel and coordinated fashion, on one hand activating the 
transcriptional machinery, as well as relieving the corepressor complex from the 
promoter. 
LXRs can also regulate gene-expression through a mechanism known as ligand-
dependent transrepression (Figure 1.1. D). Unlike transcriptional activation, they exert 
their function not by directly binding to DNA sequences, but rather by antagonizing the 
activity of other signal-dependent transcription factors, such as the nuclear factor-κβ (NF-
κβ) and activator protein 1 (AP-1). It appears this is, in part, the mechanism through 
which LXRs exert their anti-inflammatory functions (32–34). Interestingly, the same 
corepressor complexes involved in LXR ligand-independent repression can also be 
recruited to the promoters of inflammatory genes in the presence of LXR ligands and 
induce active transrepression by LXRs (35). 
LXRs must be present in the nucleus in order to regulate the transcription of their target 
genes, and the α subtype has been shown to maintain a nuclear localization both in the 
absence and presence of its ligands (36,37). Nonetheless, several studies have 
demonstrated that, at least a small fraction of LXRβ, can be found in the cytoplasm, 
suggesting that this receptor may have other non-nuclear functions involving interaction 
with other cytoplasmic proteins (38–41). This is likely to occur in a tissue- cell-specific 
manner; however, detailed enough studies are currently unavailable to conclude this.   
 
1.1.2. LXR ligands 
1.1.2.1. Endogenous agonists 
LXRs were originally classified as “orphan” receptors, meaning they had no known 
physiological ligands (2,42); however, it is now well established that oxysterols, oxidised 
metabolites of cholesterol, are the most important group of LXR natural ligands, capable 
of activating both isotypes at physiological concentrations (11,43). Oxysterols were first 
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identified as LXR ligands through the observation that gonad extracts, which contain high 
levels of sterols, were capable of strongly activating LXRs in vitro (11), which raised the 
possibility that LXRs could be sensitive to cholesterol metabolites. Subsequent 
screening of over 70 different compounds proved that only those sterols with a position-
specific monooxidation on the side chain can bind LXRs with high-affinity and induce the 
expression of its target genes (11). The establishment of this particular subset of 
naturally-occurring oxysterols as bona fide LXR ligands was later confirmed through 
proximity-binding studies (43) and reporter assays (44,45). Examples of this group of 
sterols shown to be important regulators of LXR activity in mouse liver are the 24(S)-
Hydroxycholesterol (24(S)-OHC), 25-Hydroxycholesterol (25-OHC), and 27-
hydroxycholesterol (27-OHC) (46) (Table 1.1).  
 
Nonetheless, one of the most potent LXR-activating oxysterols found to date is 24(S),25-
Epoxycholesterol (24(S),25-EC) (44,47) (Table 1.1). First discovered in the human liver 
(48), it has a different origin from the rest of oxysterols, since instead of being a 
metabolite of cholesterol, it is actually formed de novo from a parallel cholesterol 
synthesis pathway (49) (Figure 1.2). 
Later, Yang et al. found that stigmasterol, a plant sterol that shares a great similarity with 
cholesterol, increased the transcriptional activity of LXR (50). This led to the discovery 
of 24-Dehydroxycholesterol (or Desmosterol), an intermediate of the cholesterol 
biosynthetic pathway, as a molecule that binds directly to LXR and activates its 
transcriptional activity (51) (Table 1.1). Subsequent studies have shown desmosterol to 
be the main endogenous ligand found on mouse macrophage foam cells and human 
atherosclerotic lesions; where it induces LXR target genes and supresses pro-
inflammatory responses (52). Nonetheless, the effect of this ligand on LXR activity in 
other cell types and tissues is still to be determined.  
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Albeit sometimes controversial, several studies have emerged recently claiming that 
other compounds not structurally-related to cholesterol are also capable of activating 
LXRs and act as their ligand at physiological concentrations. For example, Mitro and 
colleagues suggested that glucose can bind to and consequently activate LXRs in vitro 
(53). However, it was later proposed that the aforementioned effects of glucose, a 
hydrophilic compound, were in fact caused by its downstream signalling, presumably 
through post-translational modifications, rather than the direct binding to the LXR highly 
hydrophobic ligand-binding pocket (54). 
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Table 1.1. LXR endogenous ligands
 Compound Effects References 
Endogenous 
Agonists 
22RHC 
(22(R)-Hydroxycholesterol) 
• EC50 = 1.5 μM 
• Intermediate in hepatic synthesis of bile 
acids and steroid hormones  
Janowski et al., 1996 
(11) 
24,25EC 
(24(S),25-Epoxycholesterol) 
• EC50 = 460 ± 80 nM 
• Product in cholesterol biosynthetic shunt 
pathway  
Lehmann et al., 1997 
(44) 
25-OHC 
(25-Hydroxycholesterol) 
• EC50 = 1.16 ± 0.02 μM 
• Suppressor of SREBP activity 
Spencer et al., 2001 (45) 
Adams et al., 2004 (55) 
24-OHC 
(24(S)-Hydroxycholesterol) 
• EC50 = 7 μM (LXRα) and 1.5 μM (LXRβ) 
• Most abundant oxysterol in the brain 
Lehmann et al., 1997 
(44) 
27-HC 
(27-Hydroxycholesterol) 
 EC50 = 85 nM (LXRα) and 71 nM (LXRβ) 
 Produced in response to cholesterol 
loading  
Fu et al., 2001 
(56) 
Desmosterol 
(24-Dehydroxycholesterol) 
• EC50 n/a 
• Present in high concentrations in 
atherosclerotic foam cells 
Yang et al., 2006 
(51) 
Stigmasterol 
• EC50 n/a 
• Plant sterol, source of dietary cholesterol 
Yang et al., 2004 
(50) 
Endogenous 
Antagonists 
Unsaturated Fatty Acids 
• pIC50 n/a  
• Inhibits LXR’s binding to coactivators          
  and DNA 
Ou et al., 2001 (57) 
Yoshikawa et al., 2002 (58) 
GGPP 
(Geranylgeranyl Pyrophosphate) 
• pIC50 n/a  
• Inhibits LXR/RXR heterodimerization 
and binding to DNA 
Forman et al., 1997 (59) 
Yeh et al., 2016 (60) 
2
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1.1.2.2. Synthetic agonists 
Nowadays, there are several synthetic compounds that act as potent LXR activators, the 
most commonly used in pre-clinical research being the non-steroidal full agonists 
T0901317 (61) and GW3965 (62) (Table 1.2). T0901317 was the first and most 
extensively studied synthetic LXR activator; however, later studies showed that this 
molecule can also activate the nuclear receptors FXR (63) and PXR (64), prompting the 
need for more selective ligands. On the other hand, GW3965 was initially identified by 
screening a library of tertiary amines, standing as a full and selective agonist for both 
human LXRα and LXRβ (62).  These two synthetic compounds have been shown to 
inhibit atherosclerosis development in several animal studies (65,66). Unfortunately, 
side-effects such as observed increase in hepatic and plasma triglycerides (61,65) 
haven’t allowed for these molecules to progress into human therapeutics. Although these 
first-generation agonists haven’t been proved suitable as pharmaceutical drugs, they still 
stand as one of the main tools for conducting clinical research on LXR activity. 
Concurrently, subsequent efforts on LXR therapeutics have focused on bypassing the 
afore-mentioned undesirable effects. Examples of these new compounds are the small 
intestine-specific agonist GW6340 (67) and the synthetic oxysterol DMHCA, a compound 
that has been shown to reduce atherosclerosis is mouse models in a gene-selective 
manner, avoiding induction of hepatic steatosis and hypertriglyceridemia (68) (Table 1.2). 
More recently, the pharmaceutical company GlaxoSmithKline has created new synthetic 
compounds with specific actions, i.e. GSK9772 is capable of inducing the 
transrepressive effects of LXR on inflammatory genes without promoting the expression 
of lipogenic genes (69) (Table 1.2).
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Table 1.2. LXR synthetic ligands
 Compound Effects References 
Synthetic 
agonists 
 
T0901317 
N-(2,2,2-trifluoroethyl)-N-[4–(2,2,2-trifluoro-1-
hydroxy-1-trifluoromethylethyl)- 
phenyl]-benzenesulfonamide 
• EC50 = 20 nM 
• First described LXR synthetic compound, 
can also activate FXR and PXR 
• Used in research only 
Schultz et al., 2000 (61) 
Houck et al., 2004 (63) 
Mitro et al., 2007 (64) 
GW3965 
3-[3-[N-(2-Chloro-3-trifluoromethylbenzyl)-(2,2-
diphenylethyl)amino]propyloxy]phenylacetic acid 
• EC50 = 125 nM 
• Proven to reduce atherosclerosis in two in 
vivo models 
Collins et al., 2002 (62) 
Joseph et al., 2002 (65) 
GSK9772 
4-[(Butyl{4-[2,2,2-trifluoro-1-hydroxy-1 
(trifluoromethyl)ethyl]phenyl} 
amino)methyl]-2,6-dichlorophenol 
• LXRβ EC50 = 30 nM 
• Induces great LXR transrepressive activity 
via a SUMOylation-dependent mechanism 
Chao et al., 2008  
(69) 
DMHCA 
N,N-dimethyl-3β-hydroxycholenamide 
• LXRα EC50 = 0.41 µM 
Kaneko et al., 2003 
(70) 
GW6340 
• Intestinal-specific LXR agonist, it is the 
ester form of GW3965 
• EC50 n/a 
Yasuda et al., 2010 
(67) 
Synthetic 
antagonist 
GSK2033 
(2,4,6-Trimethyl-N-{[30-(methylsulfonyl)-4-
biphenylyl]methyl}-N-{[5-(trifluoromethyl)-2-
furanyl]methyl}benzenesulfonamide) 
• LXRβ pIC50 = 7.5 nM 
• First potent synthetic LXR antagonist 
• Rapid hepatic metabolism impedes its in 
vivo use 
Zuercher et al., 2010 
(71) 
Synthetic 
inverse 
agonist 
SR9238 
Ethyl 5-[[[[3'-(Methylsulfonyl)[1,1'-biphenyl]-4-
yl]methyl][(2,4,6-
trimethylphenyl)sulfonyl]amino]methyl]-2-
furancarboxylat 
• LXRα pIC50 = 214 nM 
• LXRβ pIC50 = 43 nM  
• Acts by increasing LXR’s interaction with 
corepressor 
Griffett et al., 2013 
(72) 
2
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1.1.2.3. Antagonists and inverse agonists 
Few compounds have been shown to directly antagonise LXR activity endogenously. 
Unsaturated fatty acids, such as arachidonic acid, can inhibit the LXR-mediated 
transcription of Srebp-1c in vitro by acting as a competitive agonist of LXR endogenous 
ligands thus decreasing binding of the receptor to coactivators (57) and/or to DNA (58) 
(Table 1.1). Furthermore, geranylgeranylpyrophosphate (GGPP), a metabolite of 
mevalonic acid which is a precursor in the cholesterol biosynthetic pathway, also inhibits 
LXR activity by two different mechanisms: interfering with LXR/RXR heterodimer 
formation, and/or binding of the receptor(s) to DNA (59,60) (Table 1.1). Lastly, LXR 
antagonism through the reduction of cofactor recruitment has also been shown for 
several cholesterol sulfates found in human plasma (73).  
Regarding synthetic compounds, GlaxoSmithKline has recently identified GSK2033 as 
an LXR antagonist that displays high binding affinity for LXR and antagonises its target 
gene expression in vitro (71) (Table 1.2). However, this drug failed to repress the 
expression of LXR target genes and inflammatory genes in the liver of mice on a diet-
induced NAFLD model (74). Intriguingly, SR9238, a novel liver selective LXR inverse 
agonist, has been recently shown to suppress hepatic fatty acid synthesis and lipid 
accumulation while also inhibiting hepatic inflammation in a diet-induced obesity rodent 
model (72,75) (Table 1.2). 
 
1.1.3. LXR effects and their therapeutic opportunities  
1.1.3.1. Cholesterol homeostasis 
Cholesterol and its metabolites serve essential functions in eukaryotic cells, such as cell 
proliferation (76,77). However, abnormally high cholesterol levels in the system can have 
serious consequences leading to cellular toxicity and the development of several 
pathologies, including cardiovascular disease (78) and diabetes (79). For this reason, 
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vertebrate cells have evolved to tightly regulate cholesterol homeostasis, which involves 
the control of cholesterol uptake, biosynthesis, catabolism to bile acids and excretion. 
Numerous studies for over the past 20 years have established LXRs to play a key role 
as modulators of lipid metabolism. LXRs act as whole-body cholesterol sensors, by 
responding to high intracellular sterol levels and driving, in consequence, the expression 
of several genes involved in the transport, catabolism and elimination of cholesterol.  
Mammalian cells acquire their cholesterol from dietary sources, as well as from 
endogenous biosynthesis. Despite interpersonal differences, including genetic variations 
and dietary styles, the biggest source of cholesterol is from de novo synthesis, as dietary 
availability and intestinal absorption of cholesterol can be limited. It must be noted, 
though, that humans and mice have significant differences in their synthetic rates; 
whereas mice can synthesise an average of ∼160 mg/day/kg of cholesterol, the daily 
rate in humans is approximately ∼10 mg/day/kg (80). Moreover, cholesterol synthesis in 
the liver compared to other extrahepatic tissues has been proven to have a bigger 
contribution in mice than in humans (81). These and other differences need to be 
considered when translating findings in mice and other rodents onto humans. Indeed, 
these differences are behind the need to genetically modify mice and alter their 
cholesterol metabolism in order to use them as in vivo experimental models of disease 
that are more comparable to the human pathology.  
 
1.1.3.2. Cholesterol biosynthesis 
The cholesterol molecule is obtained from Acetyl CoA in a serial three-stage process 
consisting on a total of 30 different enzymatic reactions (82). A diagram depicting the 
cholesterol biosynthesis pathways as well as the main enzymes involved can be found 
in Figure 1.2.  
.  
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Figure 1.2. Cholesterol biosynthetic pathway  
Scheme showing the main steps and enzymes involved 
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The first part of this process is known as the Mevalonate Pathway, and it takes place in 
the cytosol. The Acetyl CoA utilised in this process is obtained as a product of 
mitochondrial (i.e. fatty acid oxidation) and cytosolic (glycolysis) metabolic processes. 
The rate-limiting enzyme of this section is hydroxymethylglutaryl CoA reductase (HMG-
CoAR), which converts HMG-CoA into mevalonic acid and is a target for the extensively 
used lipid-lowering drug statins (83). This step ends with the production of isopentenyl 
pyrophosphate (IPP), a key building block for the production of cholesterol and many 
other molecules such as steroid hormones. The second step consists of the 
condensation (chemical reaction where two or more molecules fuse to form a new one) 
of six IPP molecules into squalene. The third and last stage starts with the conversion of 
squalene into lanosterol, this being the first committed step in the synthesis of cholesterol. 
The last 19 downstream steps can occur through two different parallel pathways, that 
differ mainly on the step in which the carbon 24 double bond is reduced. That is, in the 
Kandutsch-Russell pathway, cholesterol is obtained from the reduction of 7-
dehydrocholesterol by 7-Dehydrocholesterol Reductase (DHCR7) (84); whereas in the 
Bloch pathway, desmosterol serves as the immediate cholesterol precursor and is 
catalysed by the 24-dehydrocholesterol reductase (DHCR24).  
 
1.1.3.3. Cholesterol absorption 
To relieve the energetic burden of constant cholesterol de novo synthesis, organisms 
have evolved to increase their rate of cholesterol take up, performed through its 
absorption in the gastrointestinal tract. Dietary intake provides about a quarter of the 
cholesterol entering the intestinal lumen, while the remaining three-quarters are derived 
from biliary cholesterol excretion from the liver. Due to the lipophilic nature of the 
cholesterol molecule, its absorption by intestinal enterocytes first requires its 
emulsification, solubilisation, and transportation into micelles (85). 
Several proteins have been identified for their role on intestinal cholesterol uptake. 
Absorption of free cholesterol contained in the micelles is mediated by Niemann–Pick 
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C1 Like 1 (NPC1L1), a receptor located in the brush (intestinal) border of the enterocytes 
found in the jejenum, the middle segment of the small intestine (86). Ezetimibe, a widely-
used drug for the treatment of hypercholesterolemia, effects its action by selectively 
blocking NPC1L1 (87), and thus causing a reduction in Low Density Lipoprotein (LDL)-
cholesterol in plasma of around 17% (88). NPC1L1 colocalizes with the ATP-binding 
cassette (ABC) transporters ABCG5 and ABCG8 in the proximal part of the small 
intestine (89,90). These proteins are responsible for the efflux of the intracellular 
cholesterol back into the lumen (91) and therefore antagonise the actions of NP1CL1, 
creating a fine balance between cholesterol uptake and excretion that will shift depending 
on the need for cholesterol. The remaining cholesterol in the enterocytes that has not 
been effluxed will then be esterified by the Acyl-CoA:cholesterol acyltransferase 2 
(ACAT2) and packaged into chylomicrons alongside triglycerides and phospholipids for 
its transport to the lymph. Intracellular cholesterol can also be transferred into apoAI-
High Density Lipoprotein (HDL) particles via ATP-binding cassette transporter A1 
(ABCA1). Nonetheless, in vivo studies with animals lacking the intestinal Abca1 gene 
have proven that this transporter has no effect in the regulation of cholesterol intestinal 
absorption (92). 
 
1.1.3.4. Cholesterol catabolism and excretion 
Cholesterol can be removed from the body in two different forms: either as a neutral 
sterol, or after it has been catabolised into bile acids (93). Both compounds are excreted 
mainly through the faeces, although there is also a minimal part that can be excreted 
through the skin (94).  
Cholesterol excretion is performed in great part through Reverse Cholesterol Transport 
(RCT), a multi-step process by which peripheral cholesterol is returned to the liver where 
it gets sent to the intestinal lumen through the bile for its faecal removal. In the first part 
of this process, cholesterol accumulated in peripheral cells and tissues (i.e. 
macrophages) is sent to the liver mainly through HDL particles (95). This step is 
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facilitated by the ATP-binding cassette transporters ABCA1 (96,97) and ABCG1 (98), 
which efflux intracellular cholesterol onto lipid-free apolipoproteins (such as apoAI, 
apoCII and ApoE) and mature HDL particles, respectively. Consequently, Tangier 
Disease (OMIM entry #205400), a recessive homozygous disorder that impairs the 
function of the ABCA1 gene, is characterised by low levels of circulating HDL and 
subsequent cholesterol deposition in several organs (99). 
In the second step of RCT, circulating lipoproteins are taken up by the liver primarily by 
the LDL-Receptor (LDLR) for LDL and Very Low Density Lipoproteins (VLDL) (100) 
uptake, and the scavenger receptor B1 for HDL uptake (101). Once in the liver, 
cholesterol is secreted apically from the hepatocytes to the bile duct directly as free 
cholesterol or as bile acids. Again, due to the hydrophobic nature of cholesterol and of 
phospholipids, their biliary excretion needs to be coupled with salts that will solubilize 
these compounds due to their “detergent” characteristics. Therefore, secretion rate of 
bile acids regulate cholesterol and phospholipid excretion (102). Cholesterol and plant 
sterols are secreted to the bile by the ABCG5 and ABCG8 transporters (91), whereas 
bile acid excretion is elicited mainly by ABCB11, also referred to as the bile salt export 
pump (BSEP) (103). It must be noted though, that animals deficient for the Abcb11 gene 
show no drastic phenotype as they still have considerably residual bile acid excretion 
(104), suggestive of a compensatory mechanism, found to be through an increase in the 
MDR1 (Mdr1a and Mdr1b in mice) transporter (105). Then, biliary cholesterol enters the 
lumen, where a small fraction of it will be reabsorbed and the rest will leave the body via 
faecal excretion.  
LXRs are substantially involved in hepatic lipid metabolism, and its importance was first 
shown in vivo in a mouse strain lacking the LXRα isoform (Lxra-/-) (106). These animals 
were unable to catabolise dietary cholesterol, which led to rapid accumulation of 
cholesteryl esters in the liver, in part due to their incapacity to induce the expression of 
the Cholesterol 7 alpha-hydroxylase (CYP7A1) gene, which encodes the rate-limiting 
enzyme in the classical pathway of cholesterol conversion to bile acids.  It must be noted 
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that although LXRβ is also found in the liver (4), and both isoforms share the same ligand-
binding specificity, Lxrb-/- (LXRβ knock-out) mice show resistance to dietary cholesterol 
(107), indicating that LXRα is the predominant isoform involved in hepatic cholesterol 
metabolism and that the α and β subtypes don’t necessarily have redundant roles. This 
is mainly based on their different expression patterns, since they both share a high level 
of structure homology (see section 1.1.1) and bind to the same ligands (see section 
1.1.2). 
Interestingly, mice deficient for both LXR subtypes develop several degenerative 
processes in the brain, such as enlarged brain blood vessels, in part caused by 
alterations in the cholesterol metabolism in these animals as well as an increased 
presence of lipid droplets in the brain (108).  
Nonetheless, a big part of the faecal cholesterol excretion is not done through the 
classical hepatobiliary pathway, but through an alternative mechanism known as 
Transintestinal cholesterol excretion (TICE). The finding of this mechanism arose from 
the observation that people and animals that had very low levels of biliary excretion were 
still able to maintain, or even increase, their net cholesterol excretion levels (109–111). 
Briefly, in TICE cholesterol in the blood can be excreted directly into the faeces via 
intestinal enterocytes. Even though the specific molecular mechanisms through which 
TICE occurs remain unknown, several recent studies have demonstrated that LXR and 
PPARδ agonists induce this process (110,112,113). Regardless, the contribution that 
TICE has on healthy humans is still unclear at present. 
One of the best studied effects of LXRs is the promotion of RCT (114,115), a multi-step 
process by which peripheral cholesterol is returned to the liver for excretion, hence 
making these receptors attractive drug targets to combat cardiovascular diseases. LXRs 
control the expression of members of the ATP-Binding cassette (ABC) family of 
transporters, including the members from the sub-family A1 (ABCA1) (116) and G1 
(ABCG1) (117), whose function is the efflux of cholesterol from inside the cell, i.e. 
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macrophages, to lipoproteins found in the plasma for its transport (see section 1.1.3.1; 
or the ABC transporters, sub-family G members 5 and 8 (ABCG5 and ABCG8, 
respectively), responsible for limiting sterol absorption in the gut, and mediating its 
excretion from the liver (118) (see section 1.1.3.1). In two different animal models of 
atherosclerosis, it was reported that administration of GW3965 was able to decrease the 
development of atherosclerotic lesions, as a direct result of the increased expression of 
Abca1 in macrophage foam-cells (65). However, recent studies are suggesting that it is 
indeed the activation of LXR on other tissues, like the liver (119) and intestine (115), that 
are key in the promotion of RCT and consequent reduction of atherosclerotic lesions, 
highlighting the importance of LXR activity in specific organs for whole-body effects.  
 
1.1.3.5. Fatty acid and triglyceride metabolism 
Alongside the adipose tissue, the liver is the main responsible for fatty acid and 
triglyceride synthesis from glucose and citrate, a process known as de novo lipogenesis 
(DNL). This is a highly regulated mechanism that starts with the conversion of acetyl-
CoA to malonyl-CoA by the acetyl-CoA carboxylase (ACC) enzyme, which creates the 
essential substrate for fatty acid formation (120). Then, a sequential addition of two-
carbons by fatty acid synthetase (FAS) will lead to the production of palmitate (C16:0) 
(121), which can be further elongated and/or desaturated through the introduction of 
double bonds in their structure by several enzymes located in the endoplasmic reticulum 
membrane. Fatty acid elongation is catalysed by elongation of very long-chain fatty acid 
(ELOVL) proteins; out of which Elovl6, which catalyses elongation of fatty acids 
consisting of 12, 14 or 16 carbons, is of particular importance since mice deficient for 
this protein are more susceptible to developing hepatic steatosis and obesity, but are 
somehow protected against insulin resistance (122).  
Fatty acid length and desaturation status have important consequences on the fate and 
impact that these lipid species have on hepatic homeostasis and play an important role 
in the development of diseases with a metabolic component, as is the case of Non 
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Alcoholic Fatty Liver Disease (NAFLD) (123,124). A key enzyme involved in fatty acid 
desaturation is stearoyl-CoA desaturase (SCD), a rate-limiting enzyme in the synthesis 
of monounsaturated fatty acids from saturated fatty acids (125). In rodents, this enzyme 
family contains two members, SCD-1 and SCD-2, whose expression has been shown to 
be differently regulated (126).  Lastly, these newly synthesized fatty acids will be used to 
esterify glycerol-3-phosphate in order to generate lysophosphatidic acids, which along 
the line, will be processed into diacylglycerols, followed by the formation of triglycerides 
through acyl-CoA:diacylglycerol acyltransferase (DGAT) (127).  
LXRs control the expression of several genes involved in fatty acid and triglyceride 
metabolism, mainly through the modulation of the transcription factor sterol regulatory 
element binding protein-1c (SREBP-1c) (128,129), as well as the transactivation of some 
of its direct target genes, such as Fas (130) and Scd-1 (131).  
Moreover, fatty acids can reach the liver through their uptake from the circulation (132). 
This process has proven to be more complex than initially thought, and basically depends 
on the physical properties of fatty acids (133). Initially, it was presupposed that fatty acids 
would just diffuse through the cell membrane (134), although there is now strong 
evidence for protein-mediated transfer. Some of these proteins are part of the family of 
fatty acid transport proteins (FATPs) (135) and the scavenger receptor B3 (SCARB3 or 
CD36) (136). A recent study has established Cd36 as an LXR target gene (137), and 
proposed that, besides increased de novo lipogenesis, LXR activity was promoting 
increased fat levels in the liver through the upregulation of this receptor and its 
consequential rise in fatty acid uptake.  
Once in the cytosol, and due to their intrinsic hydrophobic nature, fatty acids will need to 
be transported between organelles by a set of proteins known as fatty acid binding 
protein (FABP). Out of this family, the most highly expressed isoform in the liver is L-
FABP (138). The relevance of this protein in the regulation of hepatic fat metabolism was 
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demonstrated in mice deficient for the L-Fabp gene, which showed to be protected from 
diet-induced obesity and hepatic steatosis (139,140).  
 
1.1.3.6. Glucose metabolism 
More recently, a line of research has arisen involving LXRs with glucose homeostasis. 
Activation of LXRs by their synthetic agonists induces a significant decrease in blood 
glucose in a rat model of Type 2 Diabetes, through the suppression of gluconeogenic 
genes in the liver (141), and improves glucose tolerance in a diet-induced obesity and 
insulin resistance model (142). Moreover, deletion of both isoforms of LXR (Lxrαβ-/- or 
double knock-out) shows resistance to diet-induced obesity and its consequent insulin-
resistance (143). Tissue-specific improvement of insulin resistance was further 
confirmed on a model of mouse obesity (ob/ob background) as well as a protective effect 
against fatty liver and hepatic steatosis (144).  
 
1.1.3.7. Inflammation and fibrosis 
A large amount of evidence has emerged showing that besides its role in lipid 
homeostasis, LXRs also function as transcriptional repressors of a specific cluster of 
inflammatory genes, antagonizing several pro-inflammatory stimuli in conjunction with 
other nuclear receptors (33). LXR function in immunity regulation has been demonstrated 
through many pathological contexts; as they are expressed in several immune cells, such 
as neutrophils and T-lymphocytes (77), although their role in macrophage biology has 
received a particularly large interest, due to their contribution to the development of 
atherosclerosis (145). Indeed, Lxra– /–Lxrb– /– mice, exhibit increased susceptibility to 
infection by Mycobacterium tuberculosis, an effect caused in part by dysregulation of Th1 
and Th17 responses in the lungs of these animals (146).  
Joseph et al. showed that LXR activation inhibits the expression of several inflammatory-
mediators, such as Cox-2 and Il-6, both in an in vitro and in vivo model of contact 
dermatitis (32). This same group later showed that certain types of inflammatory stimuli 
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are capable of repressing LXR target genes, such as Abca1 and Srebp-1c (147), 
establishing a crosstalk between inflammation and lipid metabolism in macrophages, 
mediated through LXR. 
Beyer and colleagues were the first ones to demonstrate LXR’s anti-fibrotic properties, 
through the use of T0901317, the potent synthetic LXR agonist, on several animal 
models of skin fibrosis (148). Intriguingly, the authors argued that the observed effect 
upon LXR activation was mediated by a reduced expression of interleukin (IL)-6 by 
macrophages, and not through a direct effect on fibroblasts. Indeed, a recent study 
looking at the regulation of LXRα by the microRNA (miR)-155, showed that increased 
lung fibroblast LXRα expression and activity in miR-155 knock-out mice correlated with 
exacerbated bleomycin-induced lung fibrosis (149). Moreover, they also demonstrated 
that human lung fibroblasts from patients with Idiopathic Pulmonary Fibrosis (IPF) have 
constitutively higher LXRα protein levels. Therefore, these contradicting studies suggest 
that LXR activity is probably tissue and context specific.  
With regard to liver disease, LXRs have demonstrated strong anti-inflammatory and anti-
fibrotic activities in several in vivo models. Certainly, treatment of hyperlipidemic mice 
with T0901317 reduced hepatic inflammation and caused reduction of diet-induced 
NASH in these animals (150). This was due to the receptor’s ability to repress the 
expression of several pro-inflammatory mediators. Moreover, mice lacking both Liver X 
Receptors display a higher fibrotic response in a model of chemical acute liver injury 
(151). Consequently, LXRs are emerging as important therapeutic targets for the 
management of liver inflammation and fibrosis. Intriguingly, a novel liver selective LXR 
inverse agonist (SR9238) was recently shown to suppress hepatic fatty acid synthesis 
and lipid accumulation while also inhibiting hepatic inflammation in a diet-induced obesity 
rodent model (152,153). Thus, the dichotomy in LXR function as a lipogenic agent on 
one hand, and a strong inhibitor of inflammation and fibrosis on the other must be further 
elucidated in order to establish how its modulation can be translated into a therapeutic 
target. 
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1.1.4. Post-translational modifications of LXR 
1.1.4.1. Acetylation 
Acetylation of lysine residues was initially identified in histones for their critical role in the 
control of gene expression (154). Enzymes that add or remove acetyl groups from 
proteins are named histone acetyltransferases (HATs) and HDACs, respectively. 
Approximately 85% of all eukaryotic non-histone proteins are acetylated (155). In 
mammals, there are 2 different families of HDACs. The classical HDAC family 
(comprising HDAC 1-10) and the sirtuin family of NAD+-dependent deacetylases, also 
known as Type III HDACs (155). HDACs can act as part of large multiprotein complexes. 
Removal of acetyl groups from lysines in LXRs by the SIRT1 deacetylase (at K432 in 
LXRα and K433 in LXRβ), promotes the receptor’s ubiquitination and subsequent 
degradation by the proteasome, while being a positive regulator of its transcriptional 
activation (156) (Table 1.3). Li et al. suggested that ligand-dependent deacetylation of 
LXR and consequent degradation leads to its clearance from gene promoters, which 
facilitates the next round of transcription and thus increases the expression of its target 
genes. Interestingly, this study also demonstrated that animals deficient in Sirt1 showed 
higher levels of LXRA protein and displayed impaired lipid metabolism and defective 
Reverse Cholesterol Transport. This was in part due to reduced Abca1 expression and 
subsequent decrease in HDL levels, as well as increased hepatic and testicular 
cholesterol levels (Table 1.3). This mechanism was further supported by a study in 
human skeletal muscle, where SIRT1 was shown to regulate the expression of the 
lipogenic LXR target gene Srebp1c (157). 
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Table 1.3. Summary of LXR post-translational modifications with known residues 
Residues are described based on whether they refer to the human (h) or murine (m) 
sequence of the receptor. 
Adapted from Becares et al., 2016 (158)  
 
 
1.1.4.2. O-GlcNacylation 
GlcNAcylation is the addition and removal of a single sugar modification, O-linked-β-N-
acetylglucosamine (O-GlcNAc), to the hydroxyl groups of serine and/or threonine 
residues of target proteins. The majority of this modification is found on intracellular 
proteins and around one-quarter of all identified O-GlcNAcylated proteins are involved in 
transcription or translation (159). GlcNAcylation is catalysed by uridine diphospho-N-
acetylglucosamine:polypeptide β-N-acetylglucosaminyltransferase (OGT) and removed 
by O-GlcNAcase in response to several energetic and nutritional stimuli, including 
glucose (160) and phosphatidylinositol (3,4,5)-trisphosphate (161), a mediator in the 
insulin signalling pathway. The activity of these enzymes is strictly regulated and several 
pathologies have been linked to aberrant GlcNAcylation including Alzheimer’s disease 
and insulin resistance (159). 
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Albeit controversial, a study claiming that glucose is capable of activating LXRs and act 
as their ligand at physiological concentrations raised new insights into how LXR activity 
may be directly regulated by other mechanisms besides ligand binding (53). This was 
followed by a study on human hepatic cells and an animal model of streptozotocin-
induced insulitis and diabetes in which it was reported that LXRs undergo O-
GlcNacylation in response to glucose in vitro or by refeeding in vivo (54). The authors 
propose that previously reported effects by glucose (53), a hydrophilic compound, were 
caused by its downstream signalling presumably through post-translational 
modifications, rather than the direct binding to the LXR highly hydrophobic ligand-binding 
domain. This study also argues that this modification affects the expression of the 
lipogenic transcription factor Srebp1c although the exact mechanisms through which O-
GlcNacylation regulates LXR activity need to be further elucidated.  
 
1.1.4.3. Phosphorylation 
Phosphorylation is defined as the covalent modification of phosphate groups to specific 
amino acids; the most common in eukaryotic cells being serine, threonine and tyrosine. 
Phosphorylation is catalysed by kinases, and removal of phosphate groups is performed 
by phosphatases. These processes regulate of almost every single basic cellular process 
(162).  
LXRα is phosphorylated at Serine198 (Ser198 or Ser196 in the human and murine 
sequence, respectively) both in vitro, and in vivo in atherosclerotic plaques of 
ApolipoproteinE-deficient mice (163–165). This modulates LXRα transcriptional activity 
in a gene-selective manner (see Table 1.3), and is enhanced by both endogenous (24S, 
25-epoxycholesterol) and synthetic (T0901317 and GW3965) LXR ligands (163,165). In 
a murine macrophage cell line stably expressing LXRα ligands for the RXR receptor, 
such as the 9-cis-retinoic acid (9cRA) and bexarotene inhibited Ser198 phosphorylation, 
leading to changes in LXR/RXR-regulated gene expression, particularly on genes 
sensitive to changes in LXRα phosphorylation at this residue, such as Ccl24 (163). The 
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Ser198 residue is located in the hinge region of LXRα, and was shown to be targeted by 
Casein Kinase 2 (CK2) (163). Peptide molecular modelling studies suggest Ser198 
phosphorylation affects LXRα conformation, possibly influencing the recruitment of 
cofactors such as NCoR (163,165). In their article, Pineda and colleagues have 
mentioned they didn’t observe changes in DNA binding by the non-phosphorylatable 
S198A mutant version of the receptor (163). Nonetheless, how changes in 
phosphorylation specifically at the S198 residue affects the receptor’s binding to DNA or 
nuclear localisation remains to be shown. Further evidence also supports these gene-
selective changes by LXRα phosphorylation. For instance, macrophage expression of 
CCR7 is markedly induced by LXRα when the receptor is not phosphorylated at Ser198 
(165). This is associated with decreased levels of chromatin repression marks 
(H3K9me3 and H3K27me3) at the Ccr7 locus in cells expressing the non-phosphorylated 
version of the receptor. 
Phosphorylation of LXRα by other kinases, including Protein Kinase A (PKA), has been 
reported at several residues (Ser195, Ser196, Thr290, Ser291) in rat primary 
hepatocytes and mouse liver, although detailed mutagenesis studies were not performed 
(166). PKA-mediated phosphorylation of LXRα leads to the repression of Srebp1c 
expression, a well-established LXR target gene, caused by decreased binding of the 
RXR/LXRα heterodimer to DNA, as well as reduced coactivator (steroid receptor 
coactivator-1 or SRC-1) and increased corepressor (NCoR) occupancy (Table 1.3).  The 
regulation of LXRα phosphorylation by cholesterol and oxysterols (163) prompted other 
studies investigating the effect of nutrient-regulated kinases. Oltipraz [4-methyl-5-(2-
pyrazynyl)-1,2-dithiole-3-thione] is a member of the dithiolethione family, a series of 
compounds naturally found in cruciferous vegetables with a broad range of therapeutic 
uses including chemoprevention (167) and liver fibrosis (168). Interestingly, oltipraz 
attenuates LXRα phosphorylation at an unspecified serine residue(s) in mouse liver 
through the inhibition of p70 ribosomal S6 kinase-1 (S6K1) (169), a major downstream 
effector of the mammalian target of rapamycin (mTOR) signalling pathway. This 
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decrease in LXRα serine phosphorylation leads to a reduction in Srebp1c target gene 
expression in culture. In addition, oltipraz administration to mice fed a high fat diet caused 
a decrease in hepatic fat content, pointing to oltipraz and the modulation of LXR 
phosphorylation as potential therapeutic targets for the treatment of fatty liver. 
Furthermore, a recent report examining the metabolic effects of metformin showed this 
compound induces LXRα phosphorylation (at a threonine residue) in rat pituitary cells. 
This in turn causes a reduction in the expression of its target gene Pomc, a precursor of 
the adrenocorticotropic hormone, leading to an overall reduction of systemic cortisol and 
glucose (170). In this context, LXRα threonine phosphorylation is shown to be induced 
by activated AMPK, which had been previously associated with the pleiotropic actions of 
metformin.  
 
1.1.4.4. Sumoylation 
SUMOylation is the covalent binding or conjugation of members of the small-ubiquitin 
modifier (SUMO) family to proteins. In mammals, the SUMO family consists of three 
members: SUMO-1, SUMO-2 and SUMO-3 (171). SUMOylation is reversible, and uses 
a specific set of enzymes for processing and attachment - such as the E1 SUMO-
activating enzyme subunits 1/2 or members of the E3 ligases Protein Inhibitor of 
Activated STAT (PIAS) family (172) - and removal, known as SUMO peptidases.  
As the mechanistic basis for the transcriptional repression of pro-inflammatory genes, 
Ghisletti et al. initially demonstrated that ligand-induced SUMOylation of LXR is required 
for its interaction with the NCoR corepressor in mouse primary macrophages and 
RAW264.7 macrophage-like cells (see Table 1.3) (173). In addition to synthetic ligands, 
these authors demonstrated sumoylation was promoted by the LXR endogenous ligands 
22(R)-hydroxycholesterol, 24(S),25-epoxycholesterol, and 24S-hydroxycholesterol. In 
contrast to PPARγ, whose sumoylation is dependent on PIAS1 and SUMO 1 (174), LXR-
mediated transrepression involves SUMOylation by SUMO2 and SUMO3, with HDAC4 
acting as the SUMO E3 ubiquitin ligase. It was later shown that the interaction between 
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SUMOylated-LXR and NCoR was facilitated by Coronin 2A, a member of the actin-
binding protein family that acts both as a docking site for LXR and an exchange factor 
for NCoR, proving necessary for the derepression of several Nuclear Factor- kappa B 
(NF-κB) induced pro-inflammatory gene promoters (175). Moreover, a later study 
showed that mutant forms of both LXRs lacking SUMO acceptor sites (LXRα 
K328R/K434R and LXRβ K410R/K448R) have a decreased capacity to prevent the 
binding of the pro-inflammatory Signal Transducer and Activator of Transcription 1 
(STAT1) transcription factor to the Nos2 promoter (176) (Table 1.3), further establishing 
the importance of LXR SUMOylation on its transrepressive capacity. However, this 
transrepression model has now been challenged. Ito and colleagues recently postulated 
that repression of inflammatory genes by LXRs is dependent on changes in cellular lipid 
metabolism rather than SUMOylation of the receptor (177). In their report, the authors 
propose a mechanism whereby LXR-dependent expression of the ATP-Binding Cassette 
transporter A1 (ABCA1), which mediates intracellular cholesterol efflux to Apolipoprotein 
A1, is critical for the repression of pro-inflammatory genes by LXR. Increased ABCA1 
expression leads to a decrease in membrane cholesterol levels as a result of a higher 
rate of cholesterol efflux by ABCA1, thus increasing membrane permeability and 
disrupting Toll-like Receptor (TLR) signalling due to the inability of TLRs to recruit its 
signal transducers. This study demonstrates that LXRs are capable of strong repressive 
actions even in the absence of SUMOylation in immortalised mouse embryonic 
fibroblasts in vitro, suggesting that nuclear receptor activity is regulated by different 
independent pathways. It would be interesting to assess if this SUMOylation-
independent transrepression mechanism also occurs in other cell types and under 
physiological conditions. Thus, depending on the cell type and disease context, these 
two models may not be mutually exclusive. In any case, it still remains unclear what the 
consequences are of altering LXR SUMOylation on inflammatory diseases or other 
patho-physiological contexts. 
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1.2. Non-Alcoholic Fatty Liver Disease    
1.2.1. Definition and epidemiology 
Non Alcoholic Fatty Liver Disease (NAFLD) is a condition that represents a wide 
spectrum of liver diseases, ranging from simple fatty liver (steatosis), through steatosis 
accompanied by inflammation with or without fibrosis (steatohepatitis or NASH) that can 
progress to necrosis, cirrhosis and hepatocellular carcinoma (178,179). NAFLD is 
currently defined as the accumulation of fat in hepatocytes that surpasses 5% of total 
liver weight (180); with an alcohol consumption well below the threshold of other alcohol-
related diseases and no presence of any chronic viral hepatitis (181,182) or other 
competing hepatic aetiologies such as steatosis-inducing drugs (183). Even though fatty 
liver was initially considered to be relatively benign and NASH was seen as the 
pathogenic extreme of the spectrum, recent studies have established steatosis not only 
as the consequence but also as a risk factor for metabolic diseases such as insulin 
resistance and cardiovascular disease (184,185). These results have thus prompted the 
medical and scientific communities to regard the early stages of NAFLD as less benign 
than previously thought. 
NAFLD risk factors include obesity (186,187), dyslipidaemia (188) and Type 2 Diabetes 
(189,190), which has placed NAFLD to be considered as the hepatic manifestation of 
the metabolic syndrome (191,192). For this reason, the prevalence of NAFLD worldwide, 
but especially in Western countries, has suffered a rapid and dramatic increase. In a 
recent article, Younossi et al. performed a meta-analysis of over 100 different individual 
studies reaching all continents, and established that NAFLD has a prevalence of around 
25% of adults, when diagnosed by imaging (193). This prevalence varies within the 
different regions in the world, with a higher presence in the Middle East and South 
America (193). Moreover, out of all the patients diagnosed with NAFLD by biopsy, NASH 
was present in 59.10% of them, with a progression rate to fibrosis of 9% (193). NAFLD 
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is also more prevalent in males, and its occurrence has been shown to increase with age 
(193,194).  
Although liver disease is only the third cause of death amongst NAFLD patients (195), it 
is still in the trajectory of becoming the most common cause for liver transplantation by 
2030 (196,197). In addition, the contribution of NAFLD to its associated conditions, i.e. 
cardiovascular disease and Type 2 Diabetes, provokes NAFLD patients to have an 
overall higher mortality than the general population (198).  Furthermore, individuals with 
established NASH are at great risk of progressing into liver cancer, increasing their risk 
of liver-related death (199). 
 
1.2.2. Diagnosis 
The gold-standard for NAFLD diagnosis is still the liver biopsy (200), even though one of  
the main disadvantages of this procedure is its high sampling variability. Hence, in order 
to maintain some consistency and reproducibility, especially during clinical trials, a 
standardised score was created by a group of experts known as the NALFD activity score 
(NAS) (201). This grading ranges from 0 to 8, where a NAS ≥ 5 is considered a definitive 
NASH diagnosis; and is based on a sum of different scores regarding steatosis (0-3), 
lobular inflammation (0-3) and hepatocyte ballooning (0-2) (201). Even though fibrosis 
was initially included in the NAS score, it was later removed from the overall grading as 
it is less reversible than the other parameters, and thus may not truly reflect changes 
upon a therapeutic intervention. For this reason, other grading systems such as the 
“Brunt’s fibrosis score” (202), are more commonly used in clinical practice, since they 
are considered to be better predictors of disease progression (185).  
Nonetheless, the highly invasive and costly nature of liver biopsies has urged in the 
recent years for the use of new methodologies, such as radiologic imaging techniques 
like ultrasound and magnetic resonance imaging (MRI) (203). Furthermore, whenever 
diagnosis by image is not possible, serum biomarkers such as Tumour necrosis factor 
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alpha (TNF-α) and Adiponectin (204,205) can also be used as diagnostic tools. Although 
these less-invasive techniques have proven to be highly successful at diagnosing 
steatosis, the presence and location of several key NASH features such as inflammation, 
hepatocyte ballooning and fibrosis still requires histological assessment of a liver biopsy 
(200).   
 
1.2.3. Pathogenesis 
The pathogenesis behind NAFLD is not yet fully understood, although we know that the 
mechanisms behind its onset and progression are multifactorial. Initially, the progression 
from  steatosis to NASH had been explained by the “two-hit hypothesis” (206). This 
considered steatosis or hepatic fat accumulation to act as a “first hit”, increasing the 
susceptibility to liver damage caused by a “second hit”, eventually leading to 
inflammation and/or fibrosis.  This second stressor-category comprised of a variety of 
factors such as oxidative stress (207) or adipose-tissue secreted adipokines (208). 
However, more recent studies have relegated this hypothesis as oversimplifying and it 
is now believed that, in fact, it is the presence of a myriad of different factors acting 
synergistically that is behind NAFLD pathogenesis; including but not restricted to, insulin 
resistance, oxidative stress and an inflammatory cascade (209).  
 
1.2.3.1. Steatosis and lipotoxicity 
Several mechanisms can lead to accumulation of fat in the liver (210) (Figure 1.3). Firstly, 
this fat can come from external sources as a consequence of excessive dietary energy 
intake, particularly from diets high in saturated fats and carbohydrates (211), like the so-
called “Western diet” (212).  Second, expansion and inflammation of the adipose tissue 
leads to increased lipolysis and higher levels of circulating fatty acids, which will then be 
taken up by the liver. Under normal physiological conditions, the role of the white adipose 
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tissue (WAT) is to provide lipid energy to other tissues in the form of Non-Esterified Fatty 
Acids (NEFAs), which are released as a result of triglyceride hydrolysis by lipases (213). 
 
Figure 1.3. Possible sources of hepatic fatty acids and triglycerides contributing 
to NAFLD pathogenesis 
 
 
Then, when this high-energy demand is over, WAT lipolysis is suppressed by numerous 
hormones, such as catecholamine and insulin (213). However, in obese individuals with 
type 2 diabetes, the adipose tissue undergoes an increase in mass and is subjected to 
a pro-inflammatory environment, leading to insulin resistance and a consequential rise 
in the flux of NEFAs to the liver (210,214).    
As causes with a hepatic origin, deficiency in fatty acid oxidation and/or increased DNL 
programmes can also lead to a heightened hepatic fat content (see section 1.1.3.1). 
Hepatic fat originating from DNL plays a very important role in the pathogenesis of 
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NAFLD (215), and it can account for a quarter of all triglyceride levels (210). This increase 
in the lipogenic programme usually arises from hepatic insulin resistance (189,216), 
even though it remains unknown if insulin resistance is either a cause or a consequence 
of hepatic steatosis. 
The balance in triglyceride levels under steady-state is controlled, in part, by a 
mechanism known as fatty acid oxidation. This process is needed for the generation of 
adenosine triphosphate (ATP) and ketone bodies, which will be used for extrahepatic 
organs for energy whenever glucose levels are low (217). Under normal nutritional states, 
the preferred source of energy in the body is glucose. However, during prolonged 
starvation, glycogen gets quickly depleted and metabolic energy needs to be derived 
from fats (217). Fatty acid β-oxidation occurs in the mitochondria and peroxisomes, 
where mitochondrial β-oxidation is the dominant oxidative pathway for the disposal of 
fatty acids under normal physiologic conditions (217). Mitochondrial abnormalities are 
highly common in patients with both fatty liver and NASH (218–220), which demonstrates 
that defective fatty acid β-oxidation plays an important role in the pathogenesis of NAFLD. 
Lastly, impaired VLDL secretion can also exacerbate hepatic fat accumulation. VLDL is 
a triglyceride-rich lipoprotein, covered by hydrophilic phospholipids and apolipoprotein B 
(apoB) 100, and is secreted by the liver in order to transport this fat to peripheral tissues. 
The rate of VLDL secretion depends not only on the levels of intrahepatic triglycerides, 
but also on VLDL assembly (221). Thus, deficiencies in VLDL assembly and/or secretion 
will lead to increased intrahepatic triglycerides (222,223).  
As mentioned above, it is now recognised that the progression from fatty liver to NASH 
is probably due to a combination of several factors, in conjunction with the overall cellular 
injury caused by high levels of hepatic lipids, also known as lipotoxicity. Besides 
triglycerides, many other lipid metabolites like NEFAs, phospholipids and cholesterol 
may also build up; and it is now actually considered that triglyceride accumulation may 
be in fact acting as an adaptive protective mechanism by mitigating the excess of NEFAs 
(224).  
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High levels of neutral lipids will assemble in cytosolic lipid droplets (LDs), a 
heterogeneous set of structures formed by a lipidic core surrounded by a monolayer of 
phospholipids (225). Thus, the presence of very large LDs is considered the histological 
landmark of steatosis. These droplets contain a variable mixture of proteins, including 
peripilins, whose presence and function has been shown to be also involved in the 
pathogenesis of NAFLD (226). 
 
1.2.3.2. Apoptosis 
Apoptosis, or programmed cell death, can develop in response to fat accumulation 
(lipoapoptosis), and is now considered to be one of the key pathogenic mechanism 
behind liver disease (227,228). Hepatocyte apoptosis can occur via a variety of 
mechanisms: both extrinsic, known as receptor-mediated apoptosis, which is facilitated, 
for example, by the FAS and TNF-related apoptosis-inducing ligand (TRAIL) receptors 
(227,229,230); as well as intrinsic, activated by intracellular stress, such as lysosomal 
permeabilization or endoplasmic reticulum (ER) stress (230–232). Regardless of the 
activating source, apoptotic signalling cascades lead to mitochondrial permeabilization 
and activation of the downstream effector caspases 3, 6 and 7 (233), a set of cysteine 
proteases whose action is to promote the ordered disassembly of the cell. 
In the context of NAFLD, several experimental models have shown that hepatocyte 
apoptosis is profibrogenic (234,235). For instance, engulfment of apoptotic bodies by 
Hepatic Stellate Cells (HSCs), leads to their activation and subsequent increase in their 
fibrogenic activity (234). Indeed, sustained hepatocyte death is linked to the development 
of fibrosis in most types of liver disease, such as alcoholic liver disease (236) and viral 
hepatitis (237). 
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1.2.3.3. Oxidative stress 
Oxidative stress results from the imbalance between the production of Reactive Oxygen 
Species (ROS) and the presence of antioxidant defences. Characteristic NAFLD 
features, such as heightened mitochondrial β-oxidation or increased hepatic Cyp2E1 
expression can lead to oxidative stress (219,238,239). High levels of ROS induce the 
oxidative degradation of lipids, also known as lipid peroxidation; as well as oxidative 
damage to DNA (240). Both of these markers of oxidative stress are found in 
NAFLD/NASH patients (241–243), even though the specific relation between oxidative 
stress and disease progression hasn’t been fully understood yet. 
 
1.2.3.4. Endoplasmic reticulum stress 
The ER is an intracellular organelle responsible for performing essential functions, such 
as protein folding and post-translational modifications (244). Therefore, any disturbances 
in normal cell physiology will cause an accumulation of unfolded proteins in the ER lumen, 
triggering an evolutionary-conserved stress response, known as the unfolded protein 
response (UPR) (244). The UPR is an adaptive mechanism that allows for the cells to 
survive upon changes in its physiology and is particularly important in cells with a high 
secretory nature, such as hepatocytes. This adaptive mechanism involves the induction 
of a transcriptional programme designed to increase the folding capacity of the ER and 
reduce the entry of proteins to it. In mammals, the UPR is sensed by three integral 
proteins: protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme-1 (IRE1), 
and activating transcription factor-6 (ATF6) (245). Hence, their downstream mediators 
are used as markers of ER stress. Upon activation, PERK phosphorylates eukaryotic 
translation initiation factor-2α (eIF2α), which leads to the expression of activating 
transcription factor-4 and 3 (ATF-4 and ATF-3), transcription of C/EBP-homologous 
protein (CHOP) and activation of NF-κB, and growth arrest and DNA damage 34 
(GADD34) (246,247), with the aim to decrease overall protein translation. In parallel, 
IRE1 promotes the splicing of X-box-binding protein-1 (XBP1) mRNA in order to permit 
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the synthesis of this transcription factor (248), and the subsequent transcription of 
several genes involved in restoring homoeostasis and prevent cellular toxicity (249). 
Lastly, ATF6 collaborates with IRE1, where ATF6 induces transcription to increase XBP-
1 mRNA (248). 
The signalling pathways activated by ER stress have been linked to several other key 
NAFLD pathogenic pathways, such as lipotoxicity and inflammation. Thus, the link 
between ER stress and hepatic damage has been studied extensively in the recent years, 
especially in animal models of the disease (250,251).  Yet, a study looking at UPR 
markers in the livers of patients with NAFLD and NASH couldn’t establish a distinctive 
pattern that correlated with disease progression (252), which further points to NAFLD 
being a mechanistically heterogenous disease, where progression to NASH may be 
caused by different mechanisms in different people. 
  
1.2.3.5. Cholesterol 
In order to better understand the role that neutral lipids are having on NAFLD 
pathogenesis, recent studies have assessed the effects of free cholesterol on liver 
damage. Lipidomic analysis on livers and plasma of NAFLD patients showed that free 
cholesterol, but not cholesteryl esters, is increased in these patients (253,254). Moreover, 
in vitro and dietary animal models have established that free cholesterol sensitizes the 
liver to steatohepatitis (255,256). These and other studies provide the foundation that 
cholesterol metabolism is also involved in NAFLD pathogenesis, but the specific 
mechanisms linking this lipid with NAFLD pathogenesis still need to be further elucidated. 
 
1.2.3.6. Inflammation 
Stressed hepatocytes release a set of proinflammatory signals, also known as metabolic 
danger signals or DAMPs, that activate both Kupffer cells (KCs) and hepatic stellate cells 
(HSCs), triggering an inflammatory response known as “sterile inflammation” (since it is 
not caused by an infection); which, if prolonged, will result in an abnormal wound-healing 
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response leading to fibrosis (257). Interestingly, it is now recognised that DAMPs are 
able to activate many pattern recognition receptors, of which Toll-like receptors (TLRs) 
are the most well-known, and thus trigger the same downstream signalling cascades as 
in infectious inflammatory responses (258,259). Moreover, high levels of 
lipopolysaccharides and other microbial compounds that reach the liver due to gut 
bacterial translocation, can also contribute to the pro-inflammatory hepatic milieu 
(260,261).   
Acute inflammation in the liver is characterized by the production of cytokines and 
chemokines: i.e. chemokine (C-X-C motif) ligand 1 (CXCL1), IL-1β and TNF-α (262–
264); as well as platelet activation and leukocyte recruitment (265,266), including 
neutrophils and monocytes; and activation and expansion of resident cells, such as 
HSCs and dendritic cells (267).  For example, liver injury leads to the production of 
monocyte chemoattractants, like monocyte chemoattractant protein 1 (MCP-1 or CCL2) 
by hepatocytes and activated KCs (268), which in turn will lead to monocyte infiltration 
(269), that will differentiate and contribute to the pool of hepatic macrophages. Indeed, 
some lines of evidence point to the capacity of infiltrating monocytes to differentiate into 
macrophages and replenish fully differentiated KCs (270,271). Nonetheless, whether or 
not monocyte-derived macrophages ultimately replenish KCs is still a controversial 
question.  
 
1.2.3.7. Fibrosis 
Liver fibrosis and its end-stage manifestation cirrhosis, are characterised by the 
accumulation of extracellular matrix (ECM), predominantly formed by type I and type III 
collagens, and occur as the result of a sustained wound healing response to a chronic 
inflammatory stimulus (272). This accumulation of scar tissue will eventually lead to 
architectural changes and hepatic stiffness, causing portal hypertension and hepatocyte 
dysfunction (273).  
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HSCs are the main executors of hepatic fibrogenesis, after becoming activated and 
gaining a myofibroblast-like phenotype in response to a wide range of signals (i.e. 
Transforming growth factor beta or TGF-β), and through interaction with many different 
cell types, such as KCs (273–276). Moreover, once activated, their fibrotic phenotype, 
survival and proliferative capacities get perpetuated by several positive feed-back loops 
(277), which amplifies their fibrotic effects. Also, activated HSCs can acquire pro-
inflammatory and immune properties, where not only they secrete several cytokines and 
chemokines that will in turn expand the overall hepatic inflammatory milieu (278), but can 
also phagocytise and act as antigen presenting cells (279). Nonetheless, it must be noted 
that besides HSCs, ECM production in the liver can also originate from other sources, 
such as activated portal fibroblasts (280,281).  
Surprisingly, recent clinical evidence and studies performed on animal models seem to 
demonstrate that if the inflammatory signal that was driving the fibrotic response is 
extinguished, early to moderate fibrosis can regress (282,283), even though it still 
remains controversial if the regressed liver is able to reach the same point as it was “pre-
fibrosis”. This regression is thought to be mediated by active ECM degradation by matrix 
metalloproteinases (MMPs) (284,285), and the disappearance of activated 
myofibroblasts by apoptosis/senescence (286,287) or rapid killing by NK cells (288). 
 
1.2.3.8. Genetic modifiers of NAFLD 
Similar to other complex metabolic diseases (i.e. type 2 diabetes), NAFLD has a 
considerable heritable component (289). To better characterise this, genome wide 
association studies (GWAS) are employed to identify genetic susceptibility to a specific 
disease, in large populations and in an unbiased manner. In the case of NAFLD, several 
variants have been identified (289), but only a small number of these have been 
characterised in depth. A very well-validated variant, the rs738409 (Ile148Met) single 
nucleotide polymorphism (SNP) in the patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) gene, was first identified by Romeo and colleagues, in a GWA study 
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on  patients with and without established NAFLD from various ethnic groups (290). Later 
studies corroborated this variant as a strong modifier of NAFLD severity, as it highly 
associates with presence of steatosis and advanced fibrosis (291,292). Furthermore, a 
second modifier, the human transmembrane 6 superfamily member 2 (TM6SF2) variant 
encoding p.Glu167Lys, has also been established to contribute to NAFLD susceptibility 
by reducing VLDL secretion (293,294). 
 
1.2.4. Treatment 
Successful NAFLD treatments should aim at halting its comorbidities, but also reducing 
its progression to more advanced forms of the disease.  
Since assessment of histological lesions are still the only reliable method to distinguish 
between fatty liver and NASH, there are currently only a limited number of randomised 
clinical trials where disease improvement or regression is considered as an endpoint 
(200). Moreover, competing risk from other related diseases tend to be prioritised. For 
example, a recent clinical trial assessing the efficacy of the potent FXR activator 
obeticholic acid (OCA) for the treatment of steatohepatitis was interrupted, partly due to 
induced lipid abnormalities in OCA-treated patients, including increased circulating total 
cholesterol and LDL with decreased HDL (295).  For this and other reasons, such as the 
complex and multifactorial nature of the disease, as of 2016 there are still no approved 
drugs for the direct treatment of NAFLD (296). In addition, there are still no good available 
markers that allow for the early identification of those patients with the highest risk of 
progression to steatohepatitis.   
Therefore, most therapeutic efforts so far have focused on tackling other components of 
the metabolic syndrome (297). For example, lifestyle changes, such as exercise and diet 
restrictions, are commonly used in clinical practice (200). Moreover, significant weight 
loss as a result of bariatric surgery has shown to have a big impact on histological 
improvement (282,283). In regard to pharmacological therapies, the use of insulin 
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sensitizers such as pioglitazone, a selective  peroxisome proliferator-activated receptor 
γ (PPAR-γ) agonist, have demonstrated to have a strong association with significant 
reduction in steatosis, inflammation, and hepatocellular ballooning, as assessed by liver 
biopsy in a recent randomized, placebo-controlled, double-blind clinical trial (298). 
 
 
 
1.3. Project Hypothesis 
Changes in the phosphorylation status of LXRα at Ser196 specifically regulate its activity 
in vivo and have an impact on hepatic lipid metabolism and early signs of fibrosis in 
response to a high-fat high-cholesterol diet. 
 
1.4. Aims 
 Examine the impact of LXRα phosphorylation on modulation of hepatic lipid 
metabolism and inflammation in vivo on the newly generated S196A animals, using 
a dietary model of NAFLD. 
 Determine which are the molecular mechanisms underlying the effects of LXRα 
phosphorylation on target gene expression, by assessing changes in DNA and 
cofactor binding. 
 Study new stimulants that are capable of inducing LXRα phosphorylation in vitro, 
and the effects that pharmacological impairment of this modification have on the 
receptor’s activity. 
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Chapter 2. Materials and methods 
2.1. Generation of the S196A transgenic animal model  
The S196A floxed (S196Afl/fl) mouse line was generated by Ozgene Pty Ltd (Bentley WA, 
Australia). The genomic sequence for the murine LXRα (Nr1h3) gene was obtained from 
the Ensembl Mouse Genome Server (http://www.ensembl.org/Mus_musculus/), 
Ensembl gene ID: ENSMUSG00000002108. The mutant fragment, located on Exon 5, 
contains a serine-to-alanine mutation at Ser196 introduced by site-directed mutagenesis 
(Figure 2.1. A). The point-mutant exon was delivered into an intronic site inside the 
targeting vector, placed in opposite orientation and thus without coding capacity (Figure 
2.1. B). The targeting construct was electroporated into the Bruce4 C57BL/6 ES cell line. 
Homologous recombinant ES cell clones were identified by Southern hybridization and 
injected into BALB/cJ blastocysts. Male chimeric mice were obtained and crossed to 
C57BL/6J females to establish heterozygous germline offsprings on a pure C57BL/6 
background. The germline mice were crossed to a flipase (FLP) recombinase mouse line 
to remove the FLP recombinase target (FRT)-flanked selectable marker cassette (Flp’d 
mice) (299), which were used as wild-type (WT) controls throughout this study (Figure 
2.1. B). Flp’d mice were crossed with a transgenic C57BL/6 mouse strain carrying a Cre 
recombinase under the PGK-1 promoter (300), resulting in the inversion and insertion of 
the lox-flanked mutated (loxP) vector exon 5 region in the sense orientation, and deletion 
of the wild-type (WT) sequence in most adult cell lineages (S196A mice) while WT 
controls carry the WT sequence in the sense orientation (Figure 2.1. B) (301). The germ-
line expression of the Cre-recombinase causes the lox sites to be recombined 
permanently and the targeted allele becomes a constitutive knock-in of the mutant exon. 
Therefore, presence of the PGK-1 Cre is no longer necessary on following progeny. 
The offspring of S196A mice had no apparent dysmorphic phenotypes and their 
development growth was similar to wild-type C57BL/6 mice (Table 2.1) (302,303). 
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Figure 2.1. Strategy for the generation of the S196A mouse line using a Cre/loxP 
system.  
A) Scheme showing the single-point mutation (red nucleotide) introduced in the LXRα 
exon 5 sequence and its translation into a serine to alanine change on the Ser196 
residue. 
B) Targeting construct containing the loxP and FRT sites, the predicted homologous 
recombinant alleles when crossed with FLP Recombinase, and the LXR knock-in locus 
after PGK-1 Cre-mediated recombination, thus incorporating the mutated vector in most 
adult cell lineages (S196A). 
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Weeks after 
weaning 0 1 2 3 4 
WT  
(g) 
18.64  
± 0.78 
18.75  
± 0.91 
19.17 
 ± 0.84 
18.93 
± 1.61  
22.67  
± 0.84  
S196A 
(g) 
18.36 
 ± 0.95 
18.99 
 ± 1.20 
19.77  
± 1.42 
19.96 
 ± 1.37 
21.83 
 ± 0.88 
T-test 0.71 0.57 0.55 0.43 0.27 
 
Table 2.1. WT and S196A mice developmental weight 
Data represents means (n=4) ± standard deviation. Significance (p-value) was 
determined by Student’s T-test. 
 
 
2.1.2. Genetic identification of S196A mice 
Recently-weaned pups were genotyped by polymerase chain reaction (PCR) analysis of 
genomic DNA extracted from ear-clipped samples. Genotyping of S196A mice was 
performed by amplifying a specific sequence downstream of the inserted S196A vector, 
which contains a small fragment of 34 nucleotides (Figure 2.2). This region is part of the 
remaining loxP flanking sequence, as a consequence of the lox-Cre insertion of the 
vector (S196A) leading to a product size of 656 base pairs (bp) (Figure 2.2). However, 
this sequence is not found if the vector hasn’t been inserted (WT). Therefore, 
amplification product of WT sequences will be 622 bp (Figure 2.2). 
DNA was extracted by incubating ear biopsies with 200 µl of 50 mM NaOH (pH = 12) at 
95ºC for 10 min. Reaction was then neutralised by placing tubes on ice and adding 20 µl 
Tris-HCl 1M (pH = 8). Tubes were centrifuged at 13000 revolutions per minute (rpm) for 
5 min 4ºC to get rid of debris and supernatant was transferred onto a clean tube. PCR 
amplification was performed using the Jumpstart Taq DNA Polymerase (Sigma Aldrich) 
and the following primers: wild-type (WT) forward 5’GGTGTCCCCAAGGGTGTCCT, 
reverse 5’ AAGCATGACCTGCACACAAG and mutant forward 5’ 
GGTGTCCCCAAGGGTGTCCG (Figure 2.2). 
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Figure 2.2. Genetic identification of S196A mice 
Genotyping strategy with amplified sites and product size (Left). Gel electrophoresis of 
DNA amplified products using the corresponding primers (Right). 
 
 
 
 
For a single reaction, the following reagents and DNA were added to a 0.5 ml microtube:  
 
Amount Reagent 
Final 
Concentration 
24.3 µL Water - 
3 µL 10x PCR Buffer (with MgCl2) 1x (2 mM MgCl2) 
0.6 µL 10 mM dNTPs 200 µM 
0.3 µL 10 mM Primers  1 µM 
0.5 µL Taq DNA Polymerase 0.083 units/µL 
1 µL Template DNA  n/a 
30 µL Total reaction volume 
 
Amplification was undertaken by 35 cycles of 30 seconds of annealing at 60 °C, and 1 
minute of extension at 72°C. Samples were run on a 2% high resolution agarose gel 
(Sigma Aldrich) in a 1X 40 mM Tris, 20 mM acetic acid, 1mM ethylenediaminetetraacetic 
acid (EDTA) (TAE) buffer with 1X SYBR safe DNA gel stain (Invitrogen) for 120 minutes 
at 80 volts (V).  
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2.2. Animal procedures 
2.2.1. Housing and diet studies 
Mice were maintained in a pathogen-free animal facility in a 12-hour light-dark cycle and 
were housed in the same cages whenever possible. All procedures were carried under 
the UK’s Home Office Animals (Scientific Procedures) Act 1986.    
Ten-week old WT and S196A female mice were fed ad libitum a High Fat-High 
Cholesterol (HFHC) diet (17,2% Cocoa Butter, 2,8% Soybean Oil, 1,25% Cholesterol, 
0,5% Sodium Cholate; AIN-76A/Clinton Diet #4, Test Diet Limited, UK) or a chow diet 
(18% Protein, 6.2% Fat, 0% Cholesterol; Harlan Laboratories).  
 
2.2.2. Plasma and tissue collection 
Mice were fasted overnight prior to blood collection or terminal sacrifice. Animals were 
euthanized using increasing concentrations of CO2 and death was confirmed by cervical 
dislocation or by cardiac bleeding. 
In vivo blood sampling (corresponding to 4 weeks-readings) was collected by bleeding 
of the lateral saphenous vein. Saphenous vein blood collection was performed by Dr. 
Matthew C. Gage (University College London, UK). For terminal bleedings (chow and 6 
weeks), blood was collected from euthanized mice by cardiac puncture by exposing the 
rib cage and slowly drawing blood from the ventricle. Blood was transferred into an 
EDTA-containing microtube (Microvette CB 300, Sarstedt), centrifuged (3000 x g, 6 min. 
at room temperature) and plasma was aliquoted and frozen at -80°C. 
Tissues were dissected post-mortem, weighted and snap frozen by being placed in liquid 
nitrogen for lipid and protein analysis. For RNA analysis tissues were placed in RNAlater 
(Sigma Aldrich) for 24 hours at room temperature and then stored at -80°C.    
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2.2.3. Plasma and hepatic quantifications 
2.2.3.1. Hepatic lipid extraction 
For each lipid, 50 mg of frozen livers were homogenated in homogenation buffer (250 
mM sucrose, 2 mM EDTA, 10 mM Tris) using ceramic beads in a Minilys Tissue 
Homogenizer. For triglyceride extraction, 200 μl of liver homogenates were mixed with 5 
ml of isopropyl alcohol (VWR); and for total cholesterol, 150 μl of homogenates were 
mixed with 5 ml of a Chloroform:Methanol (1:1) solution (VWR). Tubes were left to 
incubate for 10 minutes at room temperature whilst shaking, and were then centrifuged 
(3000 x g, 10 min, room temperature). Supernatants were transferred onto a fresh tube, 
and for cholesterol determination were allowed to evaporate to dryness by placing the 
open tube at 65ºC. Dried cholesterol remnants were then resuspended with 200 μl of 
isopranol + 10% Triton-100X solution (Fisher Bioreagents).  
Non-Esterified Free Fatty Acids (NEFAs) were extracted by incubating 200 μl of liver 
homogenates with a 1% Triton-100X and chloroform solution. Mixture was left in ice for 
30 minutes with periodical mixing, and then spun down (13,000 x g, 10 min, 4ºC). The 
lower organic phase was collected and allowed to air-dry at 50ºC for approximately an 
hour. Dried pellet was resuspended in 200 μl of the Fatty Acid Assay Buffer (Abcam). 
 
2.2.3.2. Total cholesterol, triglycerides and NEFAs quantification 
Plasma and hepatic total cholesterol and triglyceride levels (Wako Chemicals), as well 
as NEFAs (Abcam), were determined by colorimetric enzymatic assay kits as per the 
manufacturer’s recommendations, by measuring absorbance of reaction products at 595 
nm in a TriStar² LB 942 Multidetection Microplate Reader (Berthold Technologies).  
Hepatic lipid content was normalized to total protein concentration, which was quantified 
using the Coomassie (Bradford) Protein Assay (Sigma). This normalisation strategy was 
used due to differences in liver weight between WT and S196A mice. As the degree of 
fibrosis in mice upon a HFHC diet was mild, no differences were found between both 
groups in the protein content in liver lysates.  
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For this end, 2 μl of liver homogenates in homogenization buffer were added to 8 μl of 
water (1/5 dilution) and incubated with 200 μl of Bradford Reagent for 30 minutes at room 
temperature. Absorbance was measured at 595 nm in a TriStar² LB 942 Multidetection 
Microplate Reader. 
 
2.2.3.3. HDL and LDL/VLDL 
Plasma cholesterol concentrations in the HDL and LDL/VLDL was measured using the 
EnzyChrom™ AF HDL and LDL/VLDL Assay Kit (BioAssay Systems). This kit contains 
a precipitation buffer that once mixed with plasma, causes HDL and LDL/VLDL are to 
separate, and cholesterol concentrations are determined using a single Working 
Reagent that combines cholesterol ester hydrolysis, oxidation and colour reaction in one 
step. The colour intensity of the reaction product was quantified at 570nm in a TriStar² 
LB 942 Multidetection Microplate Reader and cholesterol levels were calculated 
proportional to a standard of 300 mg/dL cholesterol.  
 
2.2.3.4. Glucose and insulin  
Blood glucose measurements (Accu-Chek, Roche Diagnostics) were taken from tail 
blood samples after overnight fasting.  
Plasma insulin concentration was measured using a rat/mouse Insulin Enzyme-Linked 
ImmunoSorbent Assay (ELISA) kit (Millipore), which contained a 96-well plate pre-
coated with a pre-titered amount of a monoclonal mouse anti-rat insulin antibodies. Once 
insulin from plasma samples was captured to the plate, it was detected with binding of 
biotinylated polyclonal antibodies to the insulin, and subsequential binding of horseradish 
peroxidase to the immobilized biotinylated antibodies. After several washes, 
quantification of immobilized antibody-enzyme conjugates was performed by monitoring 
horseradish peroxidase activities in the presence of the substrate 3,3’,5,5’-
tetramethylbenzidine; which was measured spectrophotometrically by the increased 
absorbency at 450 nm, corrected from the absorbency at 590 nm on a TriStar² LB 942 
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Multidetection Microplate Reader (Berthold Technologies). Amount of captured insulin 
was derived by interpolation from a reference curve generated in the same assay with 
reference standards of known concentrations of rat insulin (Millipore).  
 
2.2.3.5. Bile acids 
50 mg of frozen livers were homogenized in 1 ml of 75% ethyl alcohol (VWR) using a 
Dounce homogeniser and homogenates were incubated at 50ºC for 2 hours. Tubes were 
then centrifuged for 10 min. at 6000 x g, 4ºC and supernatant was transferred onto a 
clean tube. 20 μl of liver supernatants or mouse plasma were mixed with 150 μl of 
Reagent CC3 from the Mouse Total Bile Acids kit (Crystal Chem.) in a 96-well plate and 
incubated at 37ºC for 5 minutes. After this, absorbance at 540 nm (A1) was measured in 
a TriStar² LB 942 Multidetection Microplate Reader. Then, 30 μl of Reagent CC2 from 
Mouse Total Bile Acids kit (Crystal Chem.) was added to each well and mixed 
immediately, followed by another absorbance reading at 540 nm (A2). A well containing 
20 μl of 75% ethyl alcohol was used as blank, and 20 μl of a sample with a known 
concentration (35 μM) of bile acids was used as a calibrator. Total bile acid concentration 
was calculated as: 
[[(sample A2-A1) - (blank A2-A1)] / [(calibrator A2-A1) - (blank A2-A1)]] * 35 
Hepatic bile acids were normalized to total protein concentration, which was quantified 
using the Coomassie (Bradford) Protein Assay (Sigma) (see section 2.2.3.2) 
 
2.3. RNA extraction and analysis  
2.3.1. RNA extraction and cDNA synthesis 
Total Ribonucleic acid (RNA) was extracted with TRIzol Reagent (Invitrogen) following 
manufacturer’s protocol. Briefly, 50 mg of mouse liver or small intestine kept in RNAlater 
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were washed in 1 ml of cold Phosphate Buffer Saline (PBS) (Life Technologies) and then 
homogenized in 500 µl of TRIzol Reagent using ceramic beads in a Minilys Tissue 
Homogenizer (Bertin Corp.). Homogenates were spun down (12,000 x g for 10 minutes 
at 4ºC) and supernatant was transferred onto a clean 1.5 ml tube. Then, 80 µl of 
chloroform (Acros organics) was added to homogenates, vortex-mixed, incubated at 
room temperature for 2-3 minutes and then centrifuged (13,000 x g, 15 minutes at 4ºC). 
Following centrifugation, the entirety of the aqueous phase was transferred onto a new 
1.5 ml tube and 250 µl of cold isopropyl alcohol was added to precipitate the RNA. Tubes 
were left to stand at room temperature for 10 minutes and then spun down at 15,800 x 
g, 15 minutes at 4ºC. Pellets containing precipitated RNA were washed twice with 400 
µl of cold 70% molecular grade ethyl alcohol (Sigma Aldrich) and centrifuged (13,000 x 
g, 10 minutes at 4ºC). After the last wash, supernatants were removed completely and 
pellets were allowed to dry by leaving tubes uncapped at room temperature for 5 minutes. 
Pellets were then resuspended with 40 µl of molecular biology water (Sigma Aldrich). 
Sample concentration and purity was determined using a NanoDrop™ 1000 
Spectrophotometer. Sample purity was assessed by 260/280 ratio and presence of 
contaminants by the 260/280 ratio. The minimum 260/230 ratio accepted was 1.50. 1000 
µg of RNA was retrotranscripted using the qScript cDNA Synthesis Kit (Quantabio) 
following manufacturer’s protocol. 
 
2.3.2. Quantitative real-time PCR 
Specific genes were amplified and quantified by PCR, using the PerfeCTa SYBR Green 
FastMix, Low ROX (Quanta) on an MX3000p system (Agilent) under the following 
conditions: 95ºC for 30 secs followed by 40 cycles of 55ºC for 5 secs and 60ºC for 30 
secs. Amplicon specificity was assessed after every run by performing a dissociation 
(melt) curve: 95ºC for 1 min, 55ºC for 30 secs and 95ºC for 30 secs. 
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For a single reaction, the following reagents and cDNA were added to a single well in a 
96-well plate:   
Amount Reagent 
Final 
Concentration 
6.2 µL Water - 
7.5 µL 2X Reaction Buffer 1X 
0.15 µL 10 μM Primers  100 nM 
1 µL 250 ng of cDNA  - 
15 µL Total reaction volume 
 
All samples were run in duplicates and the relative amount of mRNAs was calculated 
using the comparative Ct method and normalized to the expression of Cyclophylin (304), 
which was already established in the lab not to be regulated by LXRs (data not shown). 
The following formula was used to quantify relative mRNA levels: 
∆Ct = Ctgene- Ctcyclophylin 
∆∆Ct = ∆Ctsample- average ∆Ctcontrol 
Fold induction= 2
-∆∆Ct
 
 
2.3.3. Primer design 
Transcript sequences were obtained from the from the University of California, Santa 
Cruz (UCSC) Genome Browser database (https://genome.ucsc.edu) (305). Primers 
were obtained using the Primer3 (v. 0.4.0) online software (306), under the following 
parameters: amplicon size of 60-120 base pairs, primer size of 18-25 base pairs and 
melting temperature of 60 ºC. In order to avoid amplification of contaminating genomic 
DNA, primers were designed where one half hybridized to the 3′ end of one exon and 
the other half to the 5′ end of the adjacent exon (exon spanning). Primer efficiency was 
determined by running a standard curve with known cDNA concentrations, and only 
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those primers with an efficiency of 90-110% were used. All primer sequences used are 
in Table 2.2. 
 
2.3.4. RT2 Profiler PCR Arrays 
Mouse Lipoprotein Signalling and Cholesterol Metabolism (PAMM-080Z) and Mouse 
Cytokines & Chemokines (PAMM-150Z) RT2 Profiler PCR Arrays (Qiagen) were 
performed as per the manufacturer's instructions. Firstly, RNA integrity was assessed by 
qStandard (UK). All samples used had a RNA integrity number above 7.5. Then, cDNA 
was synthesized with the RT2 HT first strand kit (Qiagen) using 500 ng of RNA, and 
quantitative PCR (qPCR) analysis was performed using RT2 SYBR Green ROX™ qPCR 
Mastermix (Qiagen) on the MX3000p detection system (Agilent). The relative amount of 
mRNAs was calculated using the comparative Ct method (see section 2.3.2) and 
normalized to an average of five housekeeping genes. The full list of analysed genes 
with these arrays can be found in Tables 3.1. and 3.2. 
 
2.4. Protein isolation, immunoprecipitation, and immunoblotting 
Single cell suspensions from livers were immunoprecipitated with antibodies that 
specifically recognise the human (8 µg LXRα, ab41902, Abcam) or murine (2 µg LXRα/β) 
(307) receptors. Antibodies were previously crosslinked to a column with Protein A/G 
Agarose following the manufacturer’s protocol (Pierce).  
Eluted protein was quantified using the BCA Protein Assay (Thermo Fisher). This assay 
uses the reduction of Cu2+ to Cu1+ by protein in an alkaline medium and produces a 
colorimetric reaction of the cuprous cation (Cu1+) by bicinchoninic acid (BCA), which 
was measured at 590 nm on a TriStar² LB 942 Multidetection Microplate Reader. 
Proteins were denaturalised by being boiled in a buffer containing 2% Sodium 
Dodecylsulfate (SDS) and 5% β-mercaptoethanol for 10 minutes, and separated on a 
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10% acrylamide gel (BioRad) for 2h 30 min at a constant voltage of 100V. Proteins were 
then transferred to a PVDF membrane (Millipore) by wet transfer at 100V for 1 hour. After 
transfer, membranes were blocked with StartingBlock™ Blocking Buffer (Thermo Fisher) 
for 1 hour at room temperature, and then blotted with primary antibody overnight at 4ºC.  
Phospho-Ser198/196 LXRα specific rabbit polyclonal antibody (163,308), mouse LXRα 
monoclonal antibody (Abcam) and Hsp90 polyclonal (sc-7947, Santa Cruz) were used 
as primary antibodies. Anti-rabbit (PO448, Dako) or anti-mouse (NA931VS, GE 
Healthcare) horseradish-peroxidase-tagged antibodies were used for secondary binding 
and chemiluminescence (ECL 2 Western Blotting Substrate, Pierce) was used to 
visualise proteins.  
 
2.5. Histopathological analysis 
2.5.1. Slide preparation and staining 
Mouse liver was dissected and the left lobe was fixed in 10% (w/v) formalin (Sigma 
Aldrich) for 24-48h, processed in a TP 1050 Tissue Processor (Leica) and embedded in 
paraffin wax. Paraffin-embedded livers were cut into 4 μM sections. Liver sectioning was 
performed by the UCL IQPath Facility (University College London, UK).  
Sections were stained with hematoxylin and eosin (H&E) in an automatic multiple slide 
stainer (Tissue-Tek DRS 2000, Sakura). 
Liver histology was blindly scored by Dr. Tu Vinh Luong (University College London, UK) 
based on three semiquantitative items: steatosis (0–3), lobular inflammation (0–3) and 
hepatocellular ballooning (0–2) (201,309) (Table 2.3). 
F4/80 (ab6640, Abcam) staining was performed by the UCL IQPath Facility (University 
College London, UK). Picrosirius Red stain was performed following manufacturer’s 
protocol (Abcam). Briefly, liver sectons were deparaffinised and hydrated by placing 
them in distilled water. Then, Picro-Sirius Red Solution (Abcam) was applied on the stain 
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until completely covered and left to incubate for 60 min at room temperature. Slides were 
quickly rinsed in two changes of Acetic Acid Solution (Abcam) and dehydrated by placing 
them in two changes of absolute ethyl alcohol. Slides were then dried and cover-slipped 
using a xylene-based mounting media.  
Stained sections were scanned with a NanoZoomer Digital slide scanner (Hamamatsu) 
and stained area quantification was performed using the ImageJ software (310) on three 
independent areas per section. Data is represented as the averaged positively-stained 
percent of area of interest.  
 
 
 
 
 
 
 
 
 
 
 
Table 2.3. Grading criteria used for NAFLD scoring of mice 
Grading criteria was adapted to murine pathology from the human Kleiner’s Score (201). 
 
2.5.2. Image processing for lipid droplet identification 
The identification and quantification of lipid droplets were made with the help of Eli (Easy 
Lipids) v1.0, an in-house software developed in collaboration with Dr. Vanessa Diaz and 
Dr. Cesar Pichardo at the Multiscale Cardiovascular Engineering (MUSE) (University 
College London, UK). Scans of H&E stained liver sections were used as input. This 
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software uses a method based on the Hough Transform (311) for the identification of the 
droplets estimating the centres and radii of each of them. A final report is generated with 
the dimensions of the droplets (i.e. diameter and area) including a histogram describing 
the frequency of lipid vacuoles within specified diameter ranges (Figure 2.3). A trial of Eli 
v1.0 is currently available upon request on the MUSE website at UCL 
(www.ucl.ac.uk/muse/software). 
 
 
 
 
Figure 2.3.  Identification of lipid droplet areas using the Eli (Easy Lipids) v1.0 
software 
Identification of lipid droplets on uploaded images of H&E-stained liver sections (1), then 
software generates a histogram (2) and a list of all the identified droplets and their area 
(3). 
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2.5.3. TUNEL staining 
Apoptosis was detected in situ using a terminal deoxynucleotidyl transferase dUTP nick 
end-labeling (TUNEL) assay as per the manufacturer’s instructions (R&D Systems). 
Paraffin-embedded liver tissue sections were incubated with a specific TdT enzyme that 
incorporates biotin on exposed nucleotides after DNA fragmentation. Biotin labelling was 
later achieved using Streptavidin-Fluorescein and sections were imaged using the Axio 
Imager.A1 Digital Microscope (Zeiss). Four different areas per slide were photographed 
at a magnification of 200X and intensity of staining was quantified by ImageJ.  
 
2.6. Oxysterol LC-MS analysis  
Oxysterol level determination was performed by Dr. Hanne Røberg-Larsen (University 
of Oslo, Norway). Protein was precipitated from plasma with 480 pM of the appropriate 
internal standards (Avanti Polar Lipids, Alabaster, AL, USA). Sample clean-up was 
conducted off-line, using solid phase extraction (SPE, SilactSPE C18 100 mg, Teknolab, 
Ski, Norway) and dryed at 30 °C, re-dissolved in 2-propanol and treated as described 
(312). Samples and calibration solutions were analysed using an Ultimate 3000 UHPLC 
connected to an Advantage QqQ (both Thermo Fisher, Waltham, MA, USA) equipped 
with an Automatic filtration and filter back-flush SPE add-on, as described (313). 
 
2.7. Lipid peroxidation quantification 
Thiobarbituric Acid Reactive Substances (TBARS) were measured in approximately 25 
mg of frozen livers as per manufacturer’s instructions (Cayman Chemicals). Briefly, lipid 
peroxidation was quantified by the reaction of Malondialdehyde (MDA), a product of lipid 
peroxidation, with thiobarbituric acid (TBA) to form a colorimetric (532 nm) product, 
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proportional to the MDA present, which was measured spectrophotometrically on a 
TriStar² LB 942 Multidetection Microplate Reader. MDA levels were calculated based by 
interpolation from a standard curve. Levels of MDA were normalised to total protein 
levels, quantified using the Bradford Assay (see section 2.2.3.2).  
 
2.8. Chromatin Immunoprecipitations 
100 mg of WT and 120 mg of S196A fatty (HFHC) livers were dissected and directly 
double crosslinked with 2 mM disuccinimidyl glutarate (DSG) (Thermo Scientific) for 30 
minutes at room temperature, followed by 1% formaldehyde (Thermo Scientific) for 10 
minutes also at room temperature. The reaction was stopped with glycine at a final 
concentration of 0.125 M for 5 min, room temperature. Livers were washed three times 
with PBS and single cell suspension was obtained by grinding liver pieces through a 70 
μM cell strainer (Fisher scientific). Nuclei were isolated by incubating cell preparations 
for 10 minutes at 4ºC with the following lysis buffers: Buffer 1 (50 mM Hepes-KOH, pH 
7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100), 
Buffer 2 (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA), and 
Buffer 3 (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-
deoxycholate, and 0.5% N-Lauroylsarcosine). Pellets resuspended in 300 μl of lysis 
buffer 3 were sonicated for 40 cycles (30 s ON/OFF) in the UCD-300 Bioruptor 
(Diagenode), to generate DNA-fragment sizes of 0.2–0.5 kb. Successful sonication was 
confirmed by running products on a 1% agarose gel (Figure 2.1.2), in a 1X TAE buffer 
with 1X SYBR safe DNA gel stain (Invitrogen) for 30 minutes at 80V.  
Soluble chromatin was diluted in Dilution Buffer (1% Triton X-100, 2 mM EDTA, 150 mM 
NaCl, 20 mM Tris.HCl pH 8.1) and immunocleared for 18 hours at 4ºC by being incubated 
with 2µg sheared Salmon sperm DNA (Invitrogen) and 2µg/ml Bovine Serum Albumin 
(Sigma Aldrich). Then, 25 µg of chromatin were immunoprecipitated with the following 
antibodies: 2.5 µg RXRα (sc-553, Santa Cruz), 2.5 µg Pol II (sc-9001, Santa Cruz), 5 µg 
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Pol II-S2P (ab5095, Abcam), 2 µg LXR (α/β) (307), 2.5 µg TBLR1 (ab24550, Abcam) 
and 5 µg NCoR (ABE251, Millipore). Antibody-protein-chromatin complexes were 
immunoprecipitated by incubating with a 50% Protein A-sepharose solution (GE Life 
Sciences) for 2 hours at 4ºC. Complex with beads was then washed once with the 
following solutions: TSE I (0,1 % SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 
mM Tris-HCl pH 8.1), TSE II (0,1 % SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 
20 mM Tris-HCl pH 8.1), Buffer III (0.25 M LiCL, 1% NP-40, 1% Deoxycholate, 1 mM 
EDTA, 10 mM Tris-HCl pH 8.1) and TE Buffer (10mM Tris-HCl pH 8.1, 1mM EDTA). 
Lastly, chromatin was eluted with three consecutive washes of Elution Buffer (1% SDS, 
0.1 M NaHCO3). 
 
 
 
 
 
 
Figure 2.4. Example of mouse liver chromatin visualization after sonication 
Sonicated DNA products were run on a 1% agarose gel. Sonication was considered 
successful when majority of DNA was lower than 500 bp.  
 
 
After RNAse A (Fermentas) and proteinase K (Fermentas) treatment, the 
immunoprecipitated DNA was purified using the QIAquick PCR purification kit (Qiagen) 
and analysed by quantitative real-time PCR with corresponding primers (sequences are 
listed in Table 2.4). Relative occupancies were normalized to input DNA (fold difference= 
2–Ct-sample-Ct-input). To control for non-specific binding, an 82 base pair fragment in a gene 
desert in chromosome 6 (ActiveMotif) was used. Pol II and Pol II-S2P antibody specificity 
was assessed against the same amount of IgG from rabbit serum (I5006, Sigma). 
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2.9. In silico screening of potential LXREs 
Screening for potential DR4 sequences was performed using the available web-based 
software NHR Scan (http://www.cisreg.ca/cgi-bin/NHR-scan/nhr_scan.cgi) (314), which 
predicts potential nuclear hormone receptor binding sites on a given genomic sequence. 
Input sequences (gene body or sequences 30 kb upstream from transcription start site) 
were obtained from UCSC Genome Browser database (see section 2.3.3) and submitted 
under FASTA format. Plausible DR4 sequences were then chosen based on similarity to 
a published consensus sequence for the murine LXRE (315) (Figure 4.8) 
 
2.10. RNA sequencing 
2.10.1. RNA preparation and sequencing 
Sequencing and pipeline analysis was performed by UCL Genomics (London, UK). Total 
RNA was extracted using TRIzol reagent (see section 2.3.1) and cDNA libraries were 
prepared using reagents and protocols supplied with the Stranded mRNA-Seq Kit (Kapa 
Biosystems). Briefly, poly-A tailed RNA was purified using paramagnetic oligo-dT beads 
from 200 nanograms of total RNA, with a RNA Integrity Number above 7.5 as determined 
by the Agilent Bioanalyzer (Agilent). The purified RNA was fragmented chemically by 
heating samples in the presence of Mg2+ and cDNA was synthesised using random 
primers supplied in the kit (Kapa Biosystems). Adapter-ligated DNA library was then 
amplified with 12 cycles of PCR and library fragment was estimated using the Agilent 
TapeStation 2200 and confirmed to be ~150bp (~280bp when including the Illumina 
adapters). Lastly, Library concentration was determined using the Qubit DNA HS assay 
(Life Technologies). Libraries were sequenced at a concentration of 1.8pM on a 
Illumina NextSeq 500, NCS v2.1.2 (Illumina), with a 43bp paired end protocol. 
Basecalling was done using the standard Illumina parameters (RTA 2.4.11).  
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Oligo design and qPCR validation (see section 2.3) of top upregulated and 
downregulated hits was performed by Lucia Martin-Gutierrez (University College London, 
UK). Primers used for qPCR validation can be found in Table 2.2. 
All RNA-seq results are available at the Gene Expression Omnibus (GEO) data 
repository, under the GEO Accession numbers GSE96650 (chow livers) and GSE95359 
(HFHC livers). 
 
2.10.2. RNA-Seq computational analysis 
Reads were demulitplexed using Illumina bcl2fastq v2.17 (Illumina) and then were 
aligned using STAR v2.5.0b to the mouse GRCm38/mm10 reference sequence. 
Transcript abundance was estimated using Illumina's RnaReadCounter tool and 
differential expression analysis performed with DESeq2. 
Pathway enrichment analysis was performed with the Gene Set Enrichment Analysis 
(GSEA) software’s pre-ranked module (316,317). A list of significant (adjusted p-value < 
0.05) differentially expressed genes in S196A livers compared to WT was analysed 
against the Hallmark gene set database (318). 
Heatmaps were created using the Multi Experiment Viewer (MeV) desktop software 
(319), based on differences on raw gene counts. 
 
2.11. RAW 264.7 in vitro experiments    
2.11.1 Cell culture 
RAW 264.7 is a murine macrophage-like cell line that was established from the ascites 
of a tumour induced in a male mouse by injections of Abelson leukemia virus (320). This 
cell line is widely used to study macrophage biology as it is easy to propagate in culture, 
and shows optimal DNA transfection efficiency, as well as sensitivity to RNA interference. 
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RAW 264.7 cells were transfected as previously described (163) and grown in High 
Glucose Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies), supplemented 
with 10% Fetal Bovine Serum (FBS) (Life Technologies), 2 mM glutamine (Lonza) and 
20 μg/ml gentamycin (Sigma Aldrich). Cells were maintained in culture in an incubator at 
37°C, 5% CO2, and passaged every 48 hours. 
 
2.11.2. Activation treatments 
Once cells had reached 80% confluency, plates were washed once with PBS and cells 
were serum starved overnight by placing them in DMEM medium with low-endotoxin 1% 
FBS (Life technologies), and were then stimulated with the correspondent stimulants.  
For mRNA experiments, cells were scrapped off the plate, counted using a Neubauer 
counting chamber under an optical microscope, and 5 x 105 cells were plated per well in 
a 6-well plate (Greiner Bio-One), before serum-starving them. Concentrations and 
incubation periods for each experiment can be found in the corresponding figure legends.  
Dimethyl sulfoxide (DMSO) (Sigma Aldrich) was used as a vehicle control for GW3965 
(Sigma Aldrich), CX-4945 (Selleckchem) and oltipraz (Sigma Aldrich); absolute ethyl 
alcohol (VWR) was used as control both for desmosterol (Insight) and 24(S),25-EC 
(Enzo Life Sciences) and PBS was used as a control for insulin (Sigma Aldrich). 
 
 
2.11.3. Immunoblotting and mRNA analysis 
RAW 264.7 nuclear extracts were prepared using the NE-PER nuclear and cytoplasmic 
extraction reagents (Pierce) following manufacturer’s protocol. Overall, addition of 300 
µl of the Cytoplasmic Extraction Reagent (CER) I and 16.5 µl of CER II to a cell pellet 
caused cell membrane disruption and release of cytoplasmic contents. After separating 
the intact nuclei from the cytoplasmic extract by centrifugation (13,500 rpm, 6 min, 4°C), 
the proteins are extracted out of the nuclei with 50 µl of the Nuclear Extraction Reagent. 
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Nuclear protein was quantified using Coomassie (Bradford) Protein Assay (see section 
2.2.3.2) and separated on a 10 % acrylamide gel (see section 2.4).  
Densitometry analysis of membranes was performed using ImageJ and normalised to 
amount of Hsp90 in each sample. All the original scans can be found in Appendix 2. 
RNA was extracted using Trizol reagent (see section 2.3.1). Transcript amplification and 
quantification by qPCR (see section 2.3.2) was performed by MSc student Daniel Wu 
(University College London, UK). 
 
2.12. Human primary HSCs gene expression 
Human primary HSCs were provided by Dr. Krista Rombouts (University College London, 
UK). 3 x 105 cells were plated per well in serum-free DMEM media, complemented with 
2 mM glutamine (GIBCO) and antibiotic-antimyocotic 1X (GIBCO). 
Unless otherwise stated, cells were used on passage 5. Cells were stimulated with 1 μM 
GW3965 or DMSO for 18 hours, then media was removed and RNA was extracted using 
the RNeasy Micro Kit (Qiagen). Briefly, cells were quickly lysed by running them through 
the QIAshredder spin columns (Qiagen). Then, the cell lysate was loaded onto the 
RNeasy MinElute spin column and spun down (10,000 rpm for 30 seconds at room 
temperature), so that RNA (up to 45 µg) would bind to the silica membrane. Membranes 
were washed once with RW1 buffer and treated with RNase-free DNase for 15 minutes 
at room temperature. Lastly, membranes were washed with 80% ethanol (Sigma), and 
RNA was eluted in RNase-free water. For qPCR see section 2.3.2. 
All primer sequences used for human genes are in Table 2.6. 
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2.13. Human liver protein and mRNA analysis 
Frozen liver biopsies obtained from males with colon carcinoma undergoing lobectomies 
were supplied by Dr. Krista Rombouts (University College London, United Kingdom). 
RNA was extracted from 5 mg of frozen liver using TRIzol Reagent following 
manufacturer’s protocol (see section 2.3.1), and genes were quantified by qPCR (see 
section 2.3.2.) 
For protein extraction and immunoblotting see section 2.4. 
 
2.14. Statistical analysis  
Unless stated otherwise, data is presented as mean ± Standard Error of Mean (SEM). 
Differences were considered significant at p < 0.05 by a two-tailed Student t-test. Two-
tailed (unpaired) t-test was performed when comparing two independent groups of 
values with normal distribution and whose means were not expected to be equal.  
For multiple comparisons, significance was assessed by single variance ANOVA 
followed by Student’s T-test. When comparing the means of more than two groups, 
ANOVA was used as a statistical test as it is more conservative (results in less type I 
error) than multiple two-sample Student t-tests. 
For correlation studies, R2 value was calculated by Pearson correlation coefficient. This 
statistical tests was used when assessing linear covariance of two variables. R2 has a 
value between +1 and −1, where 1 is total positive linear correlation, 0 is no linear 
correlation, and −1 is total negative linear correlation.  
Statistical analysis was performed using Microsoft Excel or Graph Pad Prism. 
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RT-PCR Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) 
Abca1 GGACATGCACAAGGTCCTGA CAGAAAATCCTGGAGCTTCAAA 
Abcg1 CCTTCCTCAGCATCATGCG CCGATCCCAATGTGCGA 
Abcg5 TGGATCCAACACCTCTATGCTAAA GGCAGGTTTTCTCGATGAACTG 
Abcg8 TGCCCACCTTCCACATGTC ATGAAGCCGGCAGTAAGGTAGA 
Adipophilin GACCGTGCGGACTTGCTC GCCATTTTTTCCTCCTGGAGA 
Aim GTTGGATCGTGTTTTTCAGA TCCCACTAGCTGCACTTTGGT 
a-Sma CCCAGACATCAGGGAGTAATGG TCTATCGGATACTTCAGCGTCA 
Atf3 GAGGATTTTGCTAACCTGACACC TTGACGGTAACTGACTCCAGC 
Atp6v0d2 GTGCAGTGTGAGACCTTGGA GCCAGGAAGTTGCCATAGTC 
Bex1 ATGGAGTCCAAAGATCAAGGCG CTGGCTCCCTTCTGATGGTA 
Cd36 GCCAAGCTATTGCGACATGA TCTCAATGTCCGAGACTTTTCAAC 
Ces1f TGGAGAGTCAGCAGGAGGTT ATGAAGGCCACACCACTCTC 
Chop CTGGAAGCCTGGTATGAGGAT CAGGGTCAAGAGTAGTGAAGGT 
Col1a1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG 
Col1a2 AAGACCTGGGGAGAGAGGAG CTTTGAAGCCAGGAAGTCCA 
Cyclophylin GGCCGATGACGAGCCC TGTCTTTGGAACTTTGTCTGCAA 
Cyp17a1 ACCAGCCAGATCGGTTTATG AGGGCAAATAACTGGGTGTG 
Cyp2b13 ATGCTCATGTACCCCCATGT GCCGATCACCTGATCAATCT 
Cyp2b9 CTGGCCACCATGAAAGAGTT CATTGGGCCTCCTCCTTTAT 
Cyp2c69 CACAGTGGCTCATGAAGGAA GATGAATTGGGGATCACAGG 
Cxcl1 CAGTGCACCCAAACCGAAGT GGACAATTTTCTGAACCAAGGG 
Cx3cl1 ATTTGTGTACTCTGCTGCC  TCTCCAGGACAATGGCAC 
Cx3cr1 TGAGTGACTGGCACTTCCTG AAGGAGGTGGACATGGTGAG 
Dgat2 CTGGCTGATAGCTGCTCTCTACTT TGTGATCTCCTGCCACCTTTC 
Elovl6 TGAACAAGCGAGCCAAGTTTG GAGCACCGAATATACTGAAGACG 
Fabp5 AGGATGGGAAGATGATCGTG CTGGCAGCTAACTCCTGTCC 
Fas GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
Fsp27 GTGTCCACTTGTGCCGTCTT CTCGCTTGGTTGTCTTGATT 
Hamp2 AGAAAGCAGGGCAGACATTG GCAGATGGGGAAGTTGATGT 
Idol ATGCTGTGCTATGTCACGAGG TCGATGATCCCTAGACGCCTG 
Ldlr GCATCAGCTTGGACAAGGTGT GGGAACAGCCACCATTGTTG 
L-Fabp ATGAACTTCTCCGGCAAGTACC CTGACACCCCCTTGATGTCC 
Lpcat3 CCTTCACGGGCCTCTCAATT CCATGAGTCGCAGGATGAGG 
Lpl ATCCATGGATGGACGGTAACG CTGGATCCCAATACTTCGACCA 
Lxra GGTTGCTTTAGGGATAGGGTT TTCCGCTTTTGTGGACGAAG 
Mmp9 GCGTGTCTGGAGATTCGACT ATGTCGTGTGAGTTCCAGGG 
Nnmt TGTGCAGAAAACGAGATCCTC TGTGCAGAAAACGAGATCCTC 
Ncor ACAGAGCAAAGTCGTTATCCTTC GAGCGGTAGTCAGGAACTGC 
Ncp1l1 GAGAGCCAAAGATGCTACTATCTT CCCGGGAAGTTGGTCATG 
Osbpl3 AGACACGGAGGAGCACATCT CGGTACATTCTGTGGTGACG 
Osm GCAGCTGTGGCTTTCTCTGG TCGTCCCATTCCCTGAAGAC 
Ppp1r3g CTGAGACCCCGATCCCTGAT GAGAGCGGCGATATTCCTGT 
Scara3 GCTGGTGAAGACGAGGACAT CAAAATCCGCACTGATGTGT 
Scd1 CCGGAGACCCCTTAGATCGA TAGCCTGTAAAAGATTTCTGCAAA 
Table 2.2. Mouse gene primers used for qPCR 
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RT-PCR Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) 
Slc22a26 ACAGAGCCCTGTATGGATGG AGATCCACACACCAGGTTCC 
Srebp1c CAGGAGGACATC TTGCTGCTTC TTGGGAGGCTGGTTTTGACC 
Srebp2 CTGCAGCCTCAAGTGCAAAG CAGTGTGCCATTGGCTGTCT 
Stk25 ACGTT CCTCCAACCATCCG CTTCTGTGAGCTGTGCA 
Sod2 CAGACCTGCCTTACGACTATGG CTCGGTGGCGTTGAGATTGTT 
Syngr1 CTGGTTCGTGGGTTTCTGCTT GTCCCTTCGTTCAGAGGGTTG 
Tblr1 ATCGAGTCTCTGTCCCTGATAG GCTTGTCTCTGTAGGCTTGTTG 
Tgfb2 TTTGCTCCAGACAGTCCCAG ATCTCCAGACATGCCAAGCC 
Timp1 GTGGATATGCCCACAAGTCC CTCAGAGTACGCCAGGGAAC 
Thrsp GCGGAAATACCAGGAAATGA CGGGGTCTTCATCAGTCTTC 
Tlr4 AGCCTCGAATCCTGAGCAAA AGGCCCCAGAGTTTTGTTCT 
spl Xbp1 GAGTCCGCAGCAGGTG GTGTCAGAGTCCATGGGA 
Wfdc3 CTTGGGTAGCTGCAGGAGAG ATTCGTCTCCGGTACACAGC 
Table 2.2. Mouse gene primers used for qPCR (continued) 
 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Ces1f DR4 GGTGGTGGCCATTCAATATC TGTCCACAAACCCTACCTGA 
Ces1f TSS CATTGACTTGGGAGCCTGTC ACTCACCGCAAATCACACAG 
Cyp2c69 DR4 CTACCCACTCCTGCTTCCTG GGCCTAGTTGGCCATCATTA 
Cyp2d69 TSS TGTCTGGAATGCCTGATCATA GGATCCATGGAGACCCTTCT 
Srebp1c LXRE AGGCTCTTTTCGGGGATGG TGGGGTTACTGGCGGTCAC 
Srebp1c TSS GTGGGCCTAGTCCGAAGC ATCTCGGCCAGTGTCTGTTC 
Table 2.4. Primers used for ChIP-qPCR  
 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
ABCA1 
TGAGCTACCCACCCTATGAA
CA 
CCCCTGAACCCAAGGAAGTG 
ABCG1 
TGCAATCTTGTGCCATATTT
GA 
CCAGCCGACTGTTCTGATCA 
ACTA2 
AAAAGACAGCTACGTGGGTG
A 
GCCATGTTCTATCGGGTACTT
C 
CYCLOPHYLIN 
GCATACGGGTCCTGGCATCT 
TGT 
ATGGTGATCTTCTTGCTGGTC
T 
LXRA 
AGAGGAGGAACAGGCTCAT
G 
AAAGGAGCGCCGGTTACACT 
LXRB GGAGCTGGCCATCATCTCA 
GTCTCTAGCAGCATGATCTCG
G 
SREBP1c 
TCAGCGAGGCGGCTTTGGA
G 
CATGTCTTCGATGTCGGTCAG 
Table 2.5. Human gene primers used for qPCR  
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Chapter 3. LXRα phosphorylation-deficiency at Ser196 
attenuates diet-induced liver inflammation and fibrosis 
 
3.1. Introduction 
Fatty liver (steatosis) alone is considered relatively benign. However, it is the transition 
to NASH that represents a key step into further irreversible liver damage and mortality 
(178), although the mechanisms underlying this transition are poorly understood. Hence, 
most therapies for NAFLD have focused on preventing progression of fatty liver or 
reversing already established inflammatory or fibrotic states (200). Currently available 
agents such as insulin sensitizers, antioxidants, and lipid-lowering agents are not aimed 
at treating NAFLD directly but rather its associated conditions and thus only display 
limited efficacy (see section 1.2.3). Thus, understanding the factors that trigger the 
transition from fatty liver to NASH is crucial for the development of direct pharmacological 
therapies against NAFLD. 
LXRs act as whole-body cholesterol sensors: they respond to oxysterols, as a 
consequence of increased intracellular cholesterol levels, and induce the expression of 
several genes involved in cholesterol metabolism (see section 1.1.3). Upon activation, 
LXRs prompt cholesterol catabolism and excretion, as well as decrease rates of uptake 
and cellular biosynthesis. Due to their important role in the regulation of cholesterol 
homeostasis, classic therapeutic approaches based on regulating LXR activity have 
focused on finding synthetic compounds that lead to reducing systemic  cholesterol 
burden for the treatment of diseases such as atherosclerosis (65,67,321,322). However, 
the effects of LXR activation on fatty acid and triglyceride metabolism have presented a 
major obstacle in the development of LXR agonists, as pharmacological activation of 
LXRs stimulates hepatic de novo lipogenesis, being therefore a key promoter of steatosis 
(323,324). In contrast, LXRs have also demonstrated strong anti-inflammatory and anti-
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fibrotic activities in models of acute liver disease (151,325). It would be elementary 
therefore, to find a strategy that would restrict LXR activity towards its therapeutic 
capacities without inducing the less favourable side effects. 
Besides ligand binding, LXR activity can be modulated by post-translational 
modifications (158) (see section 1.1.4). Pineda-Torra et al. previously showed that the 
human LXRα is phosphorylated at Ser198 in macrophages under basal conditions and 
upon cholesterol overload in vitro, as well as in the plaques of ApoE-knock out (KO) mice 
(163). Despite previous reports showing LXRα phosphorylation in this and other residues 
(166,169,170), the biological consequences of changes in LXRα phosphorylation on 
pathophysiology, and specifically, on the progression of diet-induced chronic liver 
disease remain unknown. To assess the impact that changes in LXRα phosphorylation 
have on the receptor’s activity in vivo, we generated a novel knock-in mice model. These 
animals are homozygous for a whole-body Serine196 to Alanine (S196A) mutation (for 
details refer to section 2.1), the homologous residue in the murine receptor to Ser198 in 
humans. For my studies, I have used a High Fat/High Cholesterol diet, as cholesterol 
metabolites are known LXR endogenous ligands (section 1.1.2.1) and cholesterol 
induces LXRα phosphorylation in vitro (163). Furthermore, diets with a high cholesterol 
content have been previously reported to activate LXR activity in vivo (143). 
 
 
Thus, the primary aims of the following experiments were to: 
 Investigate which is the phosphorylation status of hepatic LXRα in vivo 
 Employ the newly-generated S196A mouse model to investigate how changes 
in LXRα phosphorylation change the receptor’s activity on lipid homeostasis  
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3.2. LXRα is phosphorylated in human and mouse liver 
The Ser198/196 residue is conserved between human, rat and mouse (Figure 3.1. A), 
suggestive of a preserved function. To assess phosphorylation levels at this residue, 
LXRs were immunoprecipitated in liver homogenates of wild-type C57BL/6 mice fed a 
chow diet, using a polyclonal antibody that recognizes both α and β subtypes of the 
receptor (326). Although the murine S196 phosphorylation motif is not conserved in the 
LXRβ subtype (Figure 3.1. B), a liver sample from LXRα KO mice (kindly provided by Dr. 
A. Valledor, UB, Spain), was also included to control for subtype specificity. Moreover, 
total LXRα was immunoprecipitated from lysates of healthy human livers (n=2), using a 
commercial antibody. Thus, immunoblotting with our own non-commercial antibody that 
specifically recognises the phospho-Ser198/196 LXRα residue (163) proved that 
endogenous murine (Figure 3.1. C) and human (Figure 3.1. D) LXRα is phosphorylated 
in the liver under basal conditions, and that this is indeed abolished in the S196A knock-
in animals that carry the serine-to-alanine mutation (Figure 3.1. C).  
Interestingly, although the same amount of antibody and protein lysate was used in the 
immunoprecipitation for both human liver samples, a considerable difference in the 
amount of precipitated LXRα was observed between both donors (Figure 3.1. D). To rule 
out a technical error, analysis by real-time qPCR was performed and confirmed that, in 
agreement with the protein levels, Donor A also had higher mRNA levels of both LXRα 
and LXRβ (Figure 3.1. E), suggestive of inter-individual variability in LXR quantities which 
may be independent of disease. 
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Figure 3.1. Hepatic LXRα is phosphorylated under basal conditions 
A) Amino acid sequence alignment of the LXRα protein in different species containing 
the S198/196 phosphorylation motif. 
B) Alignment of the murine LXRα and LXRβ amino acid sequence showing differences 
(grey boxes) in S196 phosphorylation motifs between both subtypes. 
C) Murine LXRα phosphorylation at Ser196 analysed by LXRα/β immunoprecipitation of 
liver homogenates (WT, S196A or LXRα KO mice) and subsequent immunoblotting with 
a phospho-LXRα specific antibody. For each sample, immunoprecipitated total LXRα 
was assessed (n=2). 
D) Human LXRα phosphorylation at Ser198 analysed by LXRα immunoprecipitation of 
liver homogenates (n=2), subsequent immunoblotting with a phospho-LXRα specific 
antibody. For each sample, immunoprecipitated total LXRα was assessed. 
E) mRNA levels of LXRα and LXRβ quantified by real-time PCR in human livers (n = 2). 
Values are normalised to house-keeping gene cyclophylin. 
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3.3. Phosphorylation-deficient LXRα protects from plasma and hepatic 
dietary cholesterol accumulation 
Previous studies have extensively shown the importance of LXR activity on lipid and bile 
acid metabolism (106,324), therefore differences in several metabolic parameters 
between LXRα phosphorylation-deficient and wild-type (WT) mice were investigated. 
Interestingly, when fed a normal chow diet, S196A mutant mice showed no difference on 
body weight nor most metabolic parameters when compared to wild-type controls (Table 
3.1). It must be noted though, that levels of plasma triglycerides could not be determined 
in WT mice due to the abundant presence of hemolysis (red blood cell lysis) in those 
samples due to a technical error, which interfered with the assay and produced out of 
scale readings. 
Because of the lack of any apparent metabolic phenotype on the S196A animals under 
basal conditions, the response of the LXRα phosphorylation-deficient animals to a High 
Fat/High Cholesterol diet (HFHC diet) in comparison to wild-type controls was next 
assessed. Many previous studies on rodents have identified sex-specific differences in 
lipid metabolism, where female mice tend to have a larger basal and diet-induced pool 
of cholesterol and higher intestinal absorption efficiencies than males (327,328). 
Therefore, 10-week-old S196A and WT female mice were fed the HFHC diet for 6 weeks. 
Comparable to chow values, plasma insulin and glucose levels were similar between 
genotypes (Table 3.1). Noticeably, both groups of mice had significantly lower body 
weight than their chow-fed counterparts (Table 3.1). This weight loss has already been 
reported for this type of diet (329), and it has been postulated that is due to a shift in the 
source of caloric intake (carbohydrate to fat) and subsequent reduction in adipose tissue 
mass (143). Moreover, when comparing only experimental diet-fed animals, the S196A 
group showed a significant decrease in their body weight (Table 3.1).  
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Table 3.1. Biometric and metabolic parameters of WT and S196A mice fed a chow 
or HFHC diet 
Values for mice fed either a chow diet (n=4) or HFHC diet for 6 weeks (n=6). 
Significance (p-value) was determined by Student’s T-test. 
 
 
Parameter Diet Genotype Mean ± SEM p  
Body weight 
(grams) 
Chow 
WT 
S196A 
23.63 ± 0.6 
21.70 ± 0.75 
0.132 
HFHC 
WT 
S196A 
21.36 ± 0 .41a 
19.89 ± 0.35b 
0.012 
% Liver weight 
(Liver g/Body g) 
Chow 
 WT 
 S196A 
4.69 ± 0.25 
4.41 ± 0.07 
0.241 
Plasma glucose 
(mmol/L) 
Chow 
  WT 
  S196A 
5.35 ± 0.10 
4.63 ± 0.22 
0.268 
HFHC 
  WT 
  S196A 
4.49 ± 0.30 
4.61 ± 0.24 
0.762 
Plasma insulin 
(ng/ mL) 
Chow 
  WT 
  S196A 
0.34 ± 0.05 
0.87 ± 0.24 
0.103 
HFHC 
  WT 
  S196A 
0.60 ± 0.10 
0.87 ± 0.33 
0.498 
Hepatic total 
cholesterol 
(µg / mg protein) 
Chow 
WT 
S196A 
98.96 ± 10.48 
104.43 ± 4 .05 
0.688 
Plasma triglycerides 
(mg/dL) 
Chow 
WT 
S196A 
n/a 
89.82 ± 8.95 
n/a 
Hepatic triglycerides 
(µg / mg protein) 
Chow 
WT 
S196A 
51.95 ± 5.06 
37.63 ± 4.50 
0.116 
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An approximately 60% reduction in plasma total cholesterol was observed in the knock-
in group after being fed the HFHC diet for 6 weeks (Figure 3.2. A). In addition, whilst WT 
animals showed a significant increase of plasma total cholesterol levels between 4 and 
6 weeks, phosphorylation-deficient mice maintained their total cholesterol levels (Figure 
3.2. A). Determination of the HDL and LDL/VLDL cholesterol in both groups of mice 
revealed that, besides having overall lower cholesterol levels in all fractions (Figure 3.2. 
B), the amount of total cholesterol found in the HDL fraction was significantly higher in 
the LXRα phosphorylation-deficient mice (Figure 3.2. B). 
 
 
 
 
Figure 3.2. LXRα phosphorylation-deficient mice show reduced cholesterol levels 
in response to a HFHC diet 
A) Plasma total cholesterol levels from WT and S196A mice fed a chow diet (n=4) or a 
HFHC diet for 4 weeks (n=6) or 6 weeks (n=5-6).  
B) Plasma HDL, non-HDL (LDL and VLDL) or HDL/LDL ratio cholesterol levels from WT 
or S196A mice fed a HFHC diet for 6 weeks (n=5-6).  
Data shown as means ± SEM. ## p-value < 0.005 4 weeks vs 6 weeks in WT group by 
Student’s t-test. ** p < 0.005, *** p < 0.0005, relative to WT determined by Student’s t-
test. 
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Changes in organ weight were also determined, and a significant 20% decrease in liver 
to body weight ratio in S196A mice was detected when compared to WT controls (Figure 
3.3. A). Spleen and kidney weights were also significantly lower in the mutant group, 
whereas the rest of the organs had similar weights (Figure 3.3. B). The change in liver 
to body weight could be due to a reduction on hepatic lipid accumulation, as suggested 
by the difference in the coloration of the livers (Figure 3.3. C) and the differences in total 
cholesterol levels observed in plasma (Figure 3.2. A). Determination of hepatic total 
cholesterol levels confirmed that control animals had almost a four-fold higher amount of 
total cholesterol in liver (Figure 3.2. D), suggestive of a protective effect from cholesterol 
accumulation in tissue and plasma by the phosphorylation-deficient LXRα. Lastly, in 
order to assess if the reduction in total cholesterol levels in the mutant mice could be due 
to its increased catabolism, plasma and hepatic bile acids were quantified in WT and 
S196A animals.  Interestingly, instead of increased catabolism, LXRα phospho-mutant 
mice showed a trend towards reduced levels of plasma and hepatic bile acids (Figure 
3.2. E), suggesting that a more efficient cholesterol catabolism is probably not the reason 
behind the differences in cholesterol levels between groups of mice. 
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Figure 3.3. WT and S196A organ weights and hepatic total cholesterol content after 
being fed a HFHC diet 
A-B) WT (n = 15) and S196A (n = 16) tissue mass relative to body weight on animals fed 
a HFHC diet.  
C) Representative images of gross morphology of livers from WT and S196A mice after 
being fed a HFHC diet. 
D) Hepatic total cholesterol levels assessed from WT and S196A mice fed a HFHC diet 
for (n=6).   
E) Plasma and liver total bile acids on WT (n=5) and S196A (n=6) mice fed a HFHC diet. 
Values shown on D and E (right) are normalized to protein levels in tissue homogenates. 
Data represents means ± SEM.* p < 0.05, *** p < 0.0005, **** p < 0.00005 relative to WT 
determined by Student’s t-test. 
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3.4. Impaired LXRα phosphorylation alters hepatic cholesterol homeostasis 
in a gene-specific manner in liver but not in small intestine 
Expression of several genes involved in different cholesterol homeostasis pathways, 
including biosynthesis, catabolism and export were assessed by standard qPCR and 
through pathway-focused qPCR arrays (see section 2.3 for further details). The complete 
list with all the Lipoprotein Signalling and Cholesterol Metabolism RT2 Array results can 
be found in Table 3.2. Interestingly, analysis of pathway-focused PCR arrays showed 
that the expression of several genes involved in cholesterol biosynthesis (see Figure 1.2), 
as well as Tm7sf2 and Ebp, were significantly higher in the livers of S196A mice (Figure 
3.4. A). Cholesterogenic genes have been shown to be directly repressed by LXR activity 
(330,331), so their increased expression could be the result of an indirect feedback 
regulation caused by lower intrahepatic cholesterol levels, and thus not directly regulated 
by the non-phosphorylated LXRα. Nevertheless, investigation of the changes in 
expression of several genes between chow and HFHC diet fed mice in both groups 
revealed that, although hepatic cholesterol content remained similar in WT and S196A 
groups on chow (Table 3.1), expression of the cholesterogenic transcription factor 
Srebp2 and its target gene Ldlr are reduced in chow-fed S196A livers (Figure 3.4. B).  
As expected, expression of these genes was strongly repressed in WT mice upon 
addition of dietary cholesterol (Figure 3.4. B), whereas they were largely unaffected in 
S196A mice. This is consistent with the unvaried levels of plasma and hepatic cholesterol 
between chow and HFHC groups in the mutant animals (Figure 3.2. A, 3.3. D). 
Moreover, analysis of classic LXR target genes and other genes in cholesterol 
homeostasis, revealed that mRNA levels of the Cyp7a1 gene, involved in cholesterol 
catalysis and driving the rate-limiting step in bile acid formation (44,106), didn’t vary 
between genotypes (Figure 3.5. A). However, mRNA levels of Cyp7b1, a gene that takes 
part in the alternate/acidic pathway for primary bile acid production, and which has been 
shown previously to be actively repressed by LXRs (332,333), were significantly 
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increased in the livers of phospho-deficient mice (Figure 3.5. A).  
 
Figure 3.4. Lack of LXRα phosphorylation alters hepatic cholesterol biosynthesis 
A) Hepatic gene expression from WT or S196A mice fed a HFHC diet for 6 weeks (n = 
6). Results are normalized to an average of five different house-keeping genes and 
shown relative to WT, set as 1.  
B) Hepatic gene expression of WT and S196A mice fed either a chow (n=4) or a HFHC 
diet (n=6). Results are normalized to cyclophilin levels and shown relative to WT Chow 
group. Significance was determined using single variance ANOVA followed by Student’s 
T-test. The F-statistic (dfbetween=3, dfwithin=16) and the P value for the significant main 
effects are shown.
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Figure 3.5. Lack of LXRα phosphorylation alters hepatic cholesterol homeostasis 
in a gene-specific manner in liver but not in small intestine 
A) Hepatic gene expression from WT or S196A mice fed a HFHC diet for 6 weeks (n = 
6). Results are normalized to the average levels of five different housekeeping genes or 
cyclophilin (Abcg8 and Idol) and shown relative to WT set as 1. 
B) Hepatic gene expression of WT and S196A mice fed either a chow (n=4) or a HFHC 
diet (n=6). Results are normalized to cyclophilin levels and shown relative to WT Chow 
group. Significance was determined using single variance ANOVA followed by Student’s 
T-test. The F-statistic (dfbetween=3, dfwithin=16) and the P value for the significant main 
effect are shown.  
C) Gene expression in small intestine of WT and S196A mice fed a HFHC diet for 6 
weeks (n = 6). Results are normalized to cyclophilin levels and shown relative to WT. 
Data shown as means ± SEM. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.00005 
relative to WT determined by Student’s t-test.  
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In addition, a significant decrease in the expression of the ABC-transporters Abca1 and 
Abcg1, two classic LXR target genes, was observed in S196A genotype compared to 
the wild-type mice (Figure 3.5. A). Abca1 and Abcg1 are responsible for intracellular 
cholesterol efflux onto lipid-poor apolipoproteins and HDL, respectively; and are key 
mediators of the RCT (see section 1.2.1.3). Next, expression of other ABC transporters 
that are known LXR direct targets, Abcg5 and Abcg8 (118) which take part in the 
hepatobiliary secretion of cholesterol were quantified. Notably, whilst the expression of 
both transporters was induced in the S196A livers, only the gene encoding for Abcg5 
was significantly increased (p < 0.05) (Figure 3.5. A). As with the cholesterogenic genes, 
these results led to further exploring whether WT and mutant mice respond similarly to 
the HFHC diet. Analysis of hepatic gene expression revealed that while Abcg1 levels are 
severely induced by the diet in both groups, albeit to a different extent (9- fold for WT vs 
4.9- fold for S196A), enhanced Abcg5 expression by the diet is specific to the S196A 
genotype (Figure 3.5. B).  Lastly, no differences in gene expression were observed for 
several other genes that are well established LXR target genes, such as apolipoprotein 
E (ApoE) (334) or the inducible degrader of the LDLR (Idol) (335) (Figure 3.5. A), thus 
confirming that the transcriptional regulation by the phosphorylation-deficient LXRα is 
gene-specific.  
Intestinal absorption and excretion of cholesterol also play a very important role by which 
LXR modulates cholesterol homeostasis (see section 1.2.1.3).  Therefore, expression of 
genes involved in intestinal absorption and excretion of cholesterol were assessed. No 
changes were observed in the expression of any of the genes tested (Figure 3.5. C), 
further confirming that the difference in cholesterol accumulation seen in the mutant mice 
is most likely due to increased hepatobiliary secretion, and not to increased 
transintestinal excretion. 
Lastly, since some oxysterols such as 25-OHC and 27-OHC, have been reported to be 
significantly enhanced in patients with NAFLD (336), the levels of several circulating 
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oxysterols were investigated in plasma of WT and S196A mice after being fed the HFHC 
diet. In addition to profound differences in their cholesterol levels, LXRα phospho-mutant 
mice also showed significantly reduced levels for most of the plasma oxysterols analysed 
(Figure 3.6). Interestingly, the only oxysterol that didn’t change between WT and S196A 
was 24(S),25-EC, which is also the only oxysterol that is not a metabolite of cholesterol 
(see section 1.1.2.1). Therefore, the reduction in circulating oxysterols mirrored that of 
circulating total cholesterol, probably due to there being less available substrate for 
oxysterol production.  
Overall, these results show that S196A mice are protected from dietary cholesterol 
accumulation in liver and plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Circulating oxysterols are significantly lower in LXRα-phosphorylation 
mutant mice 
Quantification of oxysterols in plasma of WT and S196A mice (n=6) after being fed a 
HFHC diet for 6 weeks. * p < 0.05, ** p < 0.005, relative to WT determined by Student’s 
t-test. 
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Table 3.2. Lipoprotein signalling and cholesterol metabolism RT2 Array results 
Results represent means and are shown relative to WT average, p-value determined by 
Student’s t-test (n=6). n/a corresponds to those genes whose expression was below the 
level of detection. 
Gene WT S196A p-value 
Abca1 1.02 0.77 0.036 
Abca2 1.02 1.07 0.618 
Abcg1 1.01 0.56 0.00012 
Acaa2 1.01 1.37 0.027 
Akr1d1 1.02 1.29 0.163 
Angptl3 1.05 1.89 0.033 
Ankra2 1.02 1.12 0.496 
Apoa1 1.01 1.18 0.242 
Apoa2 1.06 1.56 0.043 
Apoa4 1.07 0.89 0.524 
Apob 1.01 1.01 0.991 
Apoc3 1.04 1.57 0.053 
Apod 1.06 1.62 0.058 
Apoe 1.05 1.22 0.351 
Apof 1.01 1.24 0.068 
Apol8 n/a n/a n/a 
Cdh13 1.02 1.18 0.281 
Cel n/a n/a n/a 
Cela3b n/a n/a n/a 
Cnbp 1.01 1.34 0.054 
Colec12 1.01 1.44 0.0006 
Crp 1.00 1.43 0.060 
Cxcl16 1.01 0.75 0.012 
Cyb5r3 1.00 0.93 0.482 
Cyp11a1 n/a n/a n/a 
Cyp39a1 1.02 1.49 0.127 
Cyp46a1 1.07 1.79 0.130 
Cyp51 1.03 1.38 0.182 
Cyp7a1 2.55 2.64 0.958 
Cyp7b1 1.02 1.59 0.010 
Dhcr24 1.02 1.36 0.019 
Dhcr7 1.01 0.99 0.876 
Ebp 1.01 1.93 0.002 
Fdft1 1.01 0.86 0.053 
Fdps 1.02 1.12 0.553 
Hdlbp 1.00 1.19 0.105 
Hmgcr 1.01 0.94 0.517 
Hmgcs1 1.00 1.32 0.051 
Hmgcs2 1.04 1.33 0.132 
Idi1 1.26 1.19 0.916 
Il4 1.05 1.26 0.650 
Insig1 1.03 2.24 0.029 
 
Gene WT S196A p-value 
Insig2 1.04 1.55 0.064 
Lcat 1.02 1.38 0.022 
Ldlr 1.02 1.69 0.002 
Ldlrap1 1.01 1.06 0.626 
Leptin n/a n/a n/a 
Lipe 1.03 1.35 0.031 
Lrp10 1.01 1.06 0.603 
Lrp12 1.01 0.64 0.0003 
Lrp1b n/a n/a n/a 
Lrp6 1.00 1.12 0.353 
Lrpap1 1.00 1.05 0.394 
Mbtps1 1.01 1.16 0.303 
Mvd 1.04 0.96 0.706 
Mvk 1.02 0.86 0.185 
Ncp1l1 n/a n/a n/a 
Shp 1.05 1.24 0.678 
Fxr 1.08 1.31 0.470 
Nsdhl 1.00 1.31 0.046 
Olr1 1.26 1.37 0.864 
Osbpl1a 1.00 1.06 0.633 
Osbpl5 1.01 0.66 0.0007 
Pcsk9 1.33 2.03 0.315 
Pmvk 1.01 1.31 0.018273 
Ppard 1.01 1.10 0.588 
Prkaa1 1.01 0.86 0.125 
Prkaa2 1.01 0.96 0.756 
Prkag2 1.03 0.92 0.522 
Scap 1.02 1.12 0.391 
Scarf1 1.02 1.06 0.729 
Snx17 1.01 1.13 0.148 
Soat1 1.05 0.60 0.016 
Soat2 1.05 1.08 0.880 
Sorl1 1.04 0.68 0.060 
Srebf1 1.04 2.48 0.063 
Srebf2 1.03 1.25 0.211 
Stab1 1.04 1.18 0.574 
Stab2 1.01 1.11 0.390 
Stard3 1.01 0.99 0.824 
Tm7sf2 1.02 2.57 0.002 
Trerf1 1.01 0.70 0.023 
Vldlr 1.06 1.44 0.203 
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3.5. LXRα phospho-deficient mice have more pronounced steatosis  
As LXR activity plays a key role in increased de novo lipogenesis (128,143,144), 
changes in triglyceride levels in both WT and S196A mice were assessed. Similar to 
cholesterol levels, no differences in hepatic triglycerides were found between groups 
when fed a chow diet (Table 3.1).  
Remarkably, upon being fed a HFHC diet and in contrast to plasma levels (Figure 3.7. 
A), both hepatic Non-Esterified Fatty Acids (NEFAs) and triglyceride levels in S196A 
mice were about 80% and 40% higher than in WT mice, respectively (Figure 3.7. B).  
Therefore, histological status in livers of WT and S196A mice was blindly assessed by 
an independent pathologist for markers of murine NAFLD (309). Consistent with lipid 
levels, histological scoring demonstrated that S196A mice have enhanced micro and 
macrovesicular steatosis (Figure 3.8. A,B). Further characterization of lipid droplet area 
by morphometric analysis of Hematoxylin & Eosin-stained liver sections revealed that 
mutant mice exhibit larger and more numerous lipid droplets (Figure 3.8. B,C), confirming 
their predominant macrovesicular steatosis, which was also accompanied by a higher 
expression of lipid droplet proteins (Figure 3.8. D).  
 
 
Figure 3.7. Plasma and hepatic fatty acid and triglyceride levels  
A) Plasma and B) Hepatic non-esterified fatty acids (NEFAs) or triglycerides (TGs) 
levels from WT and S196A mice fed a HFHC diet for 6 weeks (n=6). Hepatic values 
shown are normalized to protein levels in tissue homogenates. Data represents means 
± SEM. ** p < 0.005 relative to WT determined by Student’s t-test.  
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Figure 3.8. LXRα phospho-deficient mice have a more pronounced steatosis  
A) Kleiner’s Scores for macrovesicular and microvesicular steatosis (0-3) from liver 
sections of WT and S196A mice (n=5-6) after being fed a HFHC diet.   
B) Representative images of Haematoxylin and Eosin (H&E) stained liver sections from 
WT and S196A mice before (chow) and after (HFHC) being fed a HFHC diet. Images are 
at 400x magnifications. 
C) Distribution of lipid droplets by area in H&E-stained liver sections of WT and S196A 
mice (n=6) after being fed a HFHC diet.  
D) Hepatic gene expression of WT or S196A mice (n = 6) after being fed a HFHC diet. 
Data are normalized to cyclophilin and shown relative to WT, set as 1.  
Data represents means ± SEM. ** p < 0.005 or *** p < 0.001 relative to WT determined 
by Student’s t-test.  
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Increased steatosis in S196A mice was associated with enhanced hepatic expression of 
the Srebp-1c lipogenic transcription factor, and other well-established LXR target genes 
involved in fatty acid synthesis (fatty acid synthase, Fas) and desaturation (stearoyl-CoA 
desaturase-1, Scd-1) (Figure 3.9). In contrast, expression of genes involved in fatty acid 
elongation (Elovl6) or uptake (Cd36), were not affected indicating that in this model, 
changes in LXRα phosphorylation alter gene expression in a gene-specific manner 
confirming previous findings in vitro (163,165), and as seen for genes involved in 
cholesterol metabolism (Figure 3.5. A). Interestingly, the expression of angiopoietin-like 
protein 3 (Angptl3), which has been previously shown to be induced by LXRs (337,338), 
was also significantly increased in the livers of S196A mice. Increased levels of this 
protein have been shown to raise plasma triglycerides in mice (339), which insinuates of 
a possible regulatory mechanism in the liver in order to get rid of the excess in fats.  
Altogether, these results demonstrate that LXRα phosphorylation deficiency at S196 
induces hepatic steatosis in response to a HFHC diet.  
Figure 3.9. LXRα-S196A causes increased expression of genes involved in fatty 
acid and triglyceride synthesis  
Hepatic gene expression from WT or S196A mice (n = 6) after being fed a HFHC diet. 
Data are normalized to the average levels of five different housekeeping genes (for 
Angptl3 and Acaa2 genes) or cyclophilin and shown relative to WT, set as 1. Data 
represent means ± SEM. * p < 0.05, ** p < 0.005 or *** p < 0.001 relative to WT 
determined by Student’s t-test.  
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3.6. Impaired LXRα phosphorylation attenuates diet-induced hepatic 
inflammation and fibrosis 
Diet-induced hepatic steatosis precedes inflammation and progression to fibrosis in 
experimental models (340,341). Strikingly, histological analysis of liver slides showed 
that not only LXRα-S196A mice scored lower for inflammation and hepatocyte ballooning 
(Figure 3.10. A), but they also displayed significantly less fibrosis, as quantified by levels 
of picrosirius red stain (Figure 3.10. B), which allows for the visualization of collagen I 
and III fibres. Pathway-focused analysis of mRNA expression in livers of both genotypes 
confirmed that attenuated inflammation and fibrosis in the S196A mice was associated 
with a significant decrease in the expression of several pro-inflammatory and pro-fibrotic 
mediators (Figure 3.10. C), such as Oncostatin M (Osm) (342), Chemokine (C-X-C motif) 
ligand 1 (Cxcl1) (343) and Osteopontin (Opn or Spp1) (344) as well as collagen synthesis, 
like Collagen type I alpha 1 chain (Col1a1) and Transforming growth factor, beta 2 
(Tgfb2). The complete list with all the Cytokines & Chemokines RT2 Array results can be 
found in Table 3.3.  
Only a subset of genes in the panel analysed was affected by changes in LXRα 
phosphorylation upon presence of the HFHC diet (Figure 3.10. C and Table 3.3), further 
corroborating the gene specific effects this modification has on LXRα activity. 
Interestingly, changes in gene expression in response to the cholesterol-rich diet further 
evidenced the attenuated inflammatory and fibrotic response of the S196A mice (Figure 
3.11). For instance, basal expression of Spp1 and Tgfb2 is reduced in S196A mice and 
is only enhanced minimally when challenged with this diet. As expected, for all of the 
other genes examined, differences between genotypes were only revealed upon 
exposure to the HFHC diet (Figure 3.11), further establishing it as an agent of hepatic 
injury.  
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Figure 3.10. LXRα-S196A attenuates diet-induced hepatic inflammation and 
fibrosis 
A) Kleiner’s Scores for lobular inflammation (0-3) and Hepatocyte ballooning (0-2) from 
liver sections of WT and S196A mice (n=5-6).  
B) Representative images of Picrosirius Red stained liver sections from WT and S196A 
mice (left). Quantification of Picrosirius red-stained areas on three independent areas 
per section (n = 6) (Right) by Image J. Images are at 200x magnifications. 
C) Hepatic gene expression from WT or S196A mice (n = 6). Data are normalized to the 
average levels of five different housekeeping genes or cyclophilin (for Col1a1, Col1a2, 
Tlr4, a-Sma and Mmp9 genes) and shown relative to WT.  
Data represents means ± SEM. * p < 0.05, ** p < 0.005 relative to WT determined by 
Student’s t-test. 
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Figure 3.11. Differences in inflammatory gene expression in response to diet are 
gene-specific  
Hepatic gene expression in WT and S196A mice fed either a chow (n=4) or a HFHC diet 
(n=5-6). Results are normalized to cyclophilin levels and shown relative to WT Chow 
group. Significance was determined using single variance ANOVA followed by Student’s 
T-test. The F-statistic (dfbetween=3, dfwithin=15) and the P value for the significant main 
effect are shown. * p < 0.05, ** p < 0.005, *** p < 0.0005, relative to WT Chow as 
determined by Student’s t-test. Data represents means ± SEM. 
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Table 3.3. Cytokines & Chemokines RT2 Array results 
Results represent means and are shown relative to WT average, p-value determined by 
Student’s t-test (n=6). n/a corresponds to those genes whose expression was below the 
level of detection. 
Gene WT S196A p-value 
 Adipoq 1.50 1.56 0.962 
Bmp2 1.00 1.41 0.016 
Bmp4 1.04 0.95 0.677 
Bmp6 1.00 1.25 0.033 
Bmp7 1.08 1.01 0.842 
Ccl1 1.06 0.45 0.089 
Ccl11 1.25 1.35 0.917 
Ccl12 1.59 4.36 0.074 
Ccl17 1.06 2.13 0.135 
Ccl19 1.01 0.86 0.456 
Ccl2 1.04 0.49 0.078 
Ccl20 n/a n/a n/a 
Ccl22 1.21 1.71 0.395 
Ccl24 1.00 1.94 0.221 
Ccl3 1.02 0.49 0.044 
Ccl4 1.05 0.65 0.204 
Ccl5 1.01 1.50 0.011 
Ccl7 1.05 0.54 0.120 
Cd40 Ig 1.08 0.90 0.665 
Cd70 n/a n/a n/a 
Cntf 1.01 1.57 0.004 
Csf1 1.01 0.78 0.114 
Csf2 1.06 1.35 0.542 
Csf3 n/a n/a n/a 
Ctf1 1.00 1.28 0.009 
Cxc3cl1 1.01 0.57 0.027 
Cxcl1 1.04 0.41 0.036 
Cxcl10 1.07 1.18 0.721 
Cxcl11 1.26 1.55 0.724 
Cxcl12 1.00 1.11 0.435 
Cxcl13 1.16 5.93 0.002 
Cxcl16 1.00 0.74 0.014 
Cxcl3 n/a n/a n/a 
Cxcl5 1.22 0.33 0.109 
Cxcl9 1.05 1.74 0.382 
Fasl 1.03 1.69 0.020 
Gpi1 1.00 0.98 0.750 
Hc 1.00 1.26 0.062 
Ifna2 0.96 0.58 0.374 
Ifng 1.56 2.74 0.350 
Il10 1.04 1.81 0.498 
Il11 1.04 0.45 0.161 
 
Gene WT S196A p-value 
Il12a 1.07 1.23 0.697 
Il12b 1.13 0.44 0.146 
Il13 1.05 1.12 0.862 
Il15 1.00 0.81 0.023 
Il16 1.06 0.93 0.639 
Il17a n/a n/a n/a 
Il17f 1.01 1.17 0.752 
Il18 1.00 1.33 0.004 
Il1a 1.01 1.02 0.928 
Il1b 1.10 1.42 0.403 
Il1rn 1.01 0.61 0.035 
Il2 n/a n/a n/a 
Il21 n/a n/a n/a 
Il22 n/a n/a n/a 
Il23a 1.01 1.58 0.504 
Il24 n/a n/a n/a 
Il27 1.01 0.71 0.084 
Il3 n/a n/a n/a 
Il4 1.02 1.63 0.086 
Il5 1.30 3.35 0.136 
Il6 1.26 2.44 0.589 
Il7 1.00 1.01 0.972 
Il9 1.52 1.07 0.663 
Lif 1.15 0.53 0.369 
Lta 1.00 0.82 0.638 
Ltb 1.03 0.97 0.847 
Mif 1.00 1.10 0.450 
Mstn n/a n/a n/a 
Nodal 1.02 1.00 0.946 
Osm 1.02 0.16 0.007 
Pf4 1.02 0.46 0.013 
Ppbp 1.04 1.54 0.215 
Spp1 1.10 0.29 0.045 
Tgfb2 1.01 0.47 0.005 
Thpo 1.00 0.94 0.475 
Tnf 1.07 0.79 0.320 
Tnfrsf11b 1.01 1.02 0.919 
Tnfrsf10 1.00 1.16 0.488 
Tnfrsf11 1.89 2.85 0.665 
Tnfrsf13b 1.02 0.67 0.082 
Vegfa 1.00 1.22 0.363 
Xcl1 1.49 1.86 0.720 
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To further characterize the observed differences in hepatic inflammation and fibrosis, 
several pathways involved in the pathogenesis of lipid-induced liver damage were 
investigated (see section 1.2.3). The number of apoptotic cells present was similar 
between genotypes as assessed by dUTP nick end labelling (TUNEL) staining of liver 
sections (Figure 3.12. A), and lipid peroxidation levels quantified by thiobarbituric acid 
reactive substances (TBARS) assay revealed no differences in oxidative stress between 
groups (Figure 3.12. B). No significant differences were found in the percentage of areas 
in the liver positive for macrophage marker F4/80, which identifies both resident Kupffer 
cells and infiltrating macrophages (345), as assessed by immunohistochemistry staining 
(Figure 3.12. C), although there was a trend towards a decreased number of F4/80+ 
areas in S196A livers.  
Interestingly, a reduction in the expression of several factors involved in the activation of 
the ER stress pathway (Figure 3.12. D) such as the UPR target gene C/EBP homologous 
protein (Chop) and the Activating Transcription Factor (Atf3) (346) suggests that S196A 
mice are protected from lipotoxicity, likely through a reduction in ER stress activation. 
This was further supported by a significant decrease in the splicing of the transcription 
factor X-box-binding protein-1 (Xbp1) mRNA (Figure 3.12. D), which leads to the protein 
translocating to the nucleus and the induced expression of several factors in the UPR 
pathway (249).  
The link between ER stress and hepatic damage has been extensively studied (see 
section 1.2.3.4) and it is now understood that prolonged ER stress not only increases 
steatosis levels but also promotes hepatic fibrosis (347). Overall, these findings 
demonstrate that changes in LXRα-phosphorylation at S196 attenuates lipid-induced 
hepatic inflammation and fibrosis partly by reducing ER stress despite the enhanced 
steatosis.  
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Figure 3.12. Reduction in hepatic inflammation and fibrosis is associated with 
reduced ER stress 
A) Hepatic cell apoptosis assessed in situ (n = 6) by TUNEL assay (Left). Representative 
images of TUNEL-stained liver sections from WT and S196A mice at 200x magnification 
(Right).  
B) Hepatic lipid peroxidation shown as MDA levels in WT and S196A livers (n = 6) 
normalised to protein levels in tissue homogenates.  
C) Quantification of F4/80-positively stained areas in liver sections of WT and S196A 
mice at 200x magnification (n=4) and representative images of immunohistochemistry 
staining. Dots represent average of three independent areas per animal. 
D) Hepatic gene expression from WT or S196A mice (n = 6). Values shown are 
normalized to cyclophilin and shown relative to WT.  
Data are means ± SEM. * p < 0.05, ** p < 0.005 relative to WT determined by Student’s 
t-test. 
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3.7. Summary 
 Hepatic LXRα is phosphorylated under basal conditions in wild-type mice and 
human livers 
 S196A mice show impaired LXRα-Ser196 phosphorylation in liver 
 Phosphorylation-deficient mice show no apparent developmental differences  
 S196A mice are protected from dietary cholesterol accumulation in liver and 
plasma, which associates with higher expression of Abcg5  
 There are no differences in small intestine LXR target gene expression between 
WT and S196A groups 
 LXRα phosphorylation deficiency at S196 induces steatosis in response to a HFHC 
diet 
 Hindering LXRα-phosphorylation at S196 attenuates lipid-induced hepatic 
inflammation and fibrosis, partly by reducing ER stress. 
 
 
3.8. Discussion 
While studying the effect of LXRα phosphorylation on cholesterol homeostasis in vivo, 
no differences were observed between groups when animals were fed a chow diet (Table 
3.1). This phenomenon has already been reported in previous animal models of 
transgenic LXR (106,107), where no apparent phenotype is detected on animals without 
a dietary challenge. This has been hypothesised to be caused by the fact that standard 
rodent chow diets contain very little if any cholesterol (see section 2.2.1. for chow diet 
composition), and thus the impact that LXRs may have on lipid metabolism becomes 
insignificant, as most of the cholesterol in these animals comes from de novo synthesis 
(see section 1.1.3.1). Indeed, even though gene expression on chow livers revealed 
significant differences between groups, these didn’t translate into changes in plasma 
(Figure 3.2. A) or hepatic total cholesterol levels (Table 3.1). 
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Traditional understanding of NAFLD pathogenesis stated that high levels of intrahepatic 
NEFAs and their metabolites cause lipotoxic injury to liver cells, and this will sequentially 
progress into hepatic chronic inflammation and fibrosis (348). However, more recent 
studies have shown that the amount of saturated over unsaturated fatty acids could be 
key in the progression to NASH (349). Indeed, activity of SCD1, which is involved in the 
biosynthesis of monounsaturated fatty acids, has been found to be preventive of 
steatohepatitis progression (350). In our study, the S196A mice proved to have a higher 
expression of Scd1 (Figure 3.9), which could account for the lower hepatic damage. 
Determination of the hepatic fatty acid pool composition would shed more light into 
whether changes in LXRα phosphorylation skew hepatic metabolism towards the 
production of more protective unsaturated lipid species. Therefore, future work should 
investigate the exact mechanism through which the phospho-mutant LXRα induces 
steatosis. There are several possible causes for the observed increase of hepatic fats in 
this study (see section 1.2.3.1 for more details), which include: increased uptake of 
circulating free fatty acids released from the lipolysis of adipose tissue (351); increased 
de novo lipogenesis (DNL) (215,352); diminished lipid (VLDL) secretion (353); and a 
reduced capacity of fatty acid beta-oxidation (354). Based on the observation that 
plasma NEFAs, TGs and insulin levels do not differ between genotypes (Figure 3.7. A 
and Table 3.1), differences in hepatic fat accumulation in S196A mice are likely to result 
from intrahepatic causes; most probably due to an enhanced lipogenic programme, as 
observed in other LXR models (61,323,355). Moreover, DNL accounts for 25% of the 
hepatic fat in NAFLD patients (210). However, at this point I was not able to distinguish 
if this is caused by a direct LXR transcriptional activity or through the increased 
expression of Srebp-1c, since the activity of this transcription factor is also tightly 
regulated through post-transcriptional modifications (356), and thus its increased gene 
expression may not necessarily translate into increased activity. In addition, Fas (130) 
and Scd-1 (131) have been shown to be LXR direct target genes, so their increased 
expression may not necessarily be mediated through Srebp-1c. Thus, it would be 
interesting to study in the future if this phenotype can be replicated or not in S196A mice 
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lacking the Srebp1c transcription factor. This could be achieved by crossing the S196A 
mutant mice with a strain of mice in which the SREBP function can be disrupted in 
adulthood through conditional induction of the Cre recombinase (357). Furthermore, a 
preliminary study on the longer-term effect (12 weeks) of the HFHC diet on hepatic 
steatosis and fibrosis revealed that, despite the WT and S196A mice reaching the same 
degree of steatosis (Figure 3.14. A,B) at that point, protection against the onset of fibrosis 
remained in the phospho-mutant animals (Figure 3.15. A,B). Nonetheless, the specific 
mechanisms behind this protection on the S196A mice after a 12 week exposure to the 
HFHC diet will need to be investigated in the future. 
Besides the changes in liver, the spleen and kidneys of the S196A mice also displayed 
significantly reduced weight (Figure 3.3. B). Probably not coincidentally, LXRα is highly 
present in these two organs (3). Even though most of the work exploring LXR actions 
has focused on their effect on immunity in the spleen (358), and the adrenergic control 
of sodium excretion (359) as well as the renin-angiotensin system (360) in the kidney; a 
recent study addressing LXR effects on tissue cholesterol metabolism, found that upon 
administration of the GW3965 LXR agonist to LXRα/β knock-out mice, both spleen and 
kidney suffered a significant increase in cholesterol ester levels (361). It would be 
interesting in the future to assess how changes in LXRα phosphorylation at S196 
regulate lipid metabolism in other tissues besides the liver, as the phenomenon of 
cholesterol accumulation is linked to several pathologies, such as renal glomerular 
disease (362,363). 
There are also other mechanisms that have been implicated in the development of 
NAFLD and its progression to NASH, as is the role of cholesterol. Although the effects 
of dietary cholesterol on NAFLD pathogenesis remain conflicting, recent studies found a 
correlation between cholesterol intake and a higher degree of NAFLD, especially in non-
diabetic individuals with a normal body mass index (364) and non-obese animals (365). 
Moreover, several animal studies have demonstrated that free cholesterol (FC) can act 
as a hepatotoxic agent (366) and activates hepatic stellate cells, key mediators in 
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collagen deposition in hepatic fibrosis (367). Overall, the set of experiments in this 
chapter indicate that the whole-body impairment of LXRα-S196 phosphorylation confers 
protection from accumulation of dietary cholesterol. Based on the changes in the hepatic 
expression of the ABCG5/8 cholesterol transporters (Figure 3.5 A,B), I suggest a model 
whereby lower plasma and hepatic total cholesterol levels in LXRα phosphorylation-
deficient mice are caused by a higher hepatobiliary excretion rate (Figure 3.13).  
 
 
 
 
 
 
 
 
Figure 3.13. Pathways involved in the regulation of plasma and liver total 
cholesterol levels in S196A mice 
Schematic representation of the potential pathways that may lead to decreased plasma 
and hepatic total cholesterol levels, and the genes seen to be differentially expressed in 
the S196A mice (in parenthesis). 
 
Indeed, several previous studies have established that hepatic Abcg5 and Abcg8 
expression alone is a strong determinant in the rate of cholesterol excretion (368,369). 
In addition, this effect has been shown to be modulated directly by LXR (370).This model 
is corroborated by the lack of difference in the expression of intestinal cholesterol 
transporters, and decreased plasma and hepatic bile acid levels. However, this 
hypothesis will need to be further confirmed by assessing the amount of neutral 
cholesterol and bile acids found in the faeces of both groups of mice, as well as biliary 
lipid composition.  
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In rodents, LXRs have been shown to induce catabolism of cholesterol into bile acids 
through the expression of Cyp7a1 (106). Despite the beneficial effects of reducing 
cholesterol levels through its catabolism, hepatic accumulation of bile acids is damaging 
and can lead to cholestasis, a disease where bile can’t flow out of the liver causing 
hepatotoxicity (371). In this study, no significant differences were observed in plasma 
and hepatic bile acid levels between genotypes, although there was a trend towards a 
decrease in bile acids in both compartments in the S196A mice (Figure 3.3. E). Hence, 
it would be interesting in the future to assess the effect that this reduction in bile acid 
levels has on hepatic cell toxicity, and subsequent inflammation and fibrosis. 
The phospho-mutant mice proved to have a lower expression of the members of the 
ATP-binding cassette (ABC) transporter family, Abca1 and Abcg1. These transporters 
are responsible for intracellular cholesterol efflux onto lipid-poor apolipoproteins and 
HDL, respectively; and are key mediators of the RCT process. Animals deficient for any 
of these two transporters show decreased levels of circulating total cholesterol and HDL 
(372,373). In contrast, the LXRα mutant mice exhibited a higher ratio of the HDL to LDL 
fractions in plasma. Besides an increase in circulating HDL, the elevated HDL/LDL ratio 
in the S196A mice could also be accounted for by a reduced circulating LDL fraction, 
caused by the increase in hepatic LDL-Receptor (Ldlr) expression observed in the 
mutant mice (Figure 3.5. A).  In this study, distribution of total cholesterol on the two main 
lipoprotein fractions was performed by quantifying the amount of lipid found on HDL and 
LDL/VLDL fractions after separating them by density (see section 2.2.3.3). Although this 
method proves to be quick and reliable and is widely used in clinical practice to evaluate 
cholesterol distribution in relation to cardiovascular risk, it fails to provide information on 
the actual distribution of cholesterol throughout the lipoprotein classes. Therefore, future 
studies using more comprehensive techniques such as the quantification of plasma 
lipoprotein fractions by fast-performance liquid chromatography gel filtration (374) would 
provide a better understanding on how the plasma cholesterol in the S196A is distributed 
across the different lipoproteins. 
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Figure 3.14. WT and S196A mice show the same level of steatosis after being fed 
a HFHC diet for 12 weeks 
A) Representative images of H&E-stained liver sections from WT and S196A mice after 
being fed a HFHC diet for 12 weeks. Images are at 400x magnifications. 
B) Distribution of lipid droplets by area in H&E-stained liver sections of WT and S196A 
mice (n=6) after being fed a HFHC diet for 12 weeks. Data represents means ± SEM. 
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Figure 3.15. LXRα phospho-mutant mice remain protected against the onset of 
fibrosis after being fed a HFHC for 12 weeks 
A) Representative images of Picrosirius Red-stained liver sections from WT and S196A 
mice. Images are at 200x magnifications 
B) Quantification of Picrosirius red-stained areas on three independent areas per section 
(n = 6). Data represents means ± SEM. Significance determined by Student’s t-test. 
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Chapter 4. Mechanisms underlying changes in gene regulation 
by LXRα phosphorylation deficiency in response to diet 
 
4.1. Introduction 
Molecular modelling studies suggest that phosphorylation of LXRα at S198 (murine 
S196) induces a structural change in the receptor’s hinge region (163,165). This region 
is responsible for linking the DNA-binding and ligand-binding domains in nuclear 
receptors, conferring a specific structural conformation that can affect not only ligand 
binding, but also cellular localisation and cofactor recruitment (375). Indeed, previous in 
vitro studies looking at changes in LXRα phosphorylation uncovered how this 
modification affects the transcriptional activity of the receptor through several 
mechanisms, including binding to DNA as well as cofactor recruitment (163,165,166) 
(see section 1.1.4). Nonetheless, how these changes affect the receptor’s functionality 
in vivo remains unknown.  
Moreover, it has been demonstrated that certain genes are only sensitive to regulation 
by the non-phosphorylated version of LXRα (163,165); a phenomenon also attributable 
to other nuclear receptors and changes in their post-translational modifications (376). 
For example, induction of the Ccl24 gene in RAW 264.7 cells by ligand-activated LXRα 
was seen to be dependent on its non-phosphorylated state at S198, either by 
pharmacological inhibition by the CK2 inhibitor DMAT or by RXR ligands, as well as by 
the genetic inhibition on the S198A mutant (163). Therefore, hepatic LXRα-S196A 
activity could help uncover novel target genes in the context of a HFHC-diet that haven’t 
been previously identified as LXR targets. 
To explore this and better understand the extent of disparity in diet-induced responses 
between WT and S196A mice (see chapter 3); as well as to identify novel pathways and 
genes sensitive to LXRα phosphorylation in vivo, genome-wide transcriptomic 
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differences in livers of WT and S196A mice fed a chow and HFHC diet were analysed 
by RNA-sequencing (RNA-seq) analysis. RNA-seq is a high-throughput technique that 
provides several benefits over other gene screening methods (i.e. microarrays), such as 
more precise measurement of levels of transcripts due to very low, if any, levels of 
background signal (377) .     
Thus, the main focus of the work in this chapter has been to assess how changes in 
LXRα phosphorylation affect its transcriptional activity in response to a HFHC diet, and 
investigate novel target genes involved in the pathogenesis of NAFLD that may be only 
susceptible to the mutant form of the receptor. 
With this work I show that the non-phosphorylatable LXRα-S196A receptor acts as a 
nutritional sensor by regulating specific pathways in response to a HFHC-diet. Moreover, 
the S196A mutant mice revealed novel hepatic target genes for the receptor by 
increasing LXR occupancy at putative binding sites, which was associated with 
enhanced transcriptional initiation and elongation of transcripts. These results were 
accompanied by an additional increased occupancy of the TBLR1 cofactor to the same 
LXR putative binding sites, suggesting that TBLR1 may be an important component 
facilitating the transcription of these genes by the LXRα phospho-mutant. 
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4.2. WT and S196A mice display different hepatic transcriptomes under 
chow and HFHC diets  
When comparing RNA-seq results between chow and HFHC-fed WT and S196A 
samples, Principal Component Analysis (PCA) plots demonstrated that even though 
differences between the four groups are considerably high and they clustered together 
(Figure 4.1. A), samples from HFHC diet mice have a bigger intra-group variability than 
their chow-fed counterparts, which already suggests that the HFHC diet is having an 
impact on the hepatic transcriptomes of WT and S196A. RNA-seq analysis revealed that 
there are 667 genes whose hepatic expression is significantly different in the phospho-
mutant mice fed a HFHC diet, and 539 genes were significantly different between both 
groups when fed a chow diet (adjusted p-value < 0.05) (Figure 4.1. B).  
Notably, when comparing gene expression changes in response to diet in WT and S196A 
groups (chow vs HFHC for each genotype), the number of genes affected varied 
substantially between WT and phospho-mutant mice (Figure 4.2. A). Moreover, S196A 
livers appeared only to share the expression of only a certain number of these genes 
with the WT group (Figure 4.2. B). This supports the idea that impaired phosphorylation 
of LXRα at Ser196 is differentially reprogramming hepatic transcriptomes; and through 
it, altering these animal’s susceptibility to diet-induced hepatic injury. In support of this 
hypothesis, most of the top upregulated genes in S196A livers under a HFHC diet were 
shown to be modulated by the phosphorylation-mutant LXRα only in the presence of the 
diet, and not under basal conditions (chow-regulated liver expression) (Figure 4.2. C). 
Importantly, neither of these genes have been previously reported to be subject to LXR 
regulation in liver, thus highlighting the relevance of LXRα phosphorylation in modulating 
new transcriptional responses to dietary cholesterol. 
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Figure 4.1. Hepatic transcriptomes on chow and HFHC diet-fed WT and S196A 
livers  
A) Principal Component Analysis (PCA) plot showing samples analysed for RNA-seq 
divided in four different groups: WT Chow, WT HFHC, S196A Chow and S196A HFHC 
(n=3). 
B) Volcano plots of log2 ratio (fold change) versus p-value of differentially expressed 
genes in S196A vs WT livers fed either a chow or a HFHC-diet (n=3). Blue line indicates 
an adjusted p-value threshold of 0.04 of the Wald Test for logistic regression. Transcript 
abundance was estimated using Illumina's RnaReadCounter tool and differential 
expression analysis was performed with DESeq2. 
 
 
 
 
115 
 
 
 
 
 
 
 
Figure 4.2. Impaired phosphorylation of LXRα at Ser196 differentially reprograms 
hepatic transcriptomes in response to a HFHC diet 
A) Number of genes differentially expressed between Chow and HFHC-fed livers 
quantified by RNA-sequencing (n=3). 
B) Venn’s diagram of the comparison of differential gene expression between chow and 
HFHC livers for WT and S196A animals (n=3). Graph includes number of genes either 
induced (green) or repressed (red) in HFHC livers in comparison to Chow livers.   
C) Graph representing fold-change of RNA-seq gene counts in livers of S196A mice 
relative to the values in WT livers that illustrates various examples of results obtained in 
enriched S196A pathways (n=3). 
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4.3. RNA-sequencing of HFHC livers confirms pathways involved in lipid 
metabolism and fibrosis are affected by changes in LXRα phosphorylation 
Despite the robust sensitivity of RNA-seq, the strongest variation in gene expression on 
the top upregulated and downregulated hits (S196A compared to WT) was first 
confirmed by qPCR in a separate set of animals fed a HFHC diet (Figure 4.3). Therefore, 
the differences in transcript abundance reported in the RNA-seq analysis could be 
replicated in the livers of other WT and S196A HFHC-fed mice, which validates the 
robustness of the RNA-seq regardless of technical and biological sample variability. 
Confirming previous data (chapter 3), pathway enrichment analysis on HFHC-fed livers 
showed a remarkable upregulation of genes involved in different lipid metabolism 
pathways (Figure 4.4 and 4.5), as well as a robust decrease in wound healing and 
fibrosis (epithelial-mesenchymal transition) (Figure 4.4 and 4.5) on the S196A group.  
 
 
 
Figure 4.3. Validation of top regulated genes identified by RNA-seq comparing WT 
vs S196A HFHC-fed livers 
qPCR validation of top upregulated and downregulated gene candidates on 
experimentally-independent WT and S196A livers fed a HFHC diet (n=6). Results are 
normalized to cyclophilin and shown relative to WT, set as 1. Data represents mean ± 
SEM. * p < 0.05 relative to WT determined by Student’s t-test. 
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Strikingly, many of the genes that showed the most enrichment on the fatty acid 
metabolism pathway are involved in the oxidation of fatty acids (Figure 4.5), i.e. acyl-
CoA synthetase long-chain family member 1 (Acsl1), which codes for the enzyme 
responsible for catalysing the pre-step reaction for β-oxidation; or acyl-Coenzyme A 
dehydrogenase, medium chain (Acadm), which performs the first step of medium-chain 
fatty acid oxidation. This further supports the idea that the high hepatic NEFA and 
triglyceride levels observed in the S196A mice (Figure 3.7) are probably not due to a 
reduction in mitochondrial β-oxidation, but rather an increased lipogenic programme (see 
chapter 3). Indeed, it seems plausible that the induced expression of genes involved in 
fatty acid oxidation in the S196A livers appears as a compensatory mechanism, with the 
intention to get rid of the lipid surpass in these animals. 
It must be noted that due to the condensed nature of the Hallmark gene sets (318), all 
those genes that are related to the processes of wound healing, fibrosis and metastasis 
are incorporated under the “epithelial-mesenchymal transition” gene set. Amongst these, 
eleven collagen species; and importantly, several members of the Lysyl oxidase (LOX) 
and lysyl oxidase-like (LOXLs) families, responsible for collagen stabilisation through 
irreversible crosslinking (378–380) are strongly reduced in S196A mice (Figure 4.5). This 
is the first time that this class of enzymes, recently reported to promote fibrosis 
progression and limit its reversibility (381), have been linked to LXRα.  
Tables containing all the results obtained in the pathway enrichment analysis can be 
found in Appendix 1.  
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Figure 4.4. Pathway enrichment analysis of HFHC diet-fed WT and S196A livers  
GSEA analysis showing positive and negative enriched pathways in S196A livers with a 
nominal p-value < 0.5 (100 permutations) derived from HALLMARK gene sets (Top). 
Enrichment profiles of Fatty Acid Metabolism and Epithelial-Mesenchymal Transition 
HALLMARK pathways (Bottom).  
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Figure 4.5. Heatmaps from HFHC-fed WT and S196A livers for fatty acid 
metabolism and fibrosis pathways 
Heatmaps representing differences in absolute raw gene count values on WT and S196A 
HFHC-fed livers obtained by RNA-Seq (n=3). After sequencing reads were aligned to 
the mouse GRCm38/mm10 reference sequence, transcript abundance was estimated 
using Illumina's RnaReadCounter tool. Low (green), midpoint (black), and upper (red) 
limits are shown for each heatmap.   
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Moreover, the expression of a subset of genes that were shown to be part of a 
transcriptional signature that distinguishes between low-risk/mild and high-risk/severe 
NAFLD amongst pre-symptomatic patients (382), was remarkably different in WT and 
S196A mice (Figure 4.6). Interestingly, most of the genes in Figure 4.6 regarding the 
human NAFLD signature, such as Fibrillin 1 (Fbn1), Lumican (Lum) and numerous 
collagen species, are involved in extracellular matrix remodelling and tissue regeneration 
(383,384), further emphasizing a role for Ser196-LXRα phosphorylation in the regulation 
of these pathways. Overall, these differences seem to indicate that, at least at the 
transcriptional level, the HFHC-S196A model closely replicates the differences between 
early and advanced stages of human NAFLD; and suggests that changes in LXRα 
phosphorylation could alter pre-clinical NAFLD progression. 
Interestingly, the expression of Tm6sf2, one of the genes whose variants have 
extensively been shown to contribute to the development and/or progression of human 
NAFLD (see section 1.2.2.5), and whose ablation in mice produces increased liver 
triglyceride content and decreased VLDL  secretion (293), remained the same between 
groups (Figure 4.6);  
Lastly, no differences were observed in the expression of most nuclear receptors 
expressed in liver (Figure 4.6). Despite this, gene expression analysis revealed that, 
albeit to a low extent (1.45 fold-change), Lxra (N1hr3) expression was significantly higher 
in the livers of S196A mice under a HFHC diet (Figure 4.6).  
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Figure 4.6. Differences in transcript abundance on HFHC-fed WT vs S196A livers 
for genes involved in human NAFLD and hepatic nuclear receptors  
Heatmaps representing differences in absolute raw gene count values on WT and S196A 
HFHC-fed livers obtained by RNA-Seq (n=3). After sequencing reads were aligned to 
the mouse GRCm38/mm10 reference sequence, transcript abundance was estimated 
using Illumina's RnaReadCounter tool. Low (green), midpoint (black), and upper (red) 
limits are shown for each heatmap.   
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4.4. Impaired LXRα phosphorylation uncovers novel diet-modulated LXR 
target genes 
One gene shown to be highly induced in HFHC-fed mutant liver, Ces1f (Figures 4.2. C, 
4.3 and 4.7), encodes for a member of the family of carboxylesterases 1 (Ces1), a set of 
proteins that hydrolyse cholesterol esters and triglycerides and play an important role in 
hepatic lipid mobilization (385,386). RNA-seq analysis showed that in addition to Ces1f, 
other Ces1 members are differentially regulated by the LXRα phospho-mutant (Ces1b, 
Ces1c, Ces1d, Ces1e), most of which are only revealed to be sensitive to LXRα 
phosphorylation in a cholesterol-rich environment (Figure 4.7 A,B). 
Interestingly, the form previously shown to be regulated by LXR ligands in liver (Ces2c) 
(387) barely changes in S196A livers regardless of the diet used (Figure 4.7 A,B), again 
pointing at unique differences in the transcriptional response exerted by changes in 
LXRα phosphorylation upon exposure to dietary or pharmacological environments.  
 
 
 
Figure 4.7. Ces1f is highly induced in S196A livers in response to a HFHC diet 
A) Graph representing fold-change of RNA-seq gene counts in livers of S196A mice 
relative to the values in WT livers (n=3) depicting differences in expression of various 
members of the Ces family. After RNA extraction and sequencing, transcript abundance 
was estimated using Illumina's RnaReadCounter tool and differential expression 
analysis performed with DESeq2. 
B) Heatmaps illustrating differences in absolute raw gene count of several members of 
the Ces family in WT and S196A livers upon chow and HFHC diets (n=3). Low (green), 
midpoint (black), and upper (red) limits are shown for each heatmap.   
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In order to test if Ces1f could be a target gene sensible to the non-phosphorylatable form 
of LXRα, the Ces1f gene body and promoter were scanned for potential LXREs (see 
section 1.1.1). In silico analysis uncovered a degenerated DR4 sequence resembling the 
published consensus LXRE in mouse liver (315) (Figure 4.8). Thereafter, binding studies 
by Chromatin Immunoprecipitation (ChIP) of LXR as well as its heterodimerisation 
partner RXRα (see section 1.1.1), were carried out in livers of HFHC-fed WT and S196A 
mice. Interestingly, ChIP analysis demonstrated this sequence was preferentially bound 
by LXR in HFHC-fed S196A livers (Figure 4.9. A). This associated with a significant 
increase in S196A livers of RNA Polymerase II (Pol II) and phosho-Ser2 Pol II (pSer-Pol 
II) occupancy to the Ces1f transcription start site (TSS), reflecting an enhanced 
transcriptional initiation and elongation of the Ces1f transcript, respectively (Figure 4.9 
B). By comparison, binding of the LXR heterodimerisation partner RXRα to the Ces1f 
DR4 sequence was not affected (Figure 4.8. A).  
 
 
 
 
 
 
 
Figure 4.8. Comparison between analysed DR4 sequences and consensus LXRE 
A) Web logo of consensus DR4 sequence motifs on LXR-RXR (vehicle-treated mouse 
livers) binding sites. Obtained from Boergesen et al., 2012 (315). 
B) Degenerated DR4 sequences obtained in silico on Ces1f and Cyp2c69 murine genes 
and established LXRE on the Srebp1c promoter. Nucleotides in bold correspond to the 
sequence where the LXR sits (5’) and those in red signal the nucleotides that differ from 
the consensus sequence. 
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Figure 4.9. LXRα-S196A preferentially binds to degenerated DR4 sequences in 
novel target genes 
A,C,E) LXR and RXRα occupancy at Ces1f and Cyp2c69 putative DR4 sequences and 
Srebp-1c LXRE in livers of WT and S196A mice fed a HFHC in comparison to a non-
specific sequence (n=3-6). 
B,D,F) RNA Pol II and pSer2-Pol II occupancy at Ces1f, Cyp2c69 TSS and Srebp1c TSS 
in livers of WT and S196A mice fed a HFHC in comparison to a non-specific sequence 
(n=3-6).  
Results are normalized to input values and shown relative to WT. Data represents mean 
± SEM. * p < 0.05, ** p < 0.005 relative to WT determined by Student’s t-test. 
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Moreover, this binding pattern was similar, except for RNA Pol II binding, for another 
potential degenerated DR4 sequence identified in the Cyp2c69 gene (Figure 4.9. C,D), 
whose expression is enhanced by about 5-fold in LXRα-S196A mice (Figures 4.1, 4.2. 
C and 4.3). In contrast, occupancy by both LXR and RXRα to the well-established LXRE 
in the Srebp-1c promoter (388), a gene that was also induced in S196A livers (Figure 
3.9), was significantly increased (Figure 4.9. E), as were Pol II and pSer-Pol II to its TSS 
(Figure 4.9. F); although whether this pattern is also seen for other well-established LXR 
target genes should be confirmed. Globally, these results suggest that impaired LXRα 
phosphorylation at S196 allows for the transcriptional activation of a subset of genes that, 
at least in the case of Ces1f and Cyp2c69, contain degenerated DR4 sequences. 
Furthermore, the regulation of these specific set of genes seems to occur independently 
of changes in RXRα occupancy.  
It must be noted that, due to the binding nature of RNA Polymerase II, no sequences 
were found that could act as a negative control for RNA Pol II and its modification pSer2-
Pol II. Nonetheless, comparison of these antibodies against their Immunoglobin G (IgG) 
isotype control confirmed their specificity (Figure 4.10).  
 
 
Figure 4.10. RNA Pol-II and pSer2-Pol II antibody specificity 
Validation of antibodies against RNA-Pol II (Left) and pSer2-Pol II (Right) over IgG 
isotype control on mouse livers fed a HFHC diet. Results are normalised to input 
chromatin values (n=1).   
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Lastly, differential interaction of phospho-mutant LXRα with other cofactors was 
investigated as an additional possible mechanism behind changes in gene expression. 
Previous proteomic analysis by our collaborators in Prof. Garabedian’s lab (New York 
University, USA) on HEK293T cells expressing vector only (Vo), FLAG-hLXRα or FLAG-
hLXRα-S198A (389), revealed that the corepressor NCoR and the cofactor TBLR1 (see 
section 1.1.1) preferentially interact with the human LXRα-S198A in vitro (Figure 4.11. 
A), which could justify for the differences in gene expression in S196A livers. Accordingly, 
and consistent with increased LXRα binding (Figure 4.9. A-D), TBLR1 occupancy at 
Ces1f and Cyp2c69 DR4 sequences was significantly enhanced in S196A livers exposed 
to the HFHC diet (Figure 4.11. B,C). In contrast, no differences were detected in NCoR 
occupancy between genotypes (Figure 4.11. B,C). This goes against previously 
published evidence  in vitro, where expression of LXRα phosphorylation-sensitive genes 
in response to synthetic ligands was shown to be facilitated by a reduction in NCoR 
recruitment (163); which reinforces the idea that the molecular mechanisms behind the 
activity of LXRα-S196A may differ depending on the nature of the activating stimuli. 
Moreover, evaluation of transcript levels in livers of WT and S196A mice confirmed that 
changes in LXRα phosphorylation did not alter the expression of these factors (Figure 
4.11. D), suggesting that differential responses to a HFHC diet in vivo by the phospho-
mutant animals may be mediated, in part, by changes in the binding of the TBLR1 
cofactor (Figure 4.11. E). 
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Figure 4.11. TBLR1 occupancy is increased at putative LXR binding sites in S196A 
livers 
A) Total spectral counts obtained from immunoprecipitates of wild type LXRα (LXRα), 
phospho-mutant (S198A) and not expressing LXR (VO) cells identified by mass 
spectroscopy (n=1).  
B-C) TBLR1 and NCoR occupancy at Ces1f and Cyp2c69 putative DR4 sequences in 
comparison to a non-specific sequence (n = 3). Results are normalized to input values 
and shown relative to WT, set as 1 on DR4 sequences.  
D) Gene expression was measured by qPCR in livers of WT and S196A fed a HFHC diet 
(n = 6). Results are normalized to cyclophilin levels and shown relative to WT. 
E) Diagram representing the hypothetical molecular mechanism through which the 
S196A-LXRα receptor binds to and induces expression of novel target genes.  
Data shown as means ± SEM. * p < 0.05 relative to WT determined by Student’s t-test.  
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4.5. Summary 
 The LXRα-S196A receptor acts as a nutritional sensor by specifically 
reprogramming the hepatic transcriptome in response to a HFHC-diet. 
 Impaired LXRα phosphorylation reveals unique LXRα phosphorylation/diet 
sensitive target genes. 
 Expression of novel genes is mediated, in part, through differential binding of LXR 
and TBLR1 to degenerated DR4 sequences. 
 
 
4.6. Discussion 
The work in this chapter has uncovered novel genes sensitive to changes in LXRα 
phosphorylation in mouse livers, as well as the binding sequences related to the 
regulation of two of these genes, Ces1f and Cyp2c69, that are preferentially bound by 
LXRα-S196A in the context of a fat and cholesterol-rich diet. These sequences were 
revealed through in silico analysis, by high levels of homology to a previously reported 
LXR binding site in mouse liver (315) (Figure 4.8), given that there are currently no 
available high-throughput LXR binding analyses that specifically interrogate responses 
to experimental diets. To date, most of the available ChIP-seq studies exploring nuclear 
receptor cistromes – a technique used to map the global binding of a certain protein to 
DNA – have been traditionally performed on animals treated with specific synthetic 
ligands, which may not necessarily copy binding patterns observed upon activation by 
diets. Indeed, ChIP-seq analysis in livers of WT mouse fed a chow diet and treated with 
the LXR specific ligand GW3965, shows very little or no presence of LXR at the Ces1f 
and Cyp2c69 DR4 sequences identified in silico (results kindly provided by Dr. E. Treuter, 
Karolinska Institutet, Sweden) (Figure 4.12); which further supports that both 
phosphorylation status of LXRα and diet environment are critical for the regulation of 
these genes. As previously shown, LXR agonism increases phosphorylation of the 
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receptor (163) (Figure 5.2.1.) and thus I speculate that in the GW-treated livers analysed 
by ChIP-Seq (Figure 4.12), the LXRα receptor is highly phosphorylated. This aligns with 
the hypothesis that the non-phosphorylatable LXRα is able to preferentially bind and 
consequently induce the expression of these genes.  
Furthermore, despite previous studies showing that phosphorylation affects the 
transcriptional activity of LXRα by modulating recruitment to NCoR (163,165) no 
differences were detected in NCoR occupancy between genotypes at Ces1f and 
Cyp2c69 DR4 sequences (Figure 4.11 B,C). Instead, a significant increase in TBLR1 
binding could be observed. TBLR1 is as integral member of the NCoR/SMRT 
corepressor complexes (390), and alongside its heterodimeric partner, TBL1, was 
initially found to be mediating repression by unliganded Thyroid Receptor (31). However, 
following studies demonstrated that these factors were also essential for ligand-induced 
activation of gene expression, based on their ability to mediate corepressor/coactivator 
exchange (27,391). Hence, current evidence points to a model where TBLR1 may be 
recruited by both unliganded and liganded nuclear receptors and play opposite roles. 
The results in this chapter, based on proteomics data obtained from HEK293T cells, a 
human cell line of endothelial origin, shows that alongside increased LXRα-S196A 
occupancy, TBLR1 binds more to the DR4 sequences of the studied genes (Figure 4.11 
B,C) . Therefore, direct interaction between the mutant LXRα and TBLR1 in the livers of 
HFHC-fed animals should be confirmed by co-immunoprecipitation and/or re-ChIP 
studies, a method based on sequential immunoprecipitation reactions, which allows for 
the identification of multiple and concurrently binding proteins on a single DNA sequence. 
It should be noted though, that the antibody used for the ChIP studies in this chapter can 
recognize both LXR subtypes (see section 2.8), since at the moment there are no 
available LXRα-specific antibodies that provide a good signal over background in mouse 
tissues. Even though levels of LXRβ in liver are almost minimal compared to the α 
subtype (392), and its expression was not seen to be different between the WT and 
S196A genotypes (Nr1h2, Figure 4.6); it should be taken into account that there may be 
a residual signal given by the LXRβ receptor.  
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Certain members of the Ces family are modulated by nuclear receptors such as PPARα 
(387). However, hepatic expression of PPARα was not substantially altered in S196A 
mice (Figure 4.6), and no PPARα binding was observed on the identified Ces1f and 
Cyp2c69 sequences based on reported genome-wide analysis of PPARα binding sites 
in mouse liver (315) (Figure 4.12); thus, it appears unlikely that this nuclear receptor is 
participating in the regulation of Ces1f and Cyp2c69 expression by the mutant LXRα, at 
least under the experimental conditions used for my studies. However, ChIP analysis 
investigating PPARα occupancy on WT and S196A livers will need to be performed in 
order to confirm this theory. 
Interestingly, previous studies investigating the effects of ligands for different nuclear 
receptors on various Ces family members, failed to show regulation of Ces1f by LXRs 
(387) further indicating that genetic regulation by these receptors upon synthetic ligand 
activation doesn’t necessarily mirror that on a dietary environment. Recent reports have 
linked Ces1 with protection against liver inflammation and injury (393), and hepatic 
deficiency of Ces1 strongly increases the susceptibility to cholesterol-driven hepatic 
injury (394). However, the specific contribution by Ces1f in NAFLD progression has not 
been addressed to date.  
In addition, the expression of the Cyp2c69 gene was also chosen for this study as an 
example of phosphorylation-sensitive novel LXR target genes. This is a member of the 
Cyp2c cytochrome P450 subfamily, a set of enzymes that have been classically involved 
in Phase I drug metabolism, also known as xenobiotics (395,396). Interestingly, the 
presence of chronic liver diseases, and more specifically, NAFLD, has been shown to 
alter the levels of some members of this family (397). Although not much is known 
specifically about Cyp2c69, a recent study showed that its protein levels were actually 
decreased in mouse livers in response to a high fat diet (398), suggesting that, at least 
in mice, this enzyme is also involved in hepatic fat metabolism. Moreover, we know from 
gene ontology studies that it contains an arachidonic acid epoxygenase activity capacity 
(GO:0008392), which converts arachidonic acid into epoxyeicosatrienoic acids (EETs).  
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Figure 4.12. LXR and PPARα mouse liver binding upon synthetic ligand activation 
Genomic region of the Ces1f (top) and Cyp2c69 (bottom) genes. Indicated are ChIP-seq 
read alignment tracks for the LXR (gray), RXR (blue) and PPARα vehicle-treated (green) 
and synthetic ligand-treated (red) immunoprecipitated livers. Peaks symbolize binding 
enrichment for each given nuclear receptor. Red square identifies region where the 
identified degenerated DR4 sequences are found.  
Chip-seq tracks provided by Dr. E. Treuter (Karolinska Institutet, Sweden). 
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Recent evidence has demonstrated that EETs have strong anti-inflammatory properties 
(399–401), which raises the possibility that LXRα-S196A may be protecting the liver from 
diet-induced inflammation and fibrosis, in part, through the induction of this enzyme, as 
well as other members of its family, as exampled by the enrichment in the xenobiotic 
metabolism pathway in these animals (Figure 4.4). 
Lastly, the transcriptomic analysis by RNA-seq in this chapter revealed that those mice 
carrying the S196A mutation respond differently to the HFHC diet (Figure 4.2), 
establishing the non-phosphorylatable LXRα as a as a novel nutritional sensor that 
modulates specific metabolic, inflammatory and fibrotic responses that are key in diet-
induced NAFLD progression. Thus, it will be interesting in the future to compare the 
differences between LXR ligands and exposure to a HFHC diet and how these translate 
to specific molecular mechanisms.  
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Chapter 5. In vitro studies on the modulation of LXRα activity 
and phosphorylation 
 
5.1. PART A: LXR actions in human primary hepatic stellate cells 
Most research to date on LXR function in relation to NAFLD and other liver diseases has 
been performed either on rodent cells or animal models of disease (see section 1.1.3.3). 
Thus, our knowledge on the effects of LXR actions in the pathogenesis of human NAFLD 
is scarce and often contradictory. This highlights the need for further studies investigating 
how LXRα expression and activity affects chronic liver diseases in humans.  
Due to the obvious challenges of investigating ligand-induced activity in human livers in 
vivo, studies in this chapter looking at the modulation of the human receptor have been 
performed on primary human HSCs, key players in the development of fibrosis (402). 
Regarding NAFLD pathogenesis, studies in mice or in human cell lines have established 
the importance of LXR signalling on the modulation of HSC activation (403–405), yet the 
activity and expression of these receptors in human primary HSCs remains unknown. In 
healthy liver, HSCs are present in a quiescent state and fulfil the role of lipid storage 
(406,407). In response to a variety of stimuli, HSCs can undergo differentiation into 
activated myofibroblasts, which are responsible for the secretion of extracellular matrix 
and thus promote hepatic fibrogenesis (408). Activated HSCs show enhanced 
expression of α-Smooth Muscle Actin (αSMA or ACTA2) (249,409,410); and when 
cultured, these cells undergo further activation upon each culture passage, which proves 
an ideal tool to study pathophysiological mechanisms at different stages of HSC 
activation in vitro (411).  
The objectives of the experiments below were to establish the effect of LXR activity on 
the activation and gene expression of human primary hepatic stellate cells. 
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5.1.1. LXR activity dampens human primary Hepatic Stellate Cell activation 
First, LXRA (LXRα) and LXRB (LXRβ) mRNA expression was investigated in primary 
HSCs from one donor at different stages of activation. LXRA mRNA levels decreased 
dramatically with increased culture passage, possibly indicating an inverse association 
between LXRα expression and HSC activation (Figure 5.1.1). Intriguingly, this reduction 
was less accentuated for the LXRB transcript and appeared to be only transitional 
(Figure 5.1.1), further establishing that the alpha subtype may be the one having a more 
prominent role in the relation between LXRs and HSC activation.   
 
 
 
 
Figure 5.1.1. LXRα and LXRβ expression at different stages of Hepatic Stellate 
activation  
Gene expression from human primary Hepatic Stellate cells from 1 donor at different 
passages was quantified by real time-PCR. Values are normalised to cyclophylin and 
shown as fold-change to Passage 5. 
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Next, the actions of LXR activation in primary human HSCs, stimulated with the specific 
synthetic LXR ligand GW3965, were analysed in cells form three different donors. LXRα 
expression was induced by the LXR ligand in 2 out of 3 donors, consistent with previous 
reports showing human LXRα autoregulation in other cell types (10) (Figure 5.1.2. A). 
However, LXRβ levels appeared to be only slightly affected, with an induction lesser than 
1.5-fold for all the donors (Figure 5.1.2. B). In addition, induction in the levels of several 
known LXR target genes (Figure 5.1.2. C), which are implicated in cholesterol transport 
(ABCA1, ABCG1) or fatty acid synthesis (SREBP1c) were detected upon treatment with 
the LXR synthetic ligand, confirming that GW3965 can activate LXRs in primary HSCs. 
Indeed, this is the first time that LXR-mediated induction of these genes is shown in 
primary human HSCs. As expected, variability in the induction of target genes was seen 
between donors. Interestingly, induction of LXR levels by GW3965 (Figure 5.1.2. A,B) 
had no effect on the extent of target gene expression (Figure 5.1.2. C); since Donor 3 
demonstrated a large induction of LXR target genes despite eliciting no changes in LXRα 
levels upon GW3965 treatment (Figure 5.1.2. A).  
In summary, the above findings show that not only LXRs are present in primary human 
HSCs but also that they seem to be transcriptionally active in response to the GW3965 
synthetic ligand. 
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Figure 5.1.2. Induction of target genes by the LXR synthetic ligand GW3965   
A-C) Primary Hepatic Stellate Cells from three different donors were stimulated with 1 
μM GW3965 or vehicle (DMSO) for 18 hours. Gene expression was quantified by real 
time-PCR. Values are normalised to cyclophylin and shown as fold-change to vehicle 
control for each donor (n=1). 
 
 
 
LXR modulation  by ligands has been reported to inhibit HSC activation in mice (151). 
Therefore, it was next assessed whether this inhibition also occurs in primary human 
HSC cultures. Treatment of human HSCs with the LXR ligand GW3965 caused a 
substantial reduction in the expression of ACTA2, a marker for their activation state 
(249,409,410) (Figure 5.1.3. A). Remarkably, this decrease in ACTA2 expression 
inversely correlated with the levels of LXRA but not LXRB (Figure 5.1.3. B), further 
suggesting that the alpha subtype could in fact be involved in the regulation of human 
HSC activation. 
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Figure 5.1.3. LXR activity decreases HSC activation  
A) Primary Hepatic Stellate Cells were stimulated with 1 μM GW3965 or vehicle (DMSO) 
for 18 hours. Gene expression was quantified by real time-PCR. Values are normalised 
to cyclophylin and shown as fold-change to vehicle control for each donor (n=1).  
B) Correlation of mRNA levels between ACTA2 and LXRA or LXRB. Data represents 
product of Pearson’s correlation coefficient (n = 3). 
 
 
 
5.2.3. Summary and discussion 
In summary, the experiments above show that: 
 LXRs are activated by GW3965 in human primary HSCs and in consequence 
induce target gene expression 
 LXR activity leads to decreased expression of the ACTA2 activation marker, 
which correlates with LXRα mRNA levels 
 
Due to the difficulty in procuring human tissue and cells, the aforementioned work could 
only be performed in a limited number of samples. Although preliminary, these results 
establish the basis for pursuing future studies on the modulation of LXR activity in human 
primary HSCs. Besides changes in gene expression, it would be interesting to evaluate 
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how LXRs regulate HSC activation by looking at other functional markers, such as 
changes in cell morphology under light microscopy or assessment of collagen 
expression by histochemistry or immunoblotting (277).  
Previous studies using liver biopsies from NAFLD patients indicate that LXRα levels 
(transcript and protein), as well as some of its regulated target genes positively correlate 
not only with the degree of steatosis but also with hepatic inflammation and fibrosis 
(412,413). These results identified LXRα as a novel factor involved in the pathogenesis 
of human NAFLD. Nonetheless, a more recent article looking at the expression of several 
nuclear receptors in patients with either fatty liver or NASH, found that LXRα is actually 
the only nuclear receptor whose expression is not affected during the progression of the 
disease (414). Also, it is still unclear whether elevated levels of LXRα represent an 
adaptive or a maladaptive/pathogenic response to the ongoing cellular and molecular 
changes. In my experiments, I didn’t see a relation between LXR levels with target gene 
expression, although there was a trend towards decreased HSC activation. In the future, 
besides looking at global LXR levels, it would be interesting to assess the degree of 
LXRα phosphorylation, its relationship to LXR target gene expression and NAFLD 
progression; specifically, how LXR activity and phosphorylation correlate with the onset 
and development of human NAFLD. In addition, these previous studies were performed 
on whole liver tissue and obviate that NAFLD is a multifactorial disease with a 
multicellular contribution to its pathogenesis, where the specific impact of each cell type 
(e.g. hepatocytes or hepatic stellate cells) is disregarded. This has been mainly due to 
limited sample material, which also poses important technical limitations that are likely 
to affect the quality and reproducibility of results. The gap in the current knowledge could 
be addressed by studying LXR activity in different hepatic cell populations from a range 
of donors at various stages of NAFLD and analysing how this correlates with the onset 
and development of human NAFLD. 
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5.2. PART B: Investigating regulation of LXRα phosphorylation in vitro 
Previous work by Dr. Pineda-Torra and colleagues demonstrated that LXRα 
phosphorylation occurs under basal conditions in the absence of ligand and is enhanced 
upon ligand activation in the RAW 264.7 macrophage-like cell line (163). Employing 
murine RAW 264.7 cells that overexpress either the wild-type form of the human LXRα 
(RAW-hLXRα) or its non-phosphorylatable S198A mutant (RAW-S198A), they showed 
that both synthetic (T0901317) and endogenous (24S,25-epoxycholesterol) LXR ligands, 
but not ligands for RXR, were able to induce the receptor’s phosphorylation. This same 
study also showed that the inhibition of Casein Kinase 2 (CK2) by 2-dimethylamino-
4,5,6,7-tetrabromo-benzimidazole (DMAT), reduced phosphorylation of LXRα at S198, 
indicating CK2 is one of the kinases that phosphorylates this receptor. Furthermore, 
other kinases have been reported to phosphorylate LXRα by other groups in different 
cells (169,415), which suggests that regulation of LXRα phosphorylation could be 
dependent on the cellular context and susceptible to a variety of stimuli. Indeed, a recent 
report has shown that oltipraz, a member of the dithiolethione family, attenuates LXRα 
phosphorylation in mouse liver cells through the inhibition of p70 ribosomal S6 kinase-1 
(S6K1) (169), a major downstream effector of the mammalian target of rapamycin 
(mTOR) signalling pathway. However, the specific serine residue(s) phosphorylated 
were not identified and thus it remains to be clarified if Ser198/Ser196 is susceptible to 
this kinase. 
Most of the work on this thesis has been performed on a model of genetic impairment of 
LXRα phosphorylation. However, the translational capacity of LXRα post-translational 
modifications will mainly depend on the extent to which these can be replicated or 
modulated by pharmacological compounds including kinase inhibitors.  
Thus, the aims of this part of the chapter were to: 
 Further identify which other stimuli induce LXRα phosphorylation in vitro. 
 Analyse how pharmacological inhibition of LXRα phosphorylation affects the 
receptor’s transcriptional activity in vitro. 
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5.2.1. LXRα is phosphorylated by LXR ligands and insulin  
In order to explore the regulation of LXRα phosphorylation by other LXR synthetic 
agonists beyond T0901317, the effect of GW3965 (see section 1.1.2.2) was first 
evaluated. Thus, RAW-hLXRα cells were stimulated with 5 µM GW3965 and LXRα 
phosphorylation was assessed in their nuclear extracts. This concentration of GW3965 
was chosen as it had previously been shown in my lab to induce LXRα phosphorylation 
in RAW-hLXRα cells (Pineda-Torra I, unpublished). Nuclear extracts of the non-
phosphorylatable RAW-S198A cells were included in these phosphorylation experiments 
as negative controls. As previously seen with the T0901317 synthetic ligand (163), low 
levels of phosphorylation at S198 were observed in vehicle-treated cells, and these were 
enhanced after stimulation with GW3965 (Figure 5.2.1. A). Moreover, time course 
studies with this ligand demonstrated that LXRα phosphorylation occurred as early as 
one hour after stimulation, and was maintained up to 6 hours (Figure 5.2.1. A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.1. LXRα is phosphorylated by GW3965 and desmosterol with similar 
kinetics 
RAW 264.7 cells stably expressing the human LXRα (RAW-hLXRα) or the S198A mutant 
(RAW-S198A) were incubated with or without 5 μM GW3965 (A) and 10 μM desmosterol 
(B) for the indicated lengths of time. Nuclear extracts were extracted and 
phosphoSer198-LXRα, total LXRα and Heat shock protein 90 (Hsp90) were detected by 
immunoblotting (n = 1).  
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Furthermore, in order to compare synthetic versus natural ligand effects, phosphorylation 
kinetics of LXRα by the cholesterol precursor desmosterol, a recently discovered 
endogenous agonist, was also examined (see section 1.1.2.1). Due to the lower affinity 
of this ligand compared to GW3965 (see Tables 1.1. and 1.2), extended time points were 
investigated to tease out more subtle effects. Moreover, a higher concentration (10 μM) 
of desmosterol was also used, as it had been shown previously to activate LXRs in 
murine macrophages in vitro  (52). 
Similar to GW3965 (Figure 5.2.1. A), phosphorylation of the human receptor by 
desmosterol was quickly induced at 30 min (0.5 hours) post-stimulation (Figure 5.2.1. B). 
This suggests that independently of the nature, phosphorylation of LXRα may follow a 
similar pattern, where this modification emerges shortly after stimulation. Nonetheless, 
phosphorylation by desmosterol appears to have a biphasic nature, since it decreases 
after 4 hours, and then goes back up at 6 hours where it remains phosphorylated until at 
least 24 hours post-stimulation. Nonetheless, this should be confirmed by performing 
additional repeats of this experiment and certify that it is not due to technical issues.   
Even though not a direct LXR ligand, the effects of insulin on hepatic fat metabolism 
(416), and more specifically, on the expression of Srebp-1c (417,418), suggests a 
mechanism through which insulin could be regulating LXR activity without directly 
binding to it. Thus, the effect of insulin on LXRα phosphorylation was also investigated 
by treating cells at increasing concentrations of insulin for 4 hours, as LXRα had shown 
to be susceptible to phosphorylation at this time point, at least in response to GW3965 
(Figure 5.2.1. A). Concentrations of insulin were chosen to be around 100 nM, since this 
amount has been shown previously to activate LXRs in vitro (129). In comparison to 
vehicle treated cells, LXRα-S198 was strongly phosphorylated upon increasing 
concentrations of insulin (Figure 5.2.2), establishing that LXRα phosphorylation is also 
responsive to insulin.  
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Nonetheless, a slight decrease in phosphorylation is observable at 200 nM treatment 
(Figure 5.2.2). As the levels of total LXRα protein and the loading control Hsp90 remain 
unchanged, this is most probably not due to a decrease in protein levels but most likely 
a technical error when stimulating these cells. 
In summary, these experiments show that LXRα phosphorylation at S198 in induced by 
a variety of activators including a range of LXR ligands and a metabolic hormone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.2. LXRα is phosphorylated by insulin 
RAW-hLXRα and RAW-S198A cells were incubated with different concentrations of 
Insulin or PBS (vehicle) for 4 hours. Nuclear extracts were extracted and 
phosphoSer198-LXRα, total LXRα and Hsp90 were detected by immunoblotting (n = 1). 
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5.2.2. LXRα-S198 is phosphorylated by S6K1 and can be pharmaceutically 
impaired in vitro 
Oltipraz has been previously shown to hinder LXRα phosphorylation at unspecified 
serine and threonine residue(s) through the inhibition of the S6K1 kinase (169). Thus, 
impairment of LXRα-Ser198 phosphorylation by oltipraz in vitro was assessed in 
response to both synthetic (GW3965, Figure 5.2.3. A) and endogenous (24S,25-
epoxycholesterol, Figure 5.2.3. B) LXR ligands. The concentrations of oltipraz used for 
this experiment were chosen specifically as they had been used previously to alter LXR 
activity in vitro (169). 
Firstly, and in comparison to the levels of loading control heat shock protein 90 (Hsp90), 
a slight decrease in S198 phosphorylation could be observed upon treatment with the 
highest concentration (30 μM) of oltipraz (Figure 5.2.3. A). Total LXRα levels on cells 
treated with GW3965 could not be blotted due to experimental problems, and thus 
changes in phosphorylation could not be quantified. 
Then, effects of oltipraz at higher doses were tested with 24S,25-epoxycholesterol (EC), 
an endogenous ligand known to induce the receptor’s phosphorylation (163). Upon 
stimulation with EC, reduced LXRα phosphorylation was observed as expected, with the 
highest doses (30-40 µM) of the compound (Figure 5.2.3. B). Furthermore, quantification 
of the ratio of phosphorylated S198 over total levels of the receptor confirmed that 
impairment of LXRα occurs in inverse relation to oltipraz concentrations (Figure 5.2.3. 
B). 
Overall, these results show that LXRα-S198 residue is indeed susceptible to 
phosphorylation by S6K1 in RAW macrophage cells in vitro.  
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Figure 5.2.3. LXRα-S198 phosphorylation by S6K1 is impaired in vitro by oltipraz 
A,B) RAW-hLXRα cells were pre-treated for 2 hours with different concentrations of 
oltipraz and incubated with 5 µM GW3965 (A) or 10 µM 24S,25-epoxycholesterol (B) for 
4 hours.  
Nuclear extracts were prepared and phosphoSer198-LXRα, total LXRα and Hsp90 were 
detected by immunoblotting (n =1). 
Densitometry was performed for the immunoblot shown in B) on the levels of 
phosphorylated S198-LXRα over total LXRα expression, and normalised to the levels of 
the housekeeping Hsp90 (n=1).  
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5.2.3. Pharmacological inhibition of LXRα phosphorylation affects the 
transcriptional activity of the receptor 
Previous work has established that Ser198-LXRα is a target for the CK2 kinase in vitro 
(163). Hence, efficacy of the specific CK2 inhibitor CX-4945 was tested by treating RAW-
hLXRα cells with three different concentrations of the compound and then assessing its 
effect on GW3965-induced phosphorylation at S198. LXRα phosphorylation levels were 
reduced for all three concentrations tested (Figure 5.2.4. A), confirming that CK2 is 
indeed a bona fide kinase for LXRα-S198 phosphorylation in vitro and its effects on 
LXRα-S198 can be partly mitigated by CX-4945. 
Next, in order to establish whether pharmacological inhibition of LXRα phosphorylation 
affects the transcriptional activity of the receptor, expression of several LXR target genes 
that had been shown before to be expressed in RAW 264.7 cells in response to LXR 
ligands (163), were examined on cells pre-treated with two of the CX-4945 
concentrations shown to inhibit LXRα phosphorylation (Figure 5.2.4. A).  
As previous studies have shown that other LXRα residues are susceptible to 
phosphorylation (see section 1.1.4.3), the results obtained on cells expressing the wild-
type version of LXRα (hLXRα) were compared to the mutant non-phosphorylatable 
S198A to control for additional effects of the CX-4945 compound on other residues or 
on other proteins affecting LXR-mediated transcription. First, differences in the basal 
(vehicle-treated) expression of LXR target genes was investigated (Figure 5.2.4. B). 
Interestingly, treatment with CX-4945 seemed have the strongest effect on the non-
phosphorylatable (S198A) rather than the wild-type (hLXRα) cells, leading to induction 
of Aim and repression of Abca1 (Figure 5.2.4. B). This occurred in a dose-dependent 
manner of CX-4945 for both genes. However, this dose-dependent response was not 
observed for other LXR target genes, such as Lpl (Figure 5.2.4. B). These results 
suggest that, at least at the basal level, CX-4945 effect on LXR activity is not mediated 
through changes in S198 phosphorylation. 
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Figure 5.2.4. Pharmacological inhibition of LXRα phosphorylation affects the 
receptor’s transcriptional activity in vitro 
A) RAW-hLXRα were pre-treated with three different concentrations of CX-4945 for 2 
hours and then stimulated with 5 μM GW3965 for 4 hours. Nuclear extracts were 
extracted and phospho-LXRα, total LXRα and Hsp90 were detected by immunoblotting 
(n =1). 
B-C) mRNA expression on RAW-hLXRα or the RAW-S198A mutant. Cells were pre-
treated for 2 hours with different concentrations of the CK2 inhibitor CX-4945 and then 
stimulated for 18 hours with DMSO as vehicle (B) or 1 μM GW3965 (C). Data represents 
mean ± SEM. n = 2, except GW3965-treated S198A (n=1). Values were normalised to 
cyclophilin and shown as fold-induction over the untreated (DMSO) samples on the 
hLXRα samples (B) or for both hLXRα and S198A (C).   
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From the available data, it appears that in contrast to what was observed at the basal 
level, pre-treatment with CX-4945 reduced ligand-induced gene expression on the 
hLXRα wild-type but not the mutant cells (Figure 5.2.4. C). Specifically, induction of Aim 
and Lpl expression by GW3965 was seen to be gradually reduced with increasing 
concentrations of the CK2 inhibitor (Figure 5.2.4. C). This effect was weaker for other 
genes, such as Srebp-1c. Surprisingly, the decrease of Aim and Lpl expression upon 
treatment with GW3965 can be observed, although to a different extent, on cells with 
either pharmacological (CX-4945 treated-hLXRα cells) or genetic (S198A cells) 
impairment of LXRα phosphorylation. 
Collectively, these findings suggest a model where CK2 inhibition by CX-4945 affects 
LXR target genes differently depending on the ligand-activation and phosphorylation 
status of the receptor; whereby only when the receptor is strongly phosphorylated 
through GW3965, the pharmacological inhibition of this modification mirrors the genetic 
impairment (Figure 5.2.5). Moreover, this appears to occur in a gene-dependent manner. 
It must be noted that the results shown above are preliminary, as even though the 
treatment conditions were performed in duplicates, these experiments could only be 
performed once. Therefore, future studies should address if these results can be 
replicated in two or more additional independent experiments. 
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Figure 5.2.5. Diagram summarizing possible effect of CX-4945 on LXRα gene 
expression on basal and ligand-activated conditions in vitro 
Results obtained so far seem to suggest that at the basal level, CX-4945 effect on LXR 
activity is not mediated through changes in S198 phosphorylation. Moreover, upon 
treatment with the LXR ligand GW3965, and consequential induction of S198 
phosphorylation, CK2 inhibition by CX-4945 affects LXR target genes in a manner that 
mimics the effect of the genetically modified, non-phosphorylatable LXRα-S198A. 
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5.2.4. Discussion 
Despite previous work showing that the human LXRα is susceptible to phosphorylation 
by synthetic and endogenous ligands (163), this was not done exhaustively for all known 
LXR ligand. Indeed, induction of this post-translational modification by either GW3965, 
desmosterol or insulin has never been demonstrated to date. The results in this chapter 
prove that, at least in vitro, human LXRα-S198 can be phosphorylated by a variety of 
stimuli, including known ligands and nutritional /hormonal cues.  
Moreover, this work aimed to begin to study how pharmacological inhibition affects the 
receptor’s activity in vitro and how it compares to genetic inhibition of LXRα 
phosphorylation. These studies could be relevant when evaluating the translational 
capacity of genetically modified animal models into identification of novel 
pharmacological therapies to treat diseases.  The CK2 kinase is known to phosphorylate 
a myriad of different proteins; and very interestingly, its actions have been linked by other 
groups to the expression of some genes assessed in Figure 5.2.4, by mechanisms 
parallel to LXRs. For example, Harris et al. presented a study where CK2-mediated 
phosphorylation of the SP1 transcription factor reduced the expression of Lpl in response 
to interferon-γ in vitro (419). Furthermore, a study published this year looking at the 
mechanisms behind the lipogenic programme activation in response to insulin, 
demonstrated that activation of CK2 downstream from the insulin receptor led to the 
phosphorylation of the Mediator subunit 17 (MED17) cofactor, which caused the 
expression of several lipogenic genes, such as Srebp-1c or Fas (420), both known LXR 
target genes (see section 1.1.3.1). Remarkably, MED17, also known as TRAP80, is 
known to interact with LXRα and is involved in the regulation of lipogenic gene 
expression (421). Therefore, the regulation by CK2 of target gene expression through 
other proteins besides LXRs should be taken into consideration when assessing its 
pharmacological inhibition as a means to modulate LXR activity. 
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For my studies, I decided to use the more selective CK2 inhibitor CX-4945, an orally 
bioavailable small molecule that inhibits both CK2α and CK2α′ catalytic subunits (422), 
as previous reports demonstrated that DMAT, the inhibitor previously shown to abrogate 
LXRα phosphorylation, is also able to powerfully inhibit other kinases (423). Moreover, I 
have used two kinase inhibitors that are currently under clinical trial for several diseases, 
i.e. CX-4945 as an antitumorigenic (ClinicalTrials.gov Identifier: NCT02128282); and 
oltipraz for Fatty Liver disease (ClinicalTrials.gov Identifier: NCT02068339) (424). This 
has the benefit of having access to data about the safety and bioavailability of both 
compounds for human use, and through drug repurposing, raises the possibility of using 
them for the treatment of diseases that may be influenced by LXRα phosphorylation.   
The detection of endogenous LXRα and more specifically, its phosphorylation status, 
remains technically challenging depending on the cell type or tissue under study. 
Therefore, in this thesis, work looking at the regulation of LXRα phosphorylation was 
performed on a particular cell line available in the lab that overexpressed the human 
LXRα and its non-phosphorylatable mutant. Nonetheless, protocol optimization using 
these cells and our non-commercially available phospho-antibodies allowed me to 
eventually detect endogenous phosphorylation levels in human and mouse livers (Figure 
3.1. C,D); a tissue which expresses relatively large amounts of LXRα. Therefore, future 
studies should aim to use other cell types in order to look for cell-specific differences. A 
good example of these are the hepatocyte mouse cell line Hepa 1-6, as these cells 
express very low levels of endogenous LXRα (425), and would thus not confound with 
the activity of the overexpressed wild-type and mutant receptors. 
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Chapter 6. General discussion and future studies 
This thesis aimed to investigate the regulation of LXRα phosphorylation and how this 
modification impacts the receptor’s activity in vivo. To this end, a novel mouse model 
harbouring a whole-body mutation that disrupts LXRα phosphorylation at Ser196 was 
generated. Using this in vivo model, I have assessed the effect of this mutation on the 
animal’s response to a HFHC diet, and have investigated the specific molecular 
mechanisms behind the mutant LXRα’s activity. Results show that impairment of LXRα 
phosphorylation at Ser196 critically acts as a novel nutritional sensor that promotes a 
unique diet-induced transcriptome and modulates metabolic, inflammatory and fibrotic 
responses that known to be key in NAFLD progression (see Chapters 3 and 4, and 
Figure 6.1). 
Moreover, by using a murine macrophage cell line stably transfected with the human 
wild-type version of the receptor or its non-phosphorylatable mutant (163), I have sought 
to examine new stimulants capable of inducing LXRα phosphorylation in vitro, and how 
this phenomenon can be pharmacologically impaired by using commercially available 
kinase inhibitors. Lastly, and in collaboration with Dr. Krista Rombouts (University 
College London, UK), I was able to acquire several human primary HSCs preparations 
and human liver biopsies, with which I explored how LXR activation affects the activity 
of these cells, key players in the pathogenesis of NAFLD. Importantly, I have also 
demonstrated for the first time the presence of LXRα phosphorylation at Ser198 in 
healthy human liver biopsies also provided by Dr Rombouts. 
Post-translational modifications (PTMs) are a powerful means by which the function of 
nuclear receptors can be modified. Despite the documented key importance of some of 
these receptors in maintaining metabolic homeostasis in health and disease (158), our 
understanding of the functional impact that post-translational modifications have on 
metabolic diseases remains scarce. To date, the physiological roles of modifications 
such as phosphorylation, sumoylation and acetylation of LXRα have only been studied 
in vitro or non-specifically in animal models, by pharmacologically or genetically altering 
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the enzymes enhancing or inhibiting these modifications (158). For instance, mice 
deficient in Sirt1, which is the enzyme that promotes LXRα deacetylation and its 
subsequent ubiquitination and degradation, has been associated with impaired lipid 
metabolism and defective RCT, as well as increased hepatic and testicular cholesterol 
levels (156). In another study, inhibition of LXRα phosphorylation at an unspecified 
serine residue by oltipraz, an inhibitor for S6K1 kinase, was shown to attenuate hepatic 
lipogenesis and steatosis in mice fed a high-fat diet (169). Thus, this thesis is the first 
study to address the pathophysiological impact of LXRα phosphorylation by directly 
impeding this modification genetically. Moreover, the overall results of the work hereby 
presented have established the S196A mice as an optimal in vivo model for the study of 
this post-translational modification, as well as an important tool for future studies that 
further investigate regulation of LXRα phosphorylation as a potential therapeutic target. 
 
6.1. Effects of LXRα phosphorylation on hepatic lipid metabolism 
The work in chapter 3 shows that, regardless of a higher degree of steatosis consistent 
with an increase in de novo lipogenesis, S196A mice counter-intuitively exhibit less 
hepatic inflammation and fibrosis than WT animals. This protection from diet-induced 
hepatic damage was accompanied by the significant repression of numerous pro-
inflammatory and pro-fibrotic mediators, as well as by lower levels of genes that code for 
several ER stress markers. Further analysis on the metabolic profile of these animals 
revealed a resistance to plasma and hepatic total cholesterol accumulation on 
phosphorylation-deficient mice (Figure 6.1). The increased steatosis in HFHC-fed S196A 
mice was associated with a higher expression of the Srebp-1c transcription factor, a key 
regulator of hepatic lipogenesis (426). This is consistent with the work of Yamamoto T 
et al., which shows that LXRα phosphorylation at several residues by Protein Kinase A 
represses the expression of this gene in vitro by enhancing recruitment of NCoR (415). 
However, their study failed to reconcile the link between induction of Srebp-1c by LXR 
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ligands and LXRα phosphorylation; since previous studies (163,165), as well as work 
shown in this thesis (Chapter 5), have demonstrated that these compounds hyper-
phosphorylate the receptor. Moreover, the specific contribution of each phosphorylated 
residue by site-directed mutagenesis was not assessed in their study. 
 
Figure 6.1. Graphical summary of LXRα-S196A effects on hepatic lipid metabolism 
Impairment of phosphorylation of LXRα-S196 reprograms the hepatic transcriptome in 
mice, which upon being fed a HFHC diet leads to a higher degree of steatosis, as well 
as reduced hepatic inflammation and fibrosis (steatohepatitis).  
Adapted from bioRxiv 127779. 
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Even though the S196A mice carry a whole-body mutation and LXRα is expressed in 
many other extrahepatic tissues (2,3), the animals on the HFHC diet elicited a prominent 
liver phenotype. I hypothesize that these relatively short-term effects may be caused by 
the high presence of the alpha subtype in the liver and the prominent effect that this 
organ has on lipid metabolism. Examining the role that deficiency in LXRα-S196 
phosphorylation may be having on other tissues was beyond the scope of this thesis, 
and should be further explored in the future. As shown in Chapter 5, phosphorylation of 
the human LXRα at Ser198 is susceptible to a wide variety of stimuli, including the 
synthetic ligand GW3965 and insulin, which can induce the receptor’s phosphorylation 
through different kinases. This raises the possibility that LXRα phosphorylation, and 
hence its impairment, could be acting in a context and tissue-specific manner depending 
on the stimulant and consequent activation of downstream kinase signalling. 
Accordingly, it would be interesting for future studies to dissect the specific effects that 
the LXRα-S196A is having on the different hepatic cell types, and their specific 
contributions to the overall liver phenotype. This could be achieved by crossing the mice 
carrying the floxed S196A vector with other strains containing the Cre recombinase 
under cell-specific promoters, such as the lecithin-retinol acyltransferase (Lrat) for HSCs 
(427) or albumin (Alb) for hepatocytes (428).  
It should be noted that due to the nature of the work on this thesis, which has looked at 
the activity of a transcription factor and its overall effects on transcriptional regulation, 
the experiments in Chapter 3 were primarily designed to primarily assess mRNA levels. 
This poses a limitation to this study, given that changes in transcript levels don’t 
necessarily mirror by changes in protein levels. For this reason, future work should 
confirm if the changes observed at the mRNA expression level are translated into 
changes in protein expression by immunoblotting or immunohistochemistry in liver or 
hepatic cell protein extracts.  
The diet used in my studies was initially chosen with the purpose of metabolically 
challenging the mice, while providing high levels of endogenous LXR ligands. Diets high 
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in fat and cholesterol have been used in the past as experimental models of NAFLD 
(329,429), as it induces hepatic damage in a less severe manner than other dietary 
approaches, such as the methionine and choline deficiency (MCD) diet (430,431). In 
addition, the diet used in this study contained high levels of sodium cholate (see section 
2.2.1), which when added to cholesterol-supplemented diets has shown to induce 
hepatic steatosis, inflammation and fibrosis (329,432). Indeed, after only 6 weeks of 
being fed the HFHC diet, WT mice elicited prominent hepatocyte ballooning, a key 
histological feature in the human NAFLD (433,434). Nevertheless, the scientific 
community has lately advocated for the use of diets supplemented with high levels of 
sucrose or fructose, on the basis that besides promoting most hepatic characteristics of 
NAFLD, they also induce obesity and insulin resistance (435,436), and thus resemble 
more closely the dietary and phenotypical characteristics of the human disease 
(437,438). Future work could assess how the S196A mice respond to a diet high in fat, 
cholesterol and fructose, especially since LXRs also have an important role in glucose 
metabolism (see section 1.1.3.2). 
 
6.2. Impairment of LXRα-S196 phosphorylation alters the hepatic 
transcriptome  
The detailed mechanisms through which LXRα-S196A confers protection against diet-
induced hepatic injury couldn’t be fully elucidated in the period of time this thesis covered. 
Several options are possible, in reference to our current understanding on LXR actions 
and the pathogenesis of NAFLD (Chapter 1). Such options are: a decrease in hepatic 
cholesterol, a shift towards higher levels of protective fatty acid species and/or an 
increased transrepressive capacity of the LXRα-S196A receptor. Based on the observed 
reprogramming of the hepatic transcriptome in the mutant mice (Chapter 4), I speculate 
that the protective phenotype in S196A mice is probably due to a combination of all the 
above, especially in relation to such a multifactorial disease such as NAFLD. However, 
this hypothesis should be confirmed by assessing phenotype disappearance on animals 
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with a suppressed (or incremented) expression of those genes involved in the 
aforementioned pathways, which would only be definitive if there is only a major 
responsible pathway.    
One unexpected aspect revealed over RNA-seq analysis of HFHC livers (Chapter 4) was 
that LXRα expression was slightly increased in S196A mice.  Autoregulation of the 
mouse receptor is still not fully clarified, as it has been described to be present in certain 
tissues, like adipose tissue (9) but not in others, i.e.  primary macrophages (10). 
Nonetheless, previous reports have shown that murine LXRα expression in the liver can 
be induced by high fatty acid levels (8), as well as a high fat and high cholesterol diet 
(439). Therefore, the slight induction of LXRα could be explained by the higher levels of 
fats present in S196A livers. Indeed, and in accordance with this hypothesis, no 
difference could be observed in small intestine LXRα levels between genotypes (Figure 
3.5. C). Nonetheless, the gene-selective modulation of the LXRα-S196A, a phenomenon 
that had been observed previously in vitro (163,165), suggests that the phenotype 
observed in the mutant mice is most probably caused by the changes in phosphorylation 
rather than levels of the receptor. In fact, a previous report on a mouse model with a 
liver-specific increase in LXRα expression (440) showed a completely different hepatic 
transcriptome than the S196A mice, both under a chow and Western diet. For example, 
whilst the livers of chow-fed LXRα overexpressing-mice displayed no differences in the 
expression of Fas, the S196A animals suffered a significant decrease in the expression 
of this same gene compared to WT controls. This difference in transcriptomes further 
strengthens the idea that the difference in the mutant mice compared to WT is indeed 
caused by the genetic impairment of LXRα-S196A phosphorylation. 
Regarding the mechanism of action of LXRs, the initial theory described for many nuclear 
receptors was that these were sitting on the promoters of their respective target genes, 
interacting with different cofactors depending on their activation state, and inducing or 
repressing gene expression accordingly (25,441). Later studies using ChIP-sequencing 
of LXRs and other nuclear receptors have shown that, alternatively, LXRs are bound 
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primarily to different transcriptional regulatory intronic and intergenic regions (315,442), 
distal from the TSS of genes. When investigating the regulation of the LXRα 
phosphorylation-sensitive genes Ces1f and Cyp2c69 (Chapter 4), both DR4 sequences 
found in silico were located at intronic regions, suggesting that these may be actually 
acting within an enhancer region; which are short (50-1500 bp), non-protein coding 
sequences of DNA, whose function is to greatly increase the expression of genes in their 
vicinity. However, true identification of these regions as such should be confirmed in the 
future. One way to do so would be looking at the presence of putative enhancer elements, 
like the HAT p300 (443) or H3 monomethylated at K4 (H3K4me1) (444) by ChIP-seq 
analysis. Moreover, the results shown in Chapter 4 demonstrate that most of the genes 
regulated by the mutant LXRα were only modulated upon a fat and cholesterol-rich 
environment. Several recent studies have established that certain metabolic states 
induce changes in the epigenome, through chromatin modifications, both in animal 
models fed diets with a high fat diet and in obese and diabetic humans (445–447). These 
modifications, such as changes in methylation patterns, affect chromatin accessibility 
and are considered to act as a “metabolic imprint”, causing increased disease risk. As 
part of an ongoing collaboration with Dr. Eckardt Treuter’s group at the Karolinska 
Institutet (Sweden), we are now undertaking ChIP-seq studies to explore how certain 
histone modifications in the liver, such as H3K27ac (acetyl K27), a mark associated with 
“open” or active chromatin states, vary between the WT and S196A mice. This will allow 
us to better understand how the changes we have observed at the transcriptional level 
in S196A livers associate with epigenetic regulation.    
The precise mechanisms that regulate the signal-dependent exchange between 
corepressor and coactivators are still not fully understood. This is the first study to show 
that changes in LXRα post-translational modifications confer the receptor with a specific 
transcriptional signature, by possibly affecting the cofactor exchange process. The fact 
that TBLR1 and its partner TBL1 are intrinsic components of the NCoR/SMRT 
corepressor complexes, required for both the repression and de-repression of genes 
(27,391), suggests a model where co-repressors found in gene promoters or other DNA 
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regulatory regions are in a primed state that allows for their quick release. ChIP-qPCR 
analysis of genes that showed to be significantly induced in S196A livers upon a HFHC 
diet (Chapter 4), revealed a higher occupancy of TBLR1 at those sites where LXR also 
binds (LXRE and degenerated DR4s). Taking also into account the in vitro data from our 
collaborators at Prof. Garabedian’s lab (New York University, USA), showing that the 
LXRα phospho-mutant binds more to TBLR1 than the wild-type form (Figure 4.11. A), I 
hypothesise that the molecular mechanisms behind the changes in hepatic gene 
expression in S196A livers are caused, in part, through an increased presence of TBLR1-
LXR complexes and its consequential increase in cofactor exchange.    
Interestingly, TBLR1 activity itself has also been shown to be regulated by PTMs. Perissi 
and colleagues demonstrated that TBLR1-S193 is a target of ligand-induced Protein 
Kinase C δ-mediated phosphorylation, which happens in situ on the promoters of its 
regulated genes, and leads to the release and degradation of NCoR/SMRT (391). This 
further supports the idea that PTMs are used as a quick, reversible, targeted way to 
regulate the transcriptional machinery. Thus, it would be interesting for future studies to 
examine how modification of the phosphorylation status of LXRα affects TBLR1 activity, 
not only through their interaction, but possibly by also regulating its own PTMs.  
 
6.3. Therapeutic opportunities for agents that modify LXRα 
phosphorylation   
As we gradually gain more knowledge on how posttranslational modifications finely tune 
nuclear receptor actions, and how these mechanisms appear to be often dysregulated 
in pathological situations, the focus on nuclear receptor preclinical research has begun 
to shift towards elucidating how to manipulate these modifications as alternative 
therapeutic avenues. For example, several studies have now linked the phosphorylation 
status of the Estrogen Receptor α in breast tumours, with resistance to endocrine 
treatment and overall clinical outcomes (448). Importantly, this is not only restricted to 
159 
 
steroid receptors. Recently, based on initial observations that phosphorylation of PPARγ 
at Ser273 is linked to obesity and insulin resistance (449,450), a drug screening effort 
on 780 different Food and Drug Adminstration (FDA)-approved drugs using disruption of 
PPARγ phosphorylation as an endpoint (rather than PPARγ classical ligand activation) 
was reported (451). These efforts identified that Gleevec, a well-established anti-cancer 
drug, increases insulin sensitivity and overall improves the phenotype of mice fed a high-
fat diet by blocking PPARγ-Ser273 phosphorylation (451). Thus, modulating nuclear 
receptor PTMs as a strategy to modulate their activity may soon become a plausible 
alternative to current therapies 
In the UK, NAFLD affects about 25% of the adult population, and of those, around 30% 
will progress to non-alcoholic steatohepatitis (NASH) (452,453). Current treatment 
options such as lifestyle changes (diet change and weight loss) are inadequate for a 
large number of patients. Moreover, pharmacological therapies such as insulin 
sensitizers, antioxidants, and lipid-lowering agents are aimed at treating its associated 
conditions and therefore display only limited efficacy. Thus, there is a clear unmet 
medical need for development of novel direct pharmacological therapies targeting 
NAFLD. LXRα’s role in promoting fatty acid and triglyceride accumulation (7) has proven 
a major obstacle in the development of LXR ligands as human therapeutics against 
metabolic and cardiovascular disorders. Concurrently, pharmacological antagonism of 
LXRs has been proposed in recent years to be effective against NAFLD. For instance, 
the liver selective LXR inverse agonist SR9238 suppresses hepatic fatty acid synthesis 
and lipid accumulation leading to alleviated hepatic inflammation and fibrosis in an obese 
rodent model (152,153). Interestingly, a recently-published study looking at LXRα 
preservation through inhibition of its tetratricopeptide repeat domain protein 39B 
(Ttc39b)-induced ubiquitination, showed that increased levels of hepatic LXRα reduced 
steatohepatitis in a dietary animal model of the disease (455). However, this protection 
was associated with a surprising inhibition of the hepatic lipogenic programme, which 
clearly links the amelioration of hepatic damage with a reduced lipotoxic presence. 
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Despite the high prevalence of steatosis in industrialised countries, this condition is 
considered to be relatively benign, where the life-expectancy of patients with early stages 
of NAFLD is similar to the general population (see section 1.2.1). However, a proportion 
of this group of patients will progress into developing fibrosis, cirrhosis or hepatocellular 
carcinoma (453); suffering from an increased mortality rate, mainly from cardiovascular 
and liver-related causes (456). Therefore, tackling the progression of NAFLD in 
individuals with already-established steatosis is key to reducing liver-related mortality. 
To my knowledge, the work presented in this thesis is the only one to have demonstrated 
that non-pharmacological modulation LXRα activity is able to reduce diet-induced 
hepatic injury despite abundant lipid accumulation. This further supports the idea that 
NAFLD pathogenesis is more complex than initially thought, and could be exploited to 
design novel LXR-based therapies to alter the progression of disease in subjects with 
already established steatosis. Therefore, future studies could involve the use of an 
inducible LXRα-S196A mouse model, where the effect of changing LXRα’s 
phosphorylation is assessed once the early stages of NAFLD are already established. 
Indeed, such a model is already available in Prof. Garabedian’s lab and stems from the 
same floxed mice used in my study (see section 2.1),  but using the inducible tamoxifen-
driven Cre recombinase (457). 
Lastly, I have been able to show that the human LXRα is phosphorylated at Ser198 in 
healthy human livers (Chapter 5). At present, no Genome Wide Association studies 
(GWAS) on NAFLD or cardiovascular diseases have identified Single Nucleotide 
Polymorphisms (SNPs) related to neither LXRα-Ser196 nor its hinge region for that 
matter. Future studies should first address if changes in LXRα’s phosphorylation status 
can be correlated with disease onset and progression. Thus, a better understanding of 
how LXRα posttranslational modifications can be modulated and the impact that they 
have on LXR biology could open in the future alternative therapeutic avenues for 
metabolic diseases.  
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Overall, the work described in this thesis shows that impairment of LXRα phosphorylation 
at Ser196 critically acts as a novel nutritional sensor in vivo, promoting a unique diet-
induced transcriptome and modulating metabolic, inflammatory and fibrotic responses 
that are key in NAFLD progression. This novel work provides an important step forward 
towards a more exhaustive understanding of LXRα biology, and places the modulation 
of LXRα phosphorylation as a potential anti-inflammatory/anti-fibrotic therapeutic target. 
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Gene Symbol Gene title Ranking score Function 
SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 0.889 Bile acid synthesis 
RETSAT retinol saturase (all-trans-retinol 13,14-reductase) 0.858 Retinol saturation 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 0.858 Fatty acid degradation 
PECR peroxisomal trans-2-enoyl-CoA reductase 0.831 Fatty acid unsaturation 
CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1 0.694 Bile acid synthesis 
ACSL1 acyl-CoA synthetase long-chain family member 1 0.684 Fatty acid degradation 
PEX6 peroxisomal biogenesis factor 6 0.671 Peroxisome biosynthesis 
CROT carnitine O-octanoyltransferase 0.666 Fatty acid degradation 
GNMT glycine N-methyltransferase 0.652 Detoxification 
PEX11A peroxisomal biogenesis factor 11A 0.649 Peroxisome biosynthesis 
PIPOX pipecolic acid oxidase 0.603 Amino acid metabolism 
EPHX2 epoxide hydrolase 2, cytoplasmic 0.595 Arachidonic acid metabolism 
HACL1 2-hydroxyacyl-CoA lyase 1 0.585 Fatty acid degradation 
ABCD3 ATP-binding cassette, sub-family D (ALD), member 3 0.576 Peroxisome biosynthesis 
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 0.518 Bile acid transport 
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 0.480 Fatty acid degradation 
TTR transthyretin (prealbumin, amyloidosis type I) 0.480 Retinol transport 
 
Bile acid metabolism 
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Gene Symbol Gene title Ranking score Function 
RETSAT retinol saturase (all-trans-retinol 13,14-reductase) 0.858 Retinol saturation 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 0.858 Fatty acid degradation 
ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl 0.805 Fatty acid degradation 
ELOVL5 ELOVL family member 5, elongation of long chain fatty acids 0.740 Fatty acid elongation 
ACSL1 acyl-CoA synthetase long-chain family member 1 0.684 Fatty acid degradation 
PEX6 peroxisomal biogenesis factor 6 0.672 Peroxisome biosynthesis 
PEX11A peroxisomal biogenesis factor 11A 0.649 Peroxisome biosynthesis 
ALB albumin 0.611 Transport 
EPHX2 epoxide hydrolase 2, cytoplasmic 0.595 Arachidonic acid metabolism 
ABCD3 ATP-binding cassette, sub-family D (ALD), member 3 0.576 Peroxisome biosynthesis 
EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase 
0.576 Fatty acid degradation 
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 0.531 Phospholipid transport 
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 0.480 Fatty acid degradation 
TTR transthyretin (prealbumin, amyloidosis type I) 0.459 Retinol transport 
Components of peroxisome 
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Gene Symbol Gene title Ranking score Function 
CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1 1.476 Steroid biosynthesis 
RETSAT retinol saturase (all-trans-retinol 13,14-reductase) 0.858 Retinol saturation 
ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl 0.805 Fatty acid degradation 
ANGPTL3 angiopoietin-like 3 0.774 Cell adhesion 
LEAP2 liver expressed antimicrobial peptide 2 0.758 Antimicrobial 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 0.751 Cortisol inactivation 
ELOVL5 ELOVL family member 5, elongation of long chain fatty acids 0.740 Fatty acid elongation 
CROT carnitine O-octanoyltransferase 0.666 Fatty acid degradation 
MCCC2 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 0.664 Amino acid metabolism 
GNMT glycine N-methyltransferase 0.653 Detoxification 
NDRG2 NDRG family member 2 0.629 Cell proliferation 
FBP1 fructose-1,6-bisphosphatase 1 0.622 Glucose metabolism 
AHCY S-adenosylhomocysteine hydrolase 0.609 Amino acid metabolism 
HACL1 2-hydroxyacyl-CoA lyase 1 0.586 Fatty acid degradation 
ASL argininosuccinate lyase 0.584 Amino acid metabolism 
ABHD6 abhydrolase domain containing 6 0.551 Cannabinoid system 
ENPEP glutamyl aminopeptidase (aminopeptidase A) 0.516 Amino acid metabolism 
ETFDH electron-transferring-flavoprotein dehydrogenase 0.462 Mitochondrial respiration 
Xenobiotic metabolism 
2
0
1
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Gene Symbol Gene title Ranking score Function 
SLC22A5 solute carrier family 22 (organic cation transporter), member 5 0.878 Carnitine transport 
FASN fatty acid synthase 0.865 Fatty acid synthesis 
RETSAT retinol saturase (all-trans-retinol 13,14-reductase) 0.858 Retinol saturation 
INMT indolethylamine N-methyltransferase 0.807 Xenobiotic degradation 
ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl 0.805 Fatty acid degradation 
RDH16 retinol dehydrogenase 16 (all-trans) 0.747 Retinol synthesis 
ELOVL5 ELOVL family member 5, elongation of long chain fatty acids  0.740 Fatty acid elongation 
ACSL1 acyl-CoA synthetase long-chain family member 1 0.684 Fatty acid degradation 
MGLL monoglyceride lipase 0.637 Triglyceride hydrolysis 
ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 0.606 Fatty acid degradation 
AADAT aminoadipate aminotransferase 0.603 Amino acid metabolism 
EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase 
0.576 Fatty acid degradation 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit 0.563 Fatty acid synthesis 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 0.533 Fatty acid synthesis 
MDH1 malate dehydrogenase 1, NAD (soluble) 0.514 Glycogen metabolism 
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 0.513 Fatty acid degradation 
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 0.480 Fatty acid degradation 
ETFDH electron-transferring-flavoprotein dehydrogenase 0.462 Mitochondrial respiration 
Fatty acid metabolism 
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Gene Symbol Gene title Ranking score Function 
SCNN1A sodium channel, nonvoltage-gated 1 alpha 1.254 Transport 
CBFA2T3 core-binding factor, runt domain, alpha subunit 2; translocated to, 3 0.912 Transcriptional cofactor 
SLC22A5 solute carrier family 22 (organic cation transporter), member 5 0.878 Carnitine transport 
FASN fatty acid synthase 0.865 Fatty acid synthesis 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 0.858 Fatty acid degradation 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 0.851 Xenobiotic metabolism 
ELOVL5 ELOVL family member 5, elongation of long chain fatty acids 0.740 Fatty acid elongation 
KCNK5 potassium channel, subfamily K, member 5 0.725 Transport 
PEX11A peroxisomal biogenesis factor 11A 0.649 Peroxisome biosynthesis 
GFRA1 GDNF family receptor alpha 1 0.628 Cell surface receptor 
ABAT 4-aminobutyrate aminotransferase 0.574 Transaminase 
 
Estrogen early 
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Gene Symbol Gene title Ranking score Function 
MMP14 matrix metallopeptidase 14 (membrane-inserted) -0.509 Extracellular matrix degradation 
CD9 CD9 molecule -0.609 Cell adhesion  
PLEK pleckstrin -0.677 Platelet biology 
MMP2 matrix metallopeptidase 2  -0.777 Extracellular matrix degradation 
FBN1 fibrillin 1 -0.882 Extracellular matrix protein 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) -0.895 Extracellular matrix degradation 
PLAU plasminogen activator, urokinase -0.950 Extracellular matrix degradation 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) -1.036 Extracellular matrix protein 
PLAT plasminogen activator, tissue -1.140 Clotting 
ANXA1 annexin A1 -1.228 Membrane binding 
CTSK cathepsin K (pycnodysostosis) -1.422 Extracellular matrix degradation 
TIMP1 TIMP metallopeptidase inhibitor 1 -1.529 Extracellular matrix composition 
Coagulation 
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Gene Symbol Gene title Ranking score Function 
MMP14 matrix metallopeptidase 14 (membrane-inserted) -0.509 Extracellular matrix degradation 
ATOX1 ATX1 antioxidant protein 1 homolog (yeast) -0.553 Metal trafficking  
PLEK pleckstrin -0.677 Platelet biology 
GNG2 guanine nucleotide binding protein (G protein), gamma 2 -0.678 Membrane signalling 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide -0.698 Immune response mediator 
CTSD cathepsin D (lysosomal aspartyl peptidase) -0.720 Protein degradation 
PLAUR plasminogen activator, urokinase receptor -0.869 Extracellular matrix degradation 
TIMP2 TIMP metallopeptidase inhibitor 2 -0.879 Extracellular matrix composition 
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) 
-0.905 Immune response mediator 
CTSS cathepsin S -1.003 Protein degradation 
MMP12 matrix metallopeptidase 12 (macrophage elastase) -1.022 Extracellular matrix degradation 
COL4A2 collagen, type IV, alpha 2 -1.068 Extracellular matrix protein 
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) -1.107 Chemotaxis 
PLAT plasminogen activator, tissue -1.140 Clotting 
LGALS3 lectin, galactoside-binding, soluble, 3 (galectin 3) -1.365 Adhesion 
TIMP1 TIMP metallopeptidase inhibitor 1 -1.529 Extracellular matrix composition 
Complement 
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Gene Symbol Gene title Ranking score Function 
KIFC3 kinesin family member C3 -0.597 Mitosis 
LARGE like-glycosyltransferase -0.645 Glycoprotein synthesis 
SLC6A8 solute carrier family 6 (neurotransmitter transporter), member 8 -0.665 Creatinine transport 
CKB creatine kinase, brain -0.720 Creatinine metabolism 
AEBP1 AE binding protein 1 -0.726 Transcriptional repressor 
LSP1 lymphocyte-specific protein 1 -0.742 Cell motility 
PDLIM7 PDZ and LIM domain 7  -0.758 Mitosis 
CRYAB crystallin, alpha B -0.815 Chaperone 
NQO1 NAD(P)H dehydrogenase, quinone 1 -0.910 ROS detoxification 
ITGB4 integrin, beta 4 -0.924 Adhesion 
COL1A1 collagen, type I, alpha 1 -0.939 Extracellular matrix protein 
COL3A1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, 
autosomal dominant) 
-0.943 Extracellular matrix protein 
GPX3 glutathione peroxidase 3 (plasma) -0.953 ROS detoxification 
AK1 adenylate kinase 1 -0.963 Energy metabolism 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) -1.036 Extracellular matrix protein 
COL6A2 collagen, type VI, alpha 2 -1.048 Extracellular matrix protein 
COL4A2 collagen, type IV, alpha 2 -1.068 Extracellular matrix protein 
COL15A1 collagen, type XV, alpha 1 -1.168 Extracellular matrix protein 
COL6A3 collagen, type VI, alpha 3 -1.169 Extracellular matrix protein 
Myogenesis 
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Gene Symbol Gene title Ranking score Function 
CNN2 calponin 2 -0.661 Cytoskeleton 
SIRPA signal-regulatory protein alpha -0.697 Signal transduction 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -0.714 Rho GTPase 
MMP2 matrix metallopeptidase 2 -0.777 Extracellular matrix degradation 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) -0.848 Adhesion 
WNK4 WNK lysine deficient protein kinase 4 -0.874 Potassium homeostasis 
FBN1 fibrillin 1 -0.882 Extracellular matrix protein 
LAMC2 laminin, gamma 2 -0.886 Extracellular matrix protein 
ADAMTS5 ADAM metallopeptidase with thromboscdhpondin type 1 motif, 5 
(aggrecanase-2) 
-0.890 Extracellular matrix degradation 
CD276 CD276 molecule -0.899 Immune response mediator 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) -0.912 Adhesion 
ITGB4 integrin, beta 4 -0.924 Adhesion 
CLDN4 claudin 4 -0.964 Tight junction protein 
CDH3 cadherin 3, type 1, P-cadherin (placental) -0.979 Adhesion 
CLDN7 claudin 7 -0.999 Tight junction protein 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide -1.330 Ion transport 
Apical junction 
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Kras signalling 
Gene Symbol Gene title Ranking score Function 
TMEM176A transmembrane protein 176A -0.633 Immune response mediator 
LAPTM5 lysosomal associated multispanning membrane protein 5 -0.684 Lysosome biology 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide -0.698 Immune response mediator 
TMEM176B transmembrane protein 176B -0.724 Immune response mediator 
C3AR1 complement component 3a receptor 1 -0.839 Complement system 
GPRC5B G protein-coupled receptor, family C, group 5, member B -0.861 G protein signal transduction 
PLAUR plasminogen activator, urokinase receptor -0.869 Extracellular matrix degradation 
SPON1 spondin 1, extracellular matrix protein -0.875 Adhesion 
SLPI secretory leukocyte peptidase inhibitor -0.936 Epithelial tissue protection 
PLAU plasminogen activator, urokinase -0.950 Extracellular matrix degradation 
CTSS cathepsin S -1.003 Protein degradation 
F13A1 coagulation factor XIII, A1 polypeptide -1.005 Coagulation 
CPE carboxypeptidase E -1.077 Hormone synthesis 
ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 -1.084 Renin-angiotensin system 
PLAT plasminogen activator, tissue -1.140 Clotting 
IL7R interleukin 7 receptor -1.191 Immune response mediator 
EMP1 epithelial membrane protein 1 -1.349 Unknown 
HKDC1 hexokinase domain containing 1 -1.433 Glucose metabolism 
GPNMB glycoprotein (transmembrane) nmb -1.442 Matrix maturation 
LAT2 linker for activation of T cells family, member 2 -1.482 Immune response mediator 
ADAM8 ADAM metallopeptidase domain 8 -1.606 Extracellular matrix remodelling 
SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-
lymphocyte activation 1) 
-1.927 Immune response mediator 
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Gene Symbol Gene title Ranking score Function 
PCOLCE procollagen C-endopeptidase enhancer -0.832 Collagen metabolism 
TNC tenascin C (hexabrachion) -0.833 Adhesion 
PDLIM4 PDZ and LIM domain 4 -0.845 Mitosis 
PDGFRB platelet-derived growth factor receptor, beta polypeptide -0.865 Mitogen 
PLAUR plasminogen activator, urokinase receptor -0.869 Extracellular matrix degradation 
COL4A1 collagen, type IV, alpha 1 -0.875 Extracellular matrix protein 
FBN1 fibrillin 1 -0.882 Extracellular matrix protein 
SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 -0.883 Collagen metabolism 
LAMC2 laminin, gamma 2 -0.886 Extracellular matrix protein 
CAPG capping protein (actin filament), gelsolin-like -0.901 Actin regulation 
CXCL1 chemokine (C-X-C motif) ligand 1 -0.905 Immune response mediator 
LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1) -0.907 Adhesion 
THBS2 thrombospondin 2 -0.926 Cell-matrix interaction 
COL1A1 collagen, type I, alpha 1 -0.939 Extracellular matrix protein 
COL3A1 collagen, type III, alpha 1 -0.943 Extracellular matrix protein 
COL5A1 collagen, type V, alpha 1 -0.978 Extracellular matrix protein 
Epithelial-mesenchymal transition 
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Gene Symbol Gene title Ranking score Function 
EMP3 epithelial membrane protein 3 -1.019 Unknown 
FMOD fibromodulin -1.023 Collagen metabolism 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) -1.036 Extracellular matrix protein 
LOXL2 lysyl oxidase-like 2 -1.045 Extracellular matrix protein 
COL6A2 collagen, type VI, alpha 2 -1.048 Extracellular matrix protein 
COL4A2 collagen, type IV, alpha 2 -1.068 Extracellular matrix protein 
FSTL1 follistatin-like 1 -1.166 Inflammation 
COL6A3 collagen, type VI, alpha 3 -1.169 Extracellular matrix protein 
COL5A2 collagen, type V, alpha 2 -1.229 Extracellular matrix protein 
LOX lysyl oxidase -1.303 Extracellular matrix composition 
COL1A2 collagen, type I, alpha 2 -1.353 Extracellular matrix protein 
TIMP1 TIMP metallopeptidase inhibitor 1 -1.529 Extracellular matrix composition 
SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-
lymphocyte activation 1) 
-1.927 Immune response mediator 
Epithelial-mesenchymal transition (continued) 
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Appendix 2 
 
Western blot scans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
212 
 
 
 
pS198-LXRα                                                        LXRα 
 
 
Scans Figure 3.1. C 
 
 
 
 
 
   pS198-LXRα                                                   LXRα 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scans Figure 3.1. D 
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pS198-LXRα, Hsp90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LXRα  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scans Figure 5.2.1. A 
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pS198-LXRα, Hsp90 
 
 
LXRα 
 
 
Scans Figure 5.2.1. B 
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pS198-LXRα, Hsp90 
 
 
LXRα 
 
 
 
 
 
 
 
 
 
Scans Figure 5.2.2 
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pS198-LXRα, Hsp90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scan Figure 5.2.3. A 
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pS198-LXRα, Hsp90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LXRα 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scans Figure 5.2.3. B 
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pS198-LXRα, Hsp90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LXRα 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scans Figure 5.2.4 
 
 
 
